Metabolic abnormalities in women who have had gestational diabetes mellitus (GDM) one year previously by Yarahmadi, Shahin
University of Wollongong 
Research Online 
University of Wollongong Thesis Collection 
1954-2016 University of Wollongong Thesis Collections 
1996 
Metabolic abnormalities in women who have had gestational diabetes 
mellitus (GDM) one year previously 
Shahin Yarahmadi 
University of Wollongong 
Follow this and additional works at: https://ro.uow.edu.au/theses 
University of Wollongong 
Copyright Warning 
You may print or download ONE copy of this document for the purpose of your own research or study. The University 
does not authorise you to copy, communicate or otherwise make available electronically to any other person any 
copyright material contained on this site. 
You are reminded of the following: This work is copyright. Apart from any use permitted under the Copyright Act 
1968, no part of this work may be reproduced by any process, nor may any other exclusive right be exercised, 
without the permission of the author. Copyright owners are entitled to take legal action against persons who infringe 
their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court 
may impose penalties and award damages in relation to offences and infringements relating to copyright material. 
Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the 
conversion of material into digital or electronic form. 
Unless otherwise indicated, the views expressed in this thesis are those of the author and do not necessarily 
represent the views of the University of Wollongong. 
Recommended Citation 
Yarahmadi, Shahin, Metabolic abnormalities in women who have had gestational diabetes mellitus (GDM) 
one year previously, Doctor of Philosophy thesis, Medical Research Unit, University of Wollongong, 1996. 
https://ro.uow.edu.au/theses/1897 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
UNIVERSITY OF WOLLONGONG
MEDICAL RESEARCH UNIT
Metabolic abnormalities in women who have had gestational 
diabetes mellitus (GDM) one year previously
Thesis submitted in fulfilment of the requirement 







Imam Mahdi, who will rise and make the world a paradise 
My dear husband, Habib,
My lovely sons, Mohammad, Reza, and Saeed, 
and my devoted parents.
A CKNO WLEDGMENT
The author would like to thank all those people and the organisation who have 
supported her during the last few years. In particular, special thanks go to the 
following:
Professor Dennis Calvert whose supervision, dedication and enthusiasm over the last 
three and half years has been invaluable,
Dr Irene Kreis, from University of Wollongong, who provided additional advice and 
encouragement in the writing of the thesis,
The Ministry of Health and Medical Education, Iran, who provided the scholarship to 
continue her education towards the PhD degree in Australia,
Dr Mohammad taghi Iman, from University of Shiraz, Iran, for his effective statistical 
advice,
Mrs Aliya Hussain Bukhari for her effective help and encouragement,
Mrs Roza Dimeska, who accompanied her in all tears and smiles during her study 
period,
M rRajeev Daniel, who did Cobas work, for providing an excellent research assistance, 
Miss Lina Baytieh and Mrs Wendy Braddock, who did anthropometry measurements, 
for their excellent job,
Mrs Elaine Knight, the administrative officer at Medical Research Unit, University of 
Wollongong, in checking the linguistic aspects of this thesis,
Her parents, husband, and children for their patience, understanding, and encouragement. 
The author recall the dedicated efforts of her family and particularly her parents for their 




TABLE OF CONTENTS II
UST OF FIGURES VII
LIST OF TABLES VIII
ABBREVIATIONS X
SUMMARY XI
1. CHAPTER ONE 
INTRODUCTION
1.1 Background 1
1.2 Etiology of Gestational Diabetes Mellitus 2
1.3 Pathogenesis of NIDDM 4
1.3.1 Impaired glucose tolerance 4
1.3.2 Insulin Resistance 5
1.4 The Cause of NIDDM Development 6
1.4.1 The Development of Insulin Resistance 7
1.4.2 The Development of Impaired Insulin Secretion 7
1.5 Significance of the Thesis 8
1.6 Aims of the Study 9
2. CHAPTER TWO 
LITERATURE REVIEW
2.1 Introduction H
2.2 Gestational Diabetes Mellitus 12
2.2.1 Screening 13
2.2.2 Diagnostic Criteria 14
II
2.2.3 Medical Management 14
2.2.4 Diet Therapy 15
2.2.5 Exercise 16
2.2.6 Oral Hypoglycemic Agents 16
2.2.7 Insulin Therapy 16
2.3 Complications of GDM 17
2.4 Long-term Follow-up 18
2.5 Metabolic Changes in Normal Pregnancy and GDM 19
2.6 Metabolic Abnormalities in Women With Previous GDM 20
2.7 Lipid and Lipoprotein Metabolism 21
2.7.1 Endogenous and Exogenous Pathways of Lipoprotein Metabolism 21
2.7.2 Cholesterol 24
2.7.3 Triglyceride 24







2.7.11 Apolipoproteins A-I and B 33
2.8 Carbohydrate Metabolism 33
2.8.1 Factors Influencing Rates of Glucose Uptake 33
2.8.2 Insulin 34
2.8.3 Glucose Tolerance 34
2.8.4 Insulin Resistance 36
2.8.5 Insulin Resistance Syndrome 37
2.8.6 HbAlc 38
2.9 Raised Blood Pressure 39
2.9.1 Essential Hypertension and Insulin Resistance 39
2.10 Microalbuminuria 41
2.10.1 Pathophysiology of Microalbuminuria 42




2.11.1.2 Pathophysiology of Obesity 45
2.11.1.3 The Role of Obesity in the Pathogenesis of Diabetes Mellitus 46
2.11.2 Androgen Status 46
2.12 Haemostatic Disorders 48
2.12.1 Fibrinogen 48
2.12.2 Factor VII 49
2.12.3 Von Willebrand Factor (vWF) 51
2.13 Dietary Habits and Other Lifestyle Factors 52
2.13.1 Dietary Habits
2.13.1.1 Dietary Fat and Blood Lipids and Lipoproteins 53
2.13.1.2 Dietary Cholesterol and Blood Lipids and Lipoproteins 56
2.13.1.3 Dietary Carbohydrate and Blood Lipids and Lipoproteins 57
2.13.1.4 Dietary Fibre and Blood Lipids and Lipoproteins 58
2.13.1.5 Effect of Dietary Factors on Carbohydrate Metabolism and Insulin Resistance 58
2.13.2 Alcohol Consumption 60
2.13.2.1 The Effect of Alcohol Ingestion on Lipids and Lipoproteins 60
2.13.2.2 The Effect of Alcohol Ingestion on Insulin Sensitivity 62
2.14 Smoking 62
2.14.1 Effects of Smoking on Lipoprotein Metabolism 63
2.14.2 Smoking and Diabetes Mellitus 64
2.14.3 Smoking and Fibrinogen Levels 64
2.15 Physical Activity 64
2.15.1 Effects of Physical Activity on Lipids and Lipoproteins 64
2.15.2 Effects of Physical Activity on Carbohydrate Metabolism 65
2.15.3 Therapeutic Exercise for GDM Patients 66
2.16 Obstetrics and Family Medical History 66
2.16.1 Obstetrics History 66
2.16.2 Oral Contraceptive 67
2.16.2.1 Effects of Oral Contraceptive on Lipids and Lipoproteins 67
2.16.2.2 Effects of Oral Contraceptive on Carbohydrate Metabolism 68
2.16.3 Family Medical History 68
2.16.3.1 Family History of Diabetes Mellitus 69






3.3 Experimental design 72
3.3.1 Demographic information 72
3.3.2 Blood pressure measurement 72
3.3.3 Blood sample taking 73
3.4 Lipid Study 74
3.4.1 Lipids and apolipoproteins in plasma 74
3.4.2 Non-esterified fatty acids (NEFA) 77
3.4.3 Isolation of VLDL and IDL 77
3.4.4 Isolation of HDL 79
3.4.5 Isolation of all lipoproteins for determination of HDL and LDL particle sizes 79
3.4.6 Determination of HDL particle size by electrophoresis 80
3.4.7 Determination of LDL particle size by electrophoresis 82
3.4.8 HDL radiolabelled in the cholesteryl ester moiety 82
3.4.9 Cholestiyl ester transfer protein activity (CETP activity) 82
3.4.10 LDL-C Calculation 83
3.4.11 LDL-apoB Calculation 84
3.5 Tests related to carbohydrate metabolism 84
3.5.1 Fasting blood glucose (FBG) 84
3.5.2 Fasting blood insulin (FBI) 85
3.5.3 HbAlc 86
3.6 Haematological Tests 86
3.6.1 Fibrinogen 86
3.6.2 Factor VII 87
3.6.3 Von Willebrand Factor (vWF) antigen 88
3.7 Hormonal Tests 89
3.7.1 Total testosterone 89
3.7.2 Sex hormone binding globulin (SHBG) 89
3.8 Albumin in Urine 90
3.9 Anthropometry 90
V
3.10 The Dietary and Health Questionnaire Booklet 92
3.11 Data collection - validity 93
3.12 Statistical Analysis 94
4. CHAPTER FOUR 
RESULTS
4.1 Comparison of Study and Control Populations 98
4.1.1 Demographic Data of the Study 98
4.1.2 Physiological Data of the Study 103
4.1.3 Categorical Data of the Study 118
4.1.4 Cross-correlation Between Different Variables 122
4.1.5 Multiple Regression Analysis 135
4.2 Sub-population Analysis: 137
4.2.1 The Definition of Subgroups 137
4.2.2 Subgroup (A) Results 138
4.2.3 Subgroup (B) Results 142
4.2.4 Hyperinsulinémie subgroup (Subgroup C) Results 146
5. CHAPTER FIVE 
DISCUSSION
5.1 Family Medical History in Women with Previous GDM 150
5.2 Obstetrics History' in Women with Previous GDM One Year after Delivery 152
5.3 Oral Contraceptive Use in Women with Previous GDM One Year after Delivery 152
5.4 Obesity in Women with Previous GDM One Year after Delivery 153
5.5 Carbohydrate Metabolism in Women with Previous GDM One Year after Delivery 158
5.6 Lipoprotein Metabolism in Women with Previous GDM One Year after Delivery 161
5.7 Hypcrandrogenicity in Women with Previous GDM One Year after Delivery 172
5.8 Raised Blood Pressure in Women with Previous GDM One Year after Delivery 175
5.9 Microalbuminuria in Women with Previous GDM One Year after Delivery 181
VI
5.10 Coagulopathy in Women with Previous GDM One Year after Delivery 186
5.11 Dietary Habits in Women with Previous GDM One Year after Delivery 188
5.12 Alcohol Consumption in Women with Previous GDM One Year after Delivery 191
5.13 Smoking in Women with Previous GDM One Year after Delivery 192
5.14 Physical Activity in Women with Previous GDM One Year after Delivery 193
6. CHAPTER SIX 
CONCLUSION
6.1 Background 197
6.2 Insulin Resistance, Dvslipidemia, and ‘GDM’ 200
6.3 Insulin Resistance, Raised Blood Pressure, and ‘GDM’ 203
6.4 Insulin Resistance, Microalbuminuria, and ‘GDM’ 204
6.5 Insulin Resistance, IGT, NIDDM, and ‘GDM’ 205






List o f Figures
Figure 2-1 Exogenous pathway of lipoprotein metabolism 22
Figure 2-2 Endogenous pathway of lipoprotein metabolism 22
Figure 2-3 Sources and sinks for plasma glucose 35
Figure 2-4 Classical view of two independent pathways (intrinsic and extrinsic),
leading to the generation of thrombin 50
Figure 2-5 Pathway linking hyperglycaemia and thrombosis in diabetes mellitus. 52
Figure 3-1 Pattern of sample loading in 3-30% gel for identifying HDL sub-populations 80
Figure 3-2 Pattern of samples loading in 3-13% gel for identifying LDL particles 82
Figure 4-1 Means comparison of age in GDM and control subjects 100
Figure 4-2 Means comparison of baby birth-weight between GDM and controls 100
Figure 4-3 Means comparison of pre-pregnancy BMI in GDM and control subjects 101
Figure 4-4 Means comparison of BMI in GDM and control subjects 101
Figure 4-5 Means comparison of WHR in GDM and control subjects 102
Figure 4-6 Means comparison of body fat % in GDM and control subjects 102
Figure 4-7 Means comparison for plasma cholesterol concentration between GDM and
control groups 106
Figure 4-8 Means comparison for plasma triglyceride concentration between GDM and
control groups 107
Figure 4-9 Comparison between mean values of plasma apoB concentrations in GDM and
control groups 107
Figure 4-10 Comparison between mean values of plasma NEFA concentrations in GDM and
control groups 108
Figure 4-11 Means comparison for VLDL composition levels between GDM and controls 108
Figure 4-12 Means comparison for IDL-C, IDL-TG, and IDL FC concentrations between the
GDM subjects and controls 109
Figure 4-13 Comparison of means of plasma LDL-C concentration between GDM and control
subjects 109
Figure 4-14 Comparison of means of LDL-apoB between GDM and control subjects 110
Figure 4-15 Comparison of means of LDL-I (size) between GDM and control subjects 110
vm
Figure 4-16 Means comparison of HDL3 b (diameter) between GDM and control groups 111
Figure 4-17 Means comparison of HDL3c (diameter) between GDM and control groups 111
Figure 4-18 Means comparison for plasma CETP activity % between GDM and controls 112
Figure 4-19 Means comparison for fasting blood insulin between GDM and control groups 113
Figure 4-20 Means comparison for insulin / glucose ratio between GDM and control groups 115
Figure 4-21 Means comparison for plasma SHBG level between GDM and control subjects 115
Figure 4-22 Means comparison for Testosterone / SHBG ratio between GDM and control groups 116
Figure 4-23 Means comparison of systolic blood pressure in GDM subjects and controls 116
Figure 4-24 Means comparison of diastolic blood pressure in GDM subjects and controls 117
Figure 4-25 Means comparison of mean arterial pressure (MAP) in GDM subjects and controls 117
Figure 4-26 Means comparison for microalbuminuria between GDM and control subjects 118
Figure 4-27 Means comparison for dietary polyunsaturated fat between GDM and controls 121
Figure 4-28 Mean comparison for dietary vitamin E between GDM and controls 121
Figure 5-1 Alternative hypothesis to explain the association between insulin and hypertriglyceridemia 156 
Figure 5-2 The insulin resistance-hyperinsulinemia-hypertension hypothesis 177
Figure 5-3 Inter-relationship between (predisposition to) hypertension, excess weight and metabolic
disturbances 179
Figure 5-4 Pathway linking hyperglycaemia and thrombosis in diabetes mellitus 187
Figure 6-1 Hypothetical model based on the present study 199
Figure 6-2 Insulin resistance and lipoprotein abnormalities 202
Figure 6-3 Relationship between insulin resistance, hyperinsulinemia, sympathetic nervous system
activity, and hypertensioa 204
Figure 6-4 Proposed etiology for the development of NIDDM 206
IX
List o f Tables
Table 2-1 Classification of diabetes mellitus 11
Table 2-2 Procedure for diagnosis of GDM 15
Table 2-3 Follow-up studies on the GDM population 20
Table 3-1 Laboratory tests in this study 74
Table 3-2 Required solid KBr for making different density solutions in 100 mLde-ionized water 78
Table 3-3 Body fat % calculation 91
Table 4-1 Response per groups 98
Table 4-2 Demographic Data 99
Table 4-3 Frequencies of family history of diabetes mellitus in the GDM and control group 103
Table 4-4 Summarized data from lipoprotein metabolism related tests of study 105
Table 4-5 Summarized data from other physiological tests of the study 114
Table 4-6 Dietary data of the study 119
Table 4-7 Summarized categorical data of the study 122
Table 4-8 Cross-correlation between different variables in this study 127
Table 4-9 Results from the multiple regression analyses 136
Table 4-10 Frequencies for different subgroups 138
Table 4-11 Comparison of subgroup (A) with the residual GDM population and controls
(Continuous Data) 140
Table 4-12 Comparison of subgroup (A) with rest of the GDM population and controls
(Categorical Data) 141
Table 4-13 Comparison of subgroup (B) with the residual GDM population and residual controls
(Continuous Data) 144
Table 4-14 Comparison of subgroup (B) with the residual GDM population and residual controls
(Categorical Data) 145
Table 4-15 Comparison of subgroup (C) with rest of the GDM population and controls
(Continuous Data) 147
Table 4-16 Comparison of subgroup (C) with the residual GDM population and controls 
(Categorical Data)
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SUMMARY
Subjects who have had gestational diabetes mellitus (GDM) are, by definition, not 
hyperglycemic after pregnancy and do not usually receive the benefit o f detailed follow­
up of their metabolic status. We examined the metabolic status o f 65 women who had 
had a diagnosis o f GDM and 65 women who had had a normal non-diabetic pregnancy 
(control women) approximately one year after delivery. We hypothesised that the 
women who had had GDM would on the whole have more abdominal obesity than 
control women, that they would be relatively hyperinsulinemic and hyperglycemic, and 
that they would have a characteristic dyslipidemia on fasting (high VLDL, IDL and LDL 
and low HDL concentrations, high plasma non-esterified fatty acid (NEFA) concentration 
and cholesteryl ester transfer protein (CETP) activity in plasma, more small LDL and 
HDL particles). It was expected that these women would have been more likely to have a 
family history of NIDDM. We hypothesised also that the women who had had GDM  
would have a high plasma testosterone and low plasma sex hormone binding globulin 
(SHBG) concentration, would have higher blood pressure, and be more likely to have 
microalbuminuria than control women. Many of these predictions were borne out.
The study shows that the population of women who have had GDM are overall far from 
normal one year after the end of pregnancy. They are likely to have a set of abnormalities 
which our current knowledge suggests are precursors of the insulin resistance syndrome 
such as obesity, a positive family of diabetes mellitus, dyslipidemia, hyperinsulinemia, 
hyperandrogenicity, raised blood pressure, and microalbuminuria.
Many of these abnormalities are found in a subgroup of GDM subjects who appear to 




Gestational diabetes mellitus (GDM) is a problem of global significance (Boyd et al,
1991). GDM is a heterogenous clinical problem with phenotypic and genotypic variety 
(Freinkel et al, 1985). GDM is common in obese women and in those over 30 years old 
(Freinkel et al, 1985). There are geographical, ethnic, and racial differences in the 
prevalence of GDM.
The pathogenesis of GDM is not fully understood, but the syndrome is similar to non­
insulin-dependent diabetes mellitus (NIDDM). In the GDM patients, the insulin response 
to glucose intake is delayed, while the basal plasma insulin level is normal or elevated 
(Kuhlet al, 1985).
In the development of GDM, like NIDDM, at least three factors may play important 
roles. They are as follows: a genetic tendency to the disease, an impaired pancreatic (3­
cell function, and a decreased insulin action in insulin-sensitive tissues including adipose 
tissue, skeletal muscle, and the liver (Horton, 1991).
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Maternal obstetric complications of GDM include hydramnios, pregnancy-induced 
hypertension, chronic hypertension, pyelonephritis, and delivery by caesarean section 
(Goldman et al, 1991).
The Third International Workshop-Conference on GDM noted that the neonates of 
GDM mothers are at increased risk of macrosomia, neonatal hypoglycaemia, 
hypokalaemia, polycythemia, and hyperbilirubinemia (Metzger and The Organizing 
Committee, 1991). Macrosomia can cause birth trauma to both mother and neonate and 
it is thought that it may increase the risk of obesity and diabetes mellitus in later life in 
the offspring of mothers with GDM (Hod et al, 1991).
Mestman et al (1972) have reported that 30-50% of women with prior GDM develop 
diabetes mellitus during 3-5 years after delivery and the proportion is 60-100% after 12­
18 years (Mestman, 1987).
1.2 Etiology of Gestational Diabetes Mellitus
O'Sullivan (1978) reported that up to 60% of women who had had GDM eventually 
developed diabetes. Oats et al (1988) have reported that 9.1% of women who had had 
GDM were found to be diabetic and 16.9% had impaired glucose tolerance using the 
WHO criteria at intervals from 1-15 years following diagnosis in Australia.
The etiology of GDM is poorly understood. The predisposing causes are probably the 
same as for NIDDM, clearly precipitated by the metabolic and hormonal changes of 
pregnancy (Brinkman HI, 1987).
Glucose tolerance normally deteriorates in human pregnancy. It is known that plasma 
levels of the anti-insulin hormones rise in pregnancy (Peterson et al, 1991). The major
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insulin antagonists of pregnancy are estrogen, prolactin, progesterone, cortisol, and 
human placental lactogen. These are at their highest concentration in the blood at 24-28 
weeks of gestation, at which time GDM most commonly occurs (Peterson et al, 1991).
Several studies have suggested that the diabetic effect of pregnancy is not due to reduced 
secretion of insulin or disproportional secretion of pro-insulin or glucagon, nor is it due 
to an increased insulin degradation (Kuhl, 1991). The diabetogenicity of pregnancy is 
associated with induction of pronounced peripheral resistance to insulin (Kuhl, 1991, 
Buchanan, 1991).
The resistance is of a similar magnitude in normal pregnant women and those with GDM, 
and it does not seem to be caused by significant alterations in insulin receptor binding to 
target tissue (Kuhl, 1991). The insulin resistance of the whole body is increased to about 
three times that seen in the non-pregnant state. It is thought to be due to post-insulin 
receptor events and is probably caused by the cellular effects of increased plasma levels 
of one or more of the pregnancy-associated hormones and free cortisol (Kuhl, 1991). 
Evidence indicates that the insulin resistance occurs predominantly in skeletal muscle 
tissue.
Most normal pregnant women are able to counteract the peripheral insulin resistance by a 
significant increase in their basal and nutrient-stimulated insulin secretion. However, a 
few (2-3%) of the women are not able to produce a sufficiendy large increase in insulin 
secretion and hence cannot overcome the peripheral insulin resistance. Thus, they 
become glucose intolerant and fulfd the diagnostic criteria for GDM (Kuhl, 1991).
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Recent studies suggest that a high percentage of pregnant women who screen positive 
for glucose intolerance have serological evidence of an autoimmune response against the 
pancreatic islets, in spite of the state of relative immune tolerance during pregnancy. 
These data suggest that autoimmune phenomena may play a role in GDM and that the 
presence of islet cell antibodies can predict insulin-requiring gestational diabetes 
(McEvoy et al, 1991). It might be an explanation for those GDM subjects who will 
develop IDDM but the finding requires confirmation.
1.3 Pathogenesis ofNIDDM
By definition, diabetes mellitus is characterized by a rise in glycemia above normal 
concentrations which is a consequence of an inability of body tissue to dispose of 
glucose, an excess production of glucose by the liver or both (Felber et al, 1993). Non­
insulin-dependent diabetes mellitus (NIDDM) is thought to be caused by an imbalance 
between insulin sensitivity and insulin secretion (DeFronzo et al, 1992).
1.3.1 Impaired glucose tolerance
Glucose tolerance, as estimated by the oral glucose tolerance test (OGTT), depends on 
complex iteration among several physiological processes, including first-phase and 
second phase insulin secretion, insulin removal, insulin sensitivity, and the tendency of 
high glucose concentration (independent of insulin) to increase glucose utilisation 
(Martin et al, 1992).
Subjects with insulin resistance may be euglycemic maintained by hypersecretion of 
insulin, with hyperinsulinemia both in the fasting and postprandial states (Beck-Nielsen et
al, 1990).
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The risk for subsequent glucose intolerance or diabetes in women with previous GDM is 
related to pre-pregnancy body mass index (BMI) and fasting plasma glucose during 
pregnancy. Subjects who are fatter before pregnancy and whose plasma glucose 
concentrations are higher during pregnancy are more likely to develop glucose 
intolerance or diabetes after delivery (Coustan et al, 1993).
Effendic et al have reported that 60% of normal weight women with previous GDM had 
borderline or decreased oral glucose tolerance 6-36 months postpartum which could be 
explained either by low insulin response or by the combination of a low insulin sensitivity 
and low insulin response (Effendic et al, 1987).
1.3.2 Insulin Resistance
Insulin resistance may be defined as a state (of a cell, tissue, system or body) in which 
more than normal amounts of insulin are required to draw out a quantitatively normal 
response (Berson and Yalow, 1970). It should be emphasised that the level of glycemia 
may be within the normal range in a person with insulin resistance as a result of 
compensatory hyperinsulinemia (Flier, 1993).
Insulin regulates blood glucose by inhibiting hepatic glucose synthesis and by stimulating 
glucose utilization in skeletal muscle. Both insulin actions are impaired in IGT and 
NIDDM patients (Mitakou et al, 1992).
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1.4 The Cause of NIDDM Development
Several investigations including prospective studies have suggested that increased insulin 
resistance precedes the development of IGT and NIDDM (Bennett, 1990, Haffner et al, 
1990a, Skarfors et al, 1991, Martin et al, 1992).
The progression from normal glucose tolerance to IGT to NIDDM with mild fasting 
hyperglycemia (< 6.7-7.8 mmol/L) is characterized by progressive hyperinsulinemia 
(DeFronzo et al, 1992).
Most evidence indicates that insulin resistance is the major factor which initiates the 
sequence of events resulting in NIDDM. While the pancreas carries a sufficiently high 
insulin secretory response to degree of insulin resistance, glucose tolerance remains 
normal to mildly impaired. However, then the ß-cell starts to fail, glucose tolerance 
impairs rapidly and overt diabetes mellitus follows (DeFronzo et al, 1992). Most studies 
have found a reduction in ß-cell mass in NIDDM patients (Klöppel et al, 1985, Clark et 
al, 1988).
Genetic or familial factors contribute to the pathogenesis of NIDDM (Bennett, 1990, 
Martin et al, 1992, Haffner et al, 1988).
'The thrifty phenotype’ hypothesis is another proposed explanation for ß-cell failure in 
the pathogenesis of NIDDM. This hypothesis proposed that ß-cell failure is due to intra­
uterine and early postnatal malnutrition in fetus and newborn respectively (Hales and 
Barker, 1992). Malnutrition during intra-uterine period of life may lead to poor fetal 
development of the pancreas, particularly ß-cells, which consequently are not capable to 
compensate sufficiently for insulin resistance later in life (Hales and Barker, 1992).
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1.4.1 The Development of Insulin Resistance
Sedentary life-style is associated with obesity and physical inactivity, and these are 
causes of insulin resistance (Yki-Jarvinen, 1994). The distribution of fat within the body 
is an important factor in developing insulin resistance in individuals. Upper body 
(android) obesity is more common in NIDDM patients than in equally obese non-diabetic 
men and women (Bjomtorp, 1988). Helmrich et al (1991) have reported that physical 
activity even without weight loss plays an important role in the prevention of NIDDM, 
even in genetically susceptible people.
Furthermore, epidemiological studies have suggested that a high intake of dietary fat 
(Tsunehara et al, 1990, Marshall et al, 1991), an excessive consumption of refined 
carbohydrates particularly sucrose (Baird, 1972, Freskens and Kromhout, 1989), and a 
low dietary fibre intake (Truswell, 1975) play roles in the etiology of NIDDM.
1.4.2 The Development of Impaired Insulin Secretion
Several hypothesis have been proposed to account for the defect in insulin secretion in 
NIDDM.
Several studies have suggested that chronic hyperglycemia is deleterious to insulin 
secretion and also persuades insulin resistance. It may eventually result in progressive 
loss of P-cell function and in the NIDDM state (Yki-Jarvinen, 1992).
Amyloid deposition has been found frequently in NIDDM patents and amylin was shown 
to be its precursor (Clark, 1989, Nishi et al, 1990). Recently, amylin was suggested as a 
contributor to the defect in insulin secretion in isolated rat pancreatic islets (Ohsawa et
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al, 1989). Galanin is the newest hormone that has been proposed to be involved in 
impaired insulin secretion in NIDDM (Dunning and Taborsky, 1988).
1.5 Significance of the Thesis
The identification of subjects at risk for diabetes mellitus has been a goal for physicians 
and scientists (Stem and Haffner, 1986, Nelson et al, 1988). The hope is that 
identification may lead to action which may help to prevent new cases or at least delay 
the onset of disease. Furthermore, early detection of diabetes in subjects who have the 
disease will enable the physician to initiate early treatment well before the onset of long 
term complications such as atherosclerosis.
GDM is a strong predictor of glucose intolerance or NIDDM later in the life of the 
mother (O’Sullivan, 1989, Persson et al, 1991). Several studies have suggested that 
normoglycemic obese and non-obese women with previous GDM exhibit abnormalities 
of insulin response to glucose administration and evidence of increased insulin resistance 
(Ward et al, 1985, Catalano et al, 1986, Effendic et al, 1987).
The factors responsible for development of impaired glucose tolerance and NIDDM in 
subjects with previous GDM are unclear (Persson et al, 1991). Effendic et al (1987) 
have reported a significantly decreased early insulin response and insulin sensitivity in 
women of normal weight who previously had GDM and who have had normal and 
abnormal oral glucose tolerance test (OGTT) postpartum. Abnormal glucose tolerance 
arising in women who have had GDM within the first postpartum year has been reported 
by several researchers (Metzger et al, 1985, Catalano et al, 1986).
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Although several studies have shown that women have a severe risk of developing 
diabetes mellitus if they have had GDM, these have been few studies of metabolic 
abnormalities in a population of women who have had GDM.
A strategy to prevent or delay the development of NIDDM in women with previous 
GDM has the potential to save millions of health care dollars and to prevent substantial 
suffering caused by the disease (Gregory et al, 1993).
This study is of a group of such women one year after delivery, compared with a control 
group.
It is a population-based study, which should form the basis for a later longitudinal study.
1.6 Aims of the Study
The aim of this study is to test the following hypotheses:
1. We hypothesise that women who have had GDM are more likely to have known or 
postulated risk factors for NIDDM, namely age, a maternal history of diabetes mellitus 
and central obesity than controls.
2. Women who have had GDM are more likely (than controls) to have developed a high 
blood concentration of non-esterified fatty acids (NEFA) in the context of a disordered 
lipid metabolism. These are thought to be factors which predict the early development of 
NIDDM. Dyslipidemia includes moderate hypercholesterolemia, hypertriglyceridemia, 
and a low HDL-cholesterol concentration. Furthermore, correlates of dyslipidemia 
include higher plasma concentrations of apolipoprotein B, VLDL, and IDL, and lower
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apolipoprotein A-I concentrations. Other correlates include denser and smaller LDL and 
HDL particles and increased cholesteryl ester transfer protein (CETP) activity in plasma.
3. We hypothesise that women with previous GDM are more likely (than controls) to 
have accelerated insulin resistance (evidenced by fasting hyperinsulinemia).
4. We hypothesise that women with previous GDM are more likely (than controls) to 
have developed elements of the insulin resistance syndrome (obesity, associated with 
hyperandrogenesity, dyslipidemia, hyperinsulinemia, high diurnal plasma glucose 
excursion, high blood pressure).
5. We hypothesise that women with previous GDM are more likely (than controls) to 
have high dietary intake of saturated fat and lack of exercise.
6. We hypothesise that women with previous GDM are more likely (than controls) to 




Diabetes mellitus is the most common metabolic disorder in humans, affecting about 2­
5% of the general population worldwide. The National Diabetes Data Group (1970) and 
the WHO Expert Committee on Diabetes Mellitus (1980) classified the heterogenous 
syndrome diabetes mellitus according to its etiopathology (Table 2-1), but other 
classifications persist (Weiss, 1988).
Table 2-1 Classification of diabetes mellitus
* Type I: insulin dependent diabetes mellitus (IDDM)
* Type II: non-insulin-dependent diabetes mellitus (NIDDM)
Obese
Lean
* Secondary diabetes mellitus
* Impaired glucose tolerance
Obese
Lean
* Gestational diabetes mellitus
Non-insulin-dependent diabetes mellitus (NIDDM) has an insidious onset and may exist 
for years without diagnosis. A number of risk factors have been recognized, including 
hyperglycemia, hyperinsulinemia, and other metabolic abnormalities obesity, physical 
inactivity, dietary factors (a high dietary fat intake, a lack of dietary fibre, and an
3 0009  03163073  9
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excessive consumption of sucrose and other refined carbohydrates), and low socio­
economic status, (Knowler et al, 1988).
Some risk factors such as hyperinsulinemia may be recognized many years before the 
onset of NIDDM (Sicree et al, 1987, Saad et al, 1988, Lundgren et al, 1990, Haffner et 
al, 1990 b, Warram et al, 1990,Charles et al, 1991)
2.2 Gestational Diabetes Mellitus
Gestational diabetes mellitus (GDM) is the most common metabolic disorder in 
pregnancy. About 90% of all pregnant diabetic patients have GDM, and, IDDM and 
NIDDM together account for the remaining 10% (Hagay et al, 1992).
It is defined as carbohydrate intolerance of variable severity with onset or first 
recognition during pregnancy (Hunter et al, 1990). The onset is usually recognized in 
the latter part of the second and early part of the third trimester (24-36 weeks) 
(Brinkman HI, 1987).
The incidence of GDM has been reported to be 2-13% of all pregnancies (Hadden, 1980, 
Sepe et al, 1985).
The majority of women who develop GDM will return to normal glucose tolerance 
during the puerperium. However, a significant number of these women, variously 
estimated to be between 30%-60% will progress to type II (NIDDM), within 5-10 years 
(Brinkman III, 1987).
Beischer et al have studied women living in Australia and reported that there are 
significant increases in the incidence of the more severe grades of GDM in women born 
in the Mediterranean region, Asia, the Indian subcontinent, Egypt, and Arabic countries.
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The incidence of GDM increased significantly with time in all racial groups, rising from 
3.3% during 1979-1983 to 7.5% during 1984-1988 (Beischer et al, 1991).
GDM is considered to be associated with increased perinatal morbidity and mortality 
which may be reduced by adequate diagnosis and management (Backx et al, 1989). In 
addition, women who develop GDM have an increased risk of permanent diabetes which 
increases with time of follow-up (Martin, 1991).
2.2.1 Screening
Currently, most obstetricians screen all of their pregnant women for gestational diabetes. 
The simplest screening test for GDM is the taking of a history. Historic risk factors such 
as the presence of a family history of diabetes, a previous perinatal loss, or the previous 
birth of a macrosomic baby clearly identify individuals at increased risk for GDM in their 
current pregnancies. Unfortunately, the taking of a history is a relatively insensitive 
screening test, identifying only half of women who proceed to develop GDM (Coustan,
1993).
The likelihood of GDM is increased with advancing maternal age (Coustan et al, 1989).
Additionally, as hormonally produced insulin resistance in pregnancy is apparent by the 
end of the second trimester, testing is best performed between 26-30 weeks’ gestation.
Renal glycosuria is common in pregnancy and is hard to evaluate. However, women with 
unrecognized pre-existing diabetes may become pregnant and the presence of glycosuria 
on routine testing in the first 12 weeks of pregnancy may then be significant. Such 
women would be regarded as having pre-existing diabetes, not GDM (Martin, 1991).
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A modified oral glucose tolerance test (OGTT) is used to screening for GDM. A 75 g 
oral glucose load is given to all pregnant women at between 26-30 weeks’ gestation in 
the non-fasting state.
The plasma glucose level is then measured one hour later and women who ‘screen 
positive’ should have a 75g OGTT before 30 weeks’ gestation (Martin, 1991). For a 
75g glucose load the cut-off plasma glucose value at 1 hour is 8.0 mmol/L and for 50g it 
is 7.8 mmol/L (Martin, 1991).
These recommendations must not prevent the recognition and testing for diabetes at any 
stage of pregnancy if suggestive clinical features are present (Martin, 1991).
Serum fructosamine and glycosylated haemoglobin (HbAlc) give similar clinical 
information, and may be used interchangeably for the metabolic control of diabetes 
mellitus patients. Neither have diagnostic value as screening test for GDM. It may be 
because fructosamine originates mainly from the nonenzymatic glycation of albumin, so, 
its concentration depends therefore not only on the concentration of glucose but also on 
albumin (Vermes et al, 1989).
2.2.2 Diagnostic Criteria
Oral glucose tolerance tests have been used for diagnosing GDM for many years (Hunter 
et al, 1990). The Procedure for the diagnosis of GDM is shown in Table 2-2.
2.2.3 Medical Management
The goal of medical management of GDM is the prevention of perinatal mortality and 
morbidity (Coustan, 1993). Several treatment strategies have been proposed: diet,
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exercise, pharmacologic intervention using oral hypoglycemic agents, and insulin therapy 
(Langer, 1993).




Test performed Diagnostic criteria-plasma 
glucose level (mmoi/L)
Clinical suspicion of 
GDM
any time 75 g OGTT (fasting) 0 hours > 5.5 
2 hours > 8.0
Screening 26-28 50 g glucose load 
(non-fasting)
1 hour > 7.8
Confirmation of 
diagnosis after positive 
screening test
26-30 75 g OGTT (fasting) 0 hours > 5.5 
2 hours > 8.0
The majority of GDM patients can be managed by diet alone (Hoolysworth et al, 1992) 
or exercise and diet (Horton, 1991), and a small percentage may require insulin to 
achieve euglycemia (Brinkman III, 1987). These patients are not prone to develop 
ketosis (Hoolysworth et al, 1992).
2.2.4 Diet Therapy
The diet therapy mainly improves the body’s sensitivity to insulin. Diet therapy may 
include caloric restriction. It is currently recommended that diet should include 50-55% 
carbohydrate, mainly complex carbohydrate with an emphasis on reduced intake of 
simple sugars because of their high absorption rate. Fat consumption should be limited 
to 20-30%, with decreased saturated fats and cholesterol and increased polyunsaturated 
fats. The diet should include a modest 20-30% protein. This diet approach will usually
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result in a 0.83-1.1 mmol / L decline in maternal glucose level (Langer, 1993). Diet 
program must provide a caloric intake sufficient to avoid ketonuria (30 kcal / kg in 
women 80-12% ideal body weight) (Peterson et al, 1991). In addition, even a small 
weight loss will improve maternal glucose levels (Langer, 1993).
2.2.5 Exercise
GDM patients should be encouraged to walk 2-3 miles an hour for 20-30 minutes, 4 days 
a week or engage in any other equivalent activity that they enjoy (Langer, 1993). 
Cardiovascular conditioning exercise for 20 minutes three times per week has also been 
shown to be useful in lowering both fasting and post-prandial glucose levels (Mulford et 
al, 1993). Exercise has a major effect on glucose metabolism and reduction in lipid levels 
(Peterson et al, 1991).
2.2.6 Oral Hypoglycemic Agents
Oral hypoglycemic agents play a limited role in diabetes in pregnancy. The main 
objection to their use in pregnancy is the fear of congenital anomalies or fetal 
compromise through direct stimulation of the fetal pancreas (Langer, 1993). Langer et al 
recently have reported that second-generation oral hypoglycemic agents (glyburide) do 
not cross the placenta. It suggests that second-generation hypoglycemic agents may play 
a role in the management of type II and GDM in the future (Langer, 1993).
2.2.7 Insulin Therapy
If diet and exercise do not achieve the requisite glucose levels (glucose levels < 4 . 4  
mmol/L or < 7.8 mmol/L 1 hour after meals), insulin therapy based on body weight and
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gestational age is required (Peterson et al, 1991). Insulin is generally discontinued at 
delivery (Peterson et al, 1991).
2.3 Complications of GDM
The rationale for treatment of GDM is to prevent diabetic complications. Poor glycemic 
control in early pregnancy is associated with an increased risk of major congenital 
abnormalities in the fetus (Gregory et al, 1992). In managing the pregnant diabetic 
patients, two patients are being treated, the mother and fetus (Lieb, 1987). Studies both 
in vivo  and in v itro  using animal models have provided data suggesting that 
hyperglycemia, hyperketonemia, and reduced glucolysis are, under certain conditions and 
circumstances, all potentially teratogenic, particularly when they occur in the earliest 
stages of pregnancy (Baird, 1986).
Most neonatal complications such as macrosomia, hypoglycemia, hyperbilirubinemia, 
hypokalaemia, polycythemia, major congenital anomalies (Hod et al, 1991), intra-uterine 
death, prematurity, and respiratory distress syndrome are readily avoided if GDM 
diagnosed and treated early and promptly (Lieb, 1987).
The adult female offspring of GDM mothers may exhibit impaired glucose tolerance and 
develop GDM when they become pregnant (Van Assche et al, 1991).
Obstetric management centers around surveillance to detect potential fetal compromise 
and the establishment of the proper time for delivery. Other goals are the diagnosis of 
fetal macrosomia and the avoidance of shoulder dystocia. Sudden fetal death, most 
likely is related to suboptimal metabolic control, is well documented in diabetic
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pregnancies, but is less likely in GDM (Coustan, 1993). Antepartum fetal surveillance 
should begin at 28 weeks gestation (Landon et al, 1985).
Goldman et al reported that polyhydramnios, pre-term labor, and pyelonephritis were not 
more frequent in GDM, but hypertension without proteinuria and pre-eclampsia were 
more frequent in GDM patients. Despite this, cesarean delivery was more common in 
GDM (Goldman et al, 1991).
2.4 Long-term Follow-up
Women with history of GDM are at increased risk for future development of NIDDM. 
Follow-up studies have estimated that 30-50% of these women develop diabetes during 
the first 3-5 years after a pregnancy complicated by GDM, which after 12-18 years the 
proportion is 60-100% (Gregory et al, 1993). For this reason, the American Diabetes 
Association (ADA) has recommended that at the first postpartum visit, subjects who 
have had GDM should have a standard 75g 2-hours OGTT.
The high prevalence of subsequent diabetes may serve to make women with previous 
GDM an ideal group on which to attempt interventions designed to prevent the 
development of diabetes in the future (Coustan, 1993).
Persson et al speculate that an elevated proinsulin / insulin ratio in women with previous 
GDM could be a marker for later development of NIDDM (Persson et al, 1991). The 
usefulness of this measurement in follow-up is unclear.
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2.5 Metabolic Changes in Normal Pregnancy and GDM
In normal pregnancy insulin secretion increases throughout gestation whereas peripheral 
insulin sensitivity is decreased. Fasting plasma glucose levels are decreased by 
approximately 10% during the first trimester. Maternal amino acid levels are also 
reduced.
On the other hand, plasma lipids are increased. As gestation advances, progressively 
increasing concentrations of insulin antagonistic hormones are secreted by the placenta 
(Reece et al, 1994). In addition, the fasting insulin/ glucagon ratio is increased in both 
normal and gestational diabetic pregnancy (Reece et al, 1994). Plasma total cholesterol, 
LDL-cholesterol, and triglyceride concentrations are higher in pregnancy compared with 
non pregnancy (Loke et al, 1991).
GDM patients exhibit an increased insulin response to oral glucose and amino acids 
during pregnancy when compared with the postpartum period (Kuhl et al, 1985). 
Fasting insulin concentration, plasma glucose, and free fatty acids are higher in obese 
GDM women compared with normal non-obese pregnant women, whereas 3- 
hydroxybutyrate levels are similar (Carpenter, 1993). Non-obese GDM patients have 
fasting insulin levels similar to non-diabetic pregnants. Fasting plasma glucagon is 
probably not increased in GDM.
Lipids and amino acids levels are significantly elevated in GDM subjects compared with 
normal control subjects (Carpenter, 1993). The postpartum fall in insulin sensitivity 
measured by the euglycemic clam technique is also more marked in GDM than in normal 
pregnancy (Carpenter, 1993).
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2.6 Metabolic Abnormalities in Women With Previous GDM
Considerable research has been done on GDM subjects during pregnancy in the last two 
decades.
Subjects with histories of GDM, particularly those with fasting hyperglycemia, are at 
high risk for developing subsequent overt diabetes mellitus (Metzger et al, 1985, Kjos et 
al, 1990).
Several follow-up studies have been conducted on the populations with previous GDM. 
Those indicated a high prevalence of overt diabetes mellitus years after the onset of 
GDM (Table 2-3) (Mestman, 1988).
Table 2-3 Follow-up studies on the GDM population (Mestman, 1988)
Author Total subjects Follow-up period 
(years)
Overt DM
O’Sullivan (1984) 615 22-28 25%
Stowers et al (1985) 112 22 7
Metzger et al (1985) 113 1 38%
Mestman et al (1972) 232 5 23%
On the other hand, Kjos et al (1991) have reported that lipid abnormalities are 
uncommon at 36 months postpartum in women with previous GDM and manifest 
predominantly as a mild elevation in the plasma TG level.
Our current understanding of the development of metabolic disorders in women with 
previous GDM until they develop diabetes mellitus is incomplete.
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2.7 Lipid and Lipoprotein Metabolism
GDM is a potentially serious disease. Evidence from autopsy, clinical, and 
epidemiological studies indicates that atherosclerosis more readily becomes advanced in 
diabetic than in non-diabetic subjects (Stout, 1992). A group of 89 women were studied 
12-18 years after the diagnosis of GDM. The results showed that the incidence of overt 
diabetes was 65.2%. 8.6% of the subjects who developed overt diabetes mellitus had 
had a cerebral vascular accident, 6.8% had suffered a myocardial infarct, and 3.4% were 
on dialysis therapy (Mestman, 1988).
Lipid and lipoprotein abnormalities have been implicated in the pathogenesis of 
atherosclerosis in both diabetic and non-diabetic individuals (Assmann et al, 1988, Stern 
et al, 1989). Kjos et al (1991) have studied women with recent GDM for a period of 36 
months after delivery. They have reported that plasma TG level was elevated and HDL­
C was decreased in women with previous GDM at 3-11 months after delivery but not 
thereafter (Kjos et al, 1991).
These findings prompted us to examine the lipid and lipoprotein levels of women with 
recent GDM, to determine whether they have lipid and lipoprotein profiles indicative of 
increased risk for atherosclerosis in particular hypercholesterolemia and 
dyslipoproteinemia (characterized by hypertriglyceridemia and low plasma HDL-C 
concentrations).
2.7.1 Endogenous and Exogenous Pathways of Lipoprotein Metabolism
Dietary lipids are transported from the intestine to the liver via the exogenous pathway 
(Figure 2-1), and lipids synthesised by the liver are transported from the liver to
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peripheral tissues via the endogenous pathway (Figure 2-2) (Trimble and McDowell,
1992).
Dietary cholesterol, mostly as cholesteryl ester, is absorbed in the intestine. Esters are 
hydrolyzed by cholesterol esterase to release free cholesterol and fatty acids. TG are 
hydrolyzed by pancreatic and intestinal lipase and absorbed mainly as free fatty acids and 
monoglycerides. TG, cholesterol, and apolipoproteins are assembled into chylomicrons, 
lipoprotein particles which are secreted into the lymph and enter plasma thorough the 





Figure 2-1 Exogenous pathway of lipoprotein metabolism 




Figure 2-2 Endogenous pathway o f lipoprotein metabolism 
(Trimble and McDowell, 1992)
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The exogenous pathway of lipoprotein metabolism (Figure 4-1) begins with secretion of 
chylomicrons by the intestine following absorption of dietary fat. Lipoprotein lipase 
(LPL) acts on chylomicron particles to produce chylomicron remnants. Chylomicron 
remnants are removed from plasma by the liver (Trimble and McDowell, 1992). The 
nature of the receptor is unclear (Trimble and McDowell, 1992).
The endogenous pathway of lipoprotein metabolism (Figure 4-2) begins with hepatic 
secretion of the triglyceride-rich lipoprotein (VLDL) into the plasma. This apoB-100 
containing lipoprotein is converted to IDL and subsequently to LDL in the plasma 
compartment.
In the process, the particles’ core is hydrolysed by lipolytic enzymes (Trimble and 
McDowell, 1992). Both of the major plasma lipolytic enzymes, lipoprotein lipase and 
hepatic lipase (HLP) have been implicated in the metabolism of apoBlOO containing 
particles. It seems that the affinity of LPL is higher for large triglyceride-rich lipoprotein 
particles than for smaller remnants, whereas HLP, which expresses both triglyceride 
lipase and phospholipase activities, seems to have higher affinity for smaller VLDL and 
IDL particles (Nicoll and Lewis, 1980).
CETP also is involved in these processes. LPL hydrolyses TG and CETP exchanges TG 
for cholesteryl ester from HDL.
Subsequently, LDL is cleared from plasma by the LDL receptor. Chemically modified 
LDL may be cleared by other pathways such as the scavenger receptor on macrophages 
Brown and Goldstein (1990) have suggested that the macrophage scavenger pathway 
may be involved in the formation of foam cells and initiation of the atherosclerosis
process.
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2.7.2 Cholesterol
Numerous epidemiological and genetic studies have shown that hyperlipoproteinemia, in 
particular hypercholesterolemia, is one of the principal risk factors for coronary heart 
disease (Douste-Blazy and Kloer, 1989).
2.7.3 Triglyceride
Primary and secondary hypertriglyceridemias (HTG) are the commonest lipid transport 
disorders found in patients obesity and diabetes mellitus (Eisenberg, 1987).
In obese individuals with upper body obesity appear to have a higher lipolytic activity 
adipocytes compared with obese subjects with peripheral obesity (fat distribution in the 
hips, buttocks, and thighs), resulting in a greater flux of FFAs toward the liver (Kissebah 
and Peiris, 1989). High FFA concentrations have been reported to decrease the hepatic 
extraction of insulin, resulting in systemic hyperinsulinemia (Kissebah and Peiris, 1989). 
HTG in obesity is associated with increase in the hepatic production of VLDL (Howard 
et al, 1987).
Hepatic lipase is an enzyme that contains triglyceride lipase, monoglyceride lipase, and 
phospholipase activity. Hepatic lipase catalyzes the degradation HDL particles, more 
specifically HDL2 (Tikkanen, 1989). Despres et al (1990 b) have suggested that LPL 
activity is decreased and hepatic triglyceride lipase activity is increased in abdominal 
obesity. Low LPL activity results in the reduction in the catabolic rate of TG-rich 
lipoproteins and high hepatic triglyceride lipase activity causes a reduction in plasma 
HDL2 concentration.
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Thus, hypertriglyceridemia and a low concentration of HDL-C, particularly HDL2, are 
common in abdominal obesity (Despres et al, 1990 a, Kissebah and Peiris, 1989, 
Despres, 1991).
The apo CIII gene is a part of a cluster with apo A-I and apo A-IV on chromosome 11, 
and variation in this cluster has been implicated in hypertriglyceridemia. Apo CIII has 
been suggested as candidate for a rate limiting mediator in the control of plasma TG 
levels since apo CIII inhibits LPL (Talmud, 1993). Whether other factors such as diet, 
alcohol consumption, obesity, smoking, exercise and oral contraceptive use significantly 
aggravate hypertriglyceridemia (NIH Consensus Conference, 1993) via increasing apo 
CIII activity is uncertain.
In western countries, plasma TG concentrations usually are inversely related to plasma 
HDL-C (Marmot, 1993). The PROCAM study has shown that plasma TG and LDL-C 
are independent predictors of coronary heart disease (CHD) incidence, but the predictive 
effect of TG for the development of CHD is observed only where the LDL-C/ HDL-C 
ratio is high (greater than 5) (Marmot, 1993).
The association of hypertriglyceridemia with premature atherosclerosis may not be due 
to the direct effects of the TG itself, but may be associated with changes in the 
concentration and composition of lipoproteins such as IDL, LDL and HDL.
HTG may result in an alteration in CETP activity which has an important role in lipid 
transport (Deckelbaum et al, 1984). The presence of an increased mass of circulating 
VLDL and chylomicrons promotes plasma lipid transfer activity with loss of cholesteryl 
ester from HDL and production of TG-enriched HDL particles. This TG-enriched HDL
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particle is susceptible to lipolysis by hepatic lipase resulting in further HDL degradation 
and the generation of smaller HDL3 particles (Tikkanen, 1989).
Postprandial hypertriglyceridemia may be more important than the high fasting TG 
levels, but little is known about this at present (NIH Consensus Conference, 1993).
2.7.4 Non-esterified Fatty Acids (NEFA)
In human, ~ 200 g of NEFAs (often termed free fatty acids) are mobilized from adipose 
tissue each day and transported in the circulation at concentrations ~ 100-1000 fold 
higher than their monomer solubility limit (Cistola and Small, 1991). They principally 
consist of oleic (about 38%), palmitic (28%), stearic (15%) and linoleic (9%) acids 
(Fruchart et al, 1989).
Solubilization and transport is mediated primarily by serum albumin. Albumin prevents 
the combination of fatty acids into liquid-crystalline or crystalline aggregates at neutral 
pH (Cistola et al, 1988) and supplies a source of fatty acid for lipid synthesis and energy 
production (Cistola and Small, 1991).
Under normal circumstances, approximately 99% of the circulating NEFAs are bond to 
serum albumin. However, cellular membrane and plasma lipoproteins have a high affinity 
for NEFAs and under some circumstances (eg high NEFA concentration in plasma) they 
may compete with albumin for NEFA binding (Cistola and Small, 1991).
In NIDDM patients, the action of insulin in both suppressing hepatic glucose output 
(HGO) and stimulating peripheral glucose uptake into skeletal muscle is impaired, and 
the combination of these defects is the principal cause of postprandial hyperglycaemia 
(Walker et al, 1993). In addition, the action of insulin in suppressing adipose tissue
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lipolysis and increasing re-esterification is impaired, leading to increased plasma NEFA 
levels and rates of lipid oxidation in the insulin-stimulated state in both obese and non­
obese patients with NIDDM (Walker et al, 1993).
Elevated plasma NEFA concentration in NIDDM may contribute to insulin insensitivity 
(Walker et al, 1993). Studies on rat liver have shown that NEFA stimulates 
gluconeogenesis (Williamson et al, 1966). An increased NEFA concentration in plasma 
diminishes the suppressive action of insulin on hepatic glucose output (HGO) and also 
decreases peripheral insulin-mediated glucose disposal in healthy man (Lee et al, 1988).
Glucocorticoid induced insulin resistance in normal rats has been shown to be due to 
excessive NEFA oxidation; possibly via an increase in the glucose-fatty acid cycle 
ultimately inhibiting glucose transport, or via decreased glycogen synthesis, or by a direct 
effect on glucose transporter translocation or activity (Guillaume-Genil et al, 1993).
2.7.5 VLDL
VLDL is the primary lipoprotein product of the liver and the carrier of endogenous 
triglycerides. Most of the TG in the plasma is carried in VLDL, whereas LDL carries 
most of the cholesterol (Chappell and Spector, 1991).
Because of the essential role played by VLDL in lipoprotein metabolism and substrate 
flux and the possibility that VLDL may (indirectly) induce atherosclerosis (Howard et al,
1987), its concentration was measured in this study.
2.7.6 IDL
Epidemiological studies in humans suggest that plasma concentration of IDL or remnant 
lipoproteins are predictors of the severity or progression of atherosclerosis.
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Nordestgaard and Tybjaery-Hassan (1992) have suggested that IDL or remnant 
lipoprotein concentrations were better predictors of the extent of atherosclerosis than 
were LDL or VLDL. Cholesterol-fed animals also demonstrate accumulation of IDL 
and rapid development of atherosclerosis (Nordestgaard and Lewis, 1991).
Analysis of human plasma by gradient gel electrophoresis (GGE) has shown the IDL 
fraction from normal subjects consist of two major subspecies with particle diameters in 
the range of 27.5 to 30.0 nm. The larger, usually predominant, subspecies has been 
designated IDL-1, and the smaller, IDL-2 (Musliner et al, 1986).
The IDL subfractions differ in their cholesterol enrichment, with IDL-2 being more 
cholesterol enriched than IDL-1. The plasma triglyceride level influences the 
predominant IDL subfraction present in the circulation. With higher plasma TG 
concentrations, IDL-1 is predominant and may facilitate lipid transfer by CETP action to 
a greater extent. Greater CETP activity is thought to result in the formation of smaller 
and denser LDL particles (Krauss, 1987).
2.7.7 LDL
In vivo  studies of the metabolism of human VLDL and IDL subfractions in a rat model 
system have suggested pathways for production of two of the major LDL subclasses, 
LDL-I and LDL-II. Small VLDL and the larger IDL species (IDL-1) are specifically 
converted by lipolysis in the absence of CETP activity to particles of size and density 
similar to LDL-II, while IDL-2 appears to be a precursor of larger, more buoyant LDL-I 
particle. However, it is not known how the two major, discrete IDL size subspecies 
originate (Musliner et al, 1991).
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Several studies in animals and in humans have shown that the preferential substrates of 
hepatic triglyceride lipase are chylomicrons and VLDL remnants (Nicoll and Lewis, 
1980). The decreased hepatic triglyceride lipase activity may results in the accumulation 
of IDL and the TG-enrichment of LDL (Robert et al, 1989).
Austin et al (1988) identified two distinct human phenotypes (denoted A and B) by non­
denaturing gradient gel electrophoretic analysis of plasma LDL. Phenotype A was 
characterized by predominance of large, buoyant LDL particles, and phenotype B by a 
major peak of small, dense LDL particles. Phenotype B appeared to be inherited as a 
single-gene trait with a dominant mode of inheritance (Austin et al, 1988), although later 
studies revealed a more complex picture.
Pattern A is defined as an LDL subclass pattern with the major gradient gel peak at a 
particle diameter of 25.5 nm or greater and the presence of a secondary peak of smaller 
LDL particles. Pattern B has the major peak at a particle diameter of less than 25.5 nm, 
with skewing of the curve toward larger particle diameters (Austin et al, 1988).
Later the same researchers reported that LDL subclass phenotypes are related to other 
lipoproteins and also apolipoproteins (Austin et al, 1990). Phenotype B is positively 
related to plasma TG and apoB levels, and VLDL and IDL mass. In addition, there is a 
negative correlation between phenotype B and HDL-C, HDL2 mass, and plasma apoA-I 
concentration (Austin et al, 1990).
LDL subclass phenotype B is related to relatively increased plasma TG, apoB, VLDL, 
and IDL concentrations, decreased HDL and plasma apoA-I levels, and increased risk of 
coronary artery disease in comparison with subjects with LDL subclass phenotype A 
(Feingold et al, 1992). It is possible, therefore, that the initial observation by Austin et al
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suggesting a single gene trait with dominant inheritace may need to be revised, in the 
light of these more complex associations.
2.7.8 HDL
HDL appears to be associated with ‘reverse cholesterol transport’, the delivery of 
peripheral tissue cholesterol back to the liver for recycling or for excretion from the body 
(Barter, 1993).
HDL appears to protect against the development of premature coronary atherosclerosis 
probably through the reverse cholesterol transport process (Miller and Miller, 1975). 
The Framingham Study has provided evidence that HDL-C is inversely related to the 
development of a myocardial infarction in both men and women (Miller and LaRosa,
1991). Elevated HDL levels have been shown to lead to regression of atherosclerosis in 
animal models (Johnson, et al, 1991).
In addition, Schmitz and Williamson (1991) suggested that HDL metabolism plays a 
major role in cell membrane protection. Another interesting reason for the anti­
atherogenic properties of HDL may be that HDL prevents the oxidation of LDL (Tribble 
and Krauss, 1993).
HDL3 is the major substrate for the esterification of plasma cholesterol by the enzymes 
CETP and LCAT, and therefore plays an important role in the transport of cholesterol 
through the plasma (Barter et al, 1985). The reason for the increased substrate reactivity 
of smaller HDL3 particles with LCAT is not clear.
Several hypotheses have been suggested, for instance that the phospholipid / FC and 
apoA-I / apoA-II ratios in same way affect substrate reactivity (Fielding et al, 1972).
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The increasing amount of CE in particles causes enlargement and enlargement may 
reduce their ability to act as substrate for LCAT (Fielding et al, 1972).
2.7.9 Lp(a)
Lp(a) was first reported in human plasma as a genetic variant of LDL by Berg in 1963 
(Berg, 1963). Like LDL, CE is the major constituent of Lp(a), but the particle contains 
more TG than LDL (Fless et al, 1986). Lp(a) particles contain two proteins, apo(a) and 
apoB, linked together by a single di-sulfide bond (Gaubatz et al, 1983). Apo(a) is 
thought to be synthesized mainly in the liver (Tomlinson et al, 1989).
Elevated plasma Lp(a) concentration is a risk factor for coronary artery disease (CAD) 
(Loscalzo, 1990) and peripheral vascular disease (PVD) (Widmann and Sumpio, 1993). 
James et al (1995) have suggested that Lp(a) concentrations greater than 30 mg / dl are 
independently correlated with vascular disease in IDDM and NIDDM patients.
Apo(a) seems to be little affected by age, sex, and diet (Nestel et al, 1993), although a 
recent study has reported that the apo(a) level was increased 25% by the trans fatty acid, 
elaidic acid in the diet (Nestel et al, 1993). Haffner et al (1992) reported that Lp(a) 
levels were significantly higher in diabetic patients who had higher total and LDL 
cholesterol levels.
Apo(a) levels are higher in both IDDM (Jenkins et al, 1991) and NIDDM (Jenkins et al,
1992) patients with microalbuminuria and may contribute to their tendency to 
macrovascular disease and early mortality. Apo(a) is elevated in active diabetic 
retinopathy (Maioli et al, 1993) and renal failure (Black and Wilcken, 1992). Whether 
elevated Lp(a) is a consequence or a cause of diabetic microvascular disease need further 
study (Jenkins et al, 1992).
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The physiological functions of apo(a) or Lp(a) are not clear. The structural homology of 
Lp(a) with LDL and plasminogen suggests that Lp(a) may be involved in both atheroma 
formation and thrombosis which are most important mechanisms in the pathogenesis of 
atherosclerosis (Campbell et al, 1992). Lp(a) may promote thrombosis through 
interference with plasminogen activation, but it does not interfere with thrombolytic 
therapy during acute myocardial infarction (Simons, 1993).
2.7.10 CETP
Human plasma contains a lipid transfer protein commonly called cholesteryl ester transfer 
protein (CETP). CETP facilitates the transfer of cholesteryl ester, triglyceride, and 
phospholipid among lipoproteins (Albers et al, 1990). The major function of CETP in 
human plasma is believed to be the transfer of LCAT-derived cholesteryl ester to 
lipoprotein acceptors, LDL, VLDL, or lipoprotein remnants. During this process, the 
acceptor lipoproteins donate triglyceride and phospholipid to HDL. Thus, CETP play a 
key role in the ’reverse cholesterol transport’ pathway (Albers et al, 1990).
HDL cholesteryl ester also can be delivered to the liver by other mechanisms such as 
selective uptake of CE from HDL without particle endocytosis, and uptake of CE 
mediated by apoE on the hepatocyte membrane (McPherson, 1993).
A diet high in cholesterol content increases the plasma CETP concentration in man 
(Martin et al, 1991). Marcel et al (1990) reported that the levels of CETP are 25% 
higher in women compared with men.
CETP is synthesized in a number of tissues, mainly in the liver and adipose tissue 
(McPherson, 1993).
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2.7.11 Apolipoproteins A-I and B
In patients with coronary heart disease, total plasma apoB levels is often significantly 
elevated in the presence or absence of a reduction of total plasma apoA-I (Douste-Blazy 
and Kloer, 1989).
Many studies have reported that plasma apolipoprotein A-I, the major protein of HDL, is 
a good negative predictor for coronary heart disease (Fruchart, 1990).
These are at least two main lipoprotein subclasses containing apo A-I: those which 
contain, as the main protein components apoA-I and apoA-II, designated Lp A-I:A-II, 
and those contain apoA-I but not apoA-II, designated Lp A-I (Fruchart, 1990). These 
subclasses can be separated immunochemically.
Fruchart et al recently reported that cholesterol efflux from cells is mediated by Lp A-I 
and not by Lp A-IiA-II, and that the lower HDL concentrations in coronary artery 
disease were linked with lower Lp A-I levels, while Lp A-LA-II was unchanged 
(Fruchart et al, 1990).
2.8 Carbohydrate Metabolism
2.8.1 Factors Influencing Rates of Glucose Uptake
There are three major sources of plasma glucose (Figure 2-3), diet and hepatic 
gluconeogenesis and glycogenolysis (Owen et al, 1969).
Several factors influence the rate of glucose uptake. These are: plasma glucose level, 
free fatty acids, muscular work, and hormonal effects. A high concentration of available
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NEFA will result in a decrease in the rate of glucose uptake by skeletal and cardiac 
muscle at any given level of insulin (Randel et al, 1963).
2.8.2 Insulin
Insulin is secreted by the pancreas. Insulin acts in two major ways: (1) it has a key role 
in the metabolism of carbohydrate, lipid, and proteins, and (2) it has growth-promoting 
effects on DNA synthesis, cell division, and cell differentiation (Vander et al, 1994 c).
Insulin and glucagon play a major role in the regulation of glucose homeostasis. Insulin 
stimulates anabolic processes and favours energy storage, whereas glucagon stimulates 
catabolic processes, which consume energy substrates. Thus, their effects on 
glyconeogenesis, glycogenolysis and gluconeogenesis are opposed, and their activities in 
relation to these multi-enzyme systems are complex (Freychet, 1990).
The major sites of action of these hormones are the liver, adipose tissue, and skeletal 
muscles. Insulin and glucagon act via specific membrane receptors in their target cells 
(Freychet, 1990).
2.8.3 Glucose Tolerance
Glucose tolerance, as estimated by the oral glucose tolerance test (OGTT), depends
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Sources
Figure 2-3 Sources and sinks for plasma glucose (Steinberg, 1990)
on complex iteration among several physiological processes, including first-phase and 
second phase insulin secretion, insulin removal, insulin sensitivity, and the tendency of 
high glucose concentration (independent of insulin) to increase glucose utilisation 
(Martin et al, 1992). Subjects with insulin resistance may be euglycemic with normal 
blood glucose concentrations, maintained by hypersecretion of insulin. In these case,
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hyperinsulinemia may be noted both in the fasting and postprandial states (Beck-Nielsen 
et al, 1990).
The risk of subsequent glucose intolerance or diabetes in women with previous GDM is 
related to pre-pregnancy body mass index (BMI) and fasting plasma glucose during 
pregnancy (as well as current BMI). Subjects who are fatter before pregnancy and 
whose plasma glucose concentrations are higher during pregnancy are more likely to 
develop glucose intolerance or diabetes during pregnancy and/or after delivery (Coustan 
et al, 1993).
Effendic et al have reported that 60% of normal weight women with previous GDM had 
borderline or decreased oral glucose tolerance 6-36 months postpartum which could be 
explained either by low insulin response or by the combination of a low insulin sensitivity 
and low insulin response (Effendic et al, 1987).
2.8.4 Insulin Resistance
Insulin resistance may be defined as a state (of a cell, tissue, system or body) in which 
more than normal amounts of insulin are required to draw out a quantitatively normal 
response (Berson and Yalow, 1970). It should be emphasised that the level of glycemia 
may be within the normal range in a person with insulin resistance as a result of 
compensatory hyperinsulinemia (Flier, 1993).
During last two decades, several possible mechanism have been suggested for the 
pathogenesis of insulin resistance.
The classification of insulin resistance:
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(1) Circulating anti-insulin antibodies and excess insulin degrading enzymes have been 
suggested, but those have not been shown to be important causes.
(2) A primary (ie. genetically determined) defects in the ability of insulin to signal its 
target cells (ie. receptor mutations) is again not an important cause.
(3) The major category of mechanisms for insulin resistance involves post-receptor 
mechanisms. These include the mediation of local or circulating factors on target cells to 
increase resistance to one or more pathway of insulin action. This category may include 
primary genetic defects and cellular consequence of metabolic changes (Flier, 1993).
2.8.5 Insulin Resistance Syndrome
Insulin resistance is a common and multifaceted syndrome which occurs with high 
frequency in the general population. Much attention has recently been focused on the 
insulin resistance syndrome, also referred to as ‘syndrome X ’. The syndrome of insulin 
resistance may include a cluster of several common metabolic disorders: 
hyperinsulinemia, obesity, NIDDM, hypertension, dyslipidemia, and as a complication of 
these, atherosclerotic vascular disease (DeFronzo and Ferrannini, 1991). Central obesity 
also has been added to the cluster (Zammet, 1989).
The evidence suggests that hyperinsulinemia plays a major role in the development of the 
features of syndrome X. While hyperinsulinemia appears to be crucial for the 
development of syndrome X, it must usually develop secondary to a decrease in insulin 
sensitivity. In terms of etiology, therefore, a decrease in insulin sensitivity may be the 
primary event in syndrome X (Walker and Alberti, 1993).
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Insulin sensitivity has been shown to vary considerably in the normal population and be 
influenced by many different factors such as dietary composition and intake, physical 
activity, and endocrine status (Walker and Alberti, 1993).
Studies have suggested that genetic factors also may play role in the development of 
insulin insensitivity and hence syndrome X. Studies on the Pima Indian have shown that 
insulin resistance in this population may be due to an important genetic effect related to 
the fatty acid binding protein gene on chromosome 4 (Prochazka et al, 1992). In 
addition, studies on persons with a positive family history of diabetes in first degree 
relatives have suggested that these persons have insulin resistance which probably has a 
genetic basis (Eriksson et al, 1989).
Thus, it seems the likely sequence is that a combination of both environmental and 
genetic factors influence the overall insulin resistance state, then hypednsulinemia occurs, 
and then phenotypic features of syndrome X occur (Walker and Alberti, 1993).
NIDDM is the disease classically associated with insulin resistance (Seely and Olefsky,
1993). Impaired glucose tolerance is a common clinical feature in all types of insulin 
resistance syndrome and hyperinsulinemia occurs in compensation for this defect in 
affected subjects (Moller and O’Rahilly, 1993).
2.8.6 HbAlc
Haemoglobin can combine non-enzymatically with glucose, and the haemoglobin 
conjugate, haemoglobin A le, can be measured in blood. It increases in concentration 
roughly in proportion to the degree of sustained hyperglycaemia and is used clinically as 
a tool to indicate the degree of control of the hyperglycaemia in people with diabetes 
(Steinberg, 1990).
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Other plasma proteins and a number of tissue proteins are also glycated in diabetes. 
Whether such glycation of proteins contributes to clinical complications is still not clear 
(Steinberg, 1990).
The Framingham Heart Study has reported that the plasma HbAlc levels are significantly 
above normal in non-diabetic women with an early cardiovascular event (Singer et al,
1992).
Giugliano et al (1992) also reported a significant correlation between HbAlc and classic 
risk factors of cardiovascular disease such as hypertension, and cholesterol in diabetic 
patients.
2.9 Raised Blood Pressure
Hypertension is defined as a chronically elevated systemic arterial pressure. The dividing 
line between normal blood pressure and hypertension is an arbitrary one, set at 
approximately 140 /90  mm Hg.
Hypertension may be due to increased total peripheral resistance or increase in cardiac 
output or both. Increased total peripheral resistance may be the result of increased 
arteriolar constriction (Vander et al, 1994 b). About 95% of people with hypertension 
have essential hypertension (primary hypertension) in that the cause of hypertension is 
unknown (Ross, 1990).
2.9.1 Essential Hypertension and Insulin Resistance
The association between NIDDM, obesity, and essential hypertension has been known 
for many years (Kannell and McGhee, 1979, reporting data from the Framingham Heart
Study).
Chapter Two Literature Review 40
Others have linked high blood pressure to insulin resistance. Modan et al reported that 
postprandial insulin concentrations were higher in both treated and untreated 
hypertensive patients than in normotensive controls. This finding was independent of the 
presence of obesity and diabetes (Modan et al, 1985). Parillo et al reported greater 
serum insulin and glucose levels 60 to 180 minutes after a glucose tolerance test in 
hypertensive patients than in controls (Parillo et al, 1988).
The CARDIA study reported that high fasting insulin concentration was associated with 
elevation in both systolic and diastolic blood pressure in 5115 participants, aged 18-30 
years, of different sex, race, and education levels. The strength of these associations 
decreased (but the association were still significant) after adjustment for age, sex, race, 
BMI, alcohol consumption, smoking, physical activity, and exercise (Manolio et al,
1990).
Studies on hypertensive subjects using the euglycemic hyperinsulinémie clamp and 
minimal model techniques indicated that the increased insulin levels are a compensatory 
response to impaired insulin-stimulated glucose uptake (Ferrannini et al, 1987, Pollare et 
al, 1990).
Istfan et al (1992) have reported that obese hypertensive subjects had greater insulin 
resistance compared with obese non-hypertensive subjects. It is thought that the 
relationship between primary hypertension and insulin resistance is independent of 
obesity (Pollare et al, 1990).
The association between insulin resistance and high blood pressure has not been 
determined in all populations. Insulin level was correlated with blood pressure in young 
Caucasians but not in a black American population or in the Pima Indians (Saad et al,
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1991). Pima Indians have a higher prevalence of insulin resistance and hyperinsulinemia 
than other American (non- Indian American) populations but not a higher prevalence of 
hypertension (Saad et al, 1991).
It should be emphasized that the relationship between hyperinsulinemia and high blood 
pressure is not found in renal disease. Hypertension secondary to renal disease is not an 
insulin resistant state and is not associated with hyperinsulinemia (Marigliano et al, 
1990).
An abnormal lipoprotein profile has been demonstrated in patients with essential 
hypertension similar to the dyslipidemia of diabetes (hypertriglyceridemia and a low level 
of HDL-c) (Shieh et al, 1987), suggesting that a number of patients with essential 
hypertension, in fact, have hypertension associated with the insulin resistance syndrome.
It is not known whether hyperinsulinemia is a cause of high blood pressure or is 
secondary to high blood pressure, or if both hyperinsulinemia and high blood pressure 
result from other factors. Shen et al reported that the reduction of blood pressure in 
hypertensive subjects is not related to normalisation of the plasma insulin levels (Shen et 
al, 1988), suggesting that hyperinsulinemia may be a causal factor for high blood 
pressure, or both may be caused by another factor or factors.
2.10 Microalbuminuria
Qualitative and quantitative analyses of urinary protein excretion are used to diagnose 
renal disease. A urinary albumin excretion rate (UAER) of 200 |ig / min termed 
microalbuminuria (Jensen et al, 1993).
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The UAER is increased in variety of renal and urinary tract diseases. UAER also 
appears to be elevated after prolonged upright posture and vigorous muscular exercise 
(Waller et al, 1989).
2.10.1 Pathophysiology of Microalbuminuria
Healthy adults normally excrete small amounts (less than 150 mg / day) of protein in the 
urine including mainly albumin and Tamm-Horsfall protein. Excretion of greater than 
150 mg / day is termed proteinuria (Wilson, 1992).
Increased protein excretion may happen whenever there is an increased filtered load 
secondary to an increase in glomerular permeability (glomerular proteinuria), an increase 
in the plasma concentration of a protein (overflow proteinuria), or an increase in 
glomerular filtration rate (GFR).
Proteinuria will also result from a decrease in the tubular absorption of normally 
absorbed proteins (tubular or low molecular weight proteinuria) or an increase in protein 
secretion or non-specific addition of protein to the fluid in the urinary tract such as 
increase in secretory IgA during inflammation (urogenic or secretory proteinuria) 
(Beetham and Cattell, 1993).
Albuminuria associated with diabetes is usually a consequence of increased glumerular 
permeability. Diabetic nephropathy evidenced by hypertension, macroalbuminuria, and 
renal dysfunction, develops in about 40% of IDDM patients approximately 10-20 years 
after the onset of disease (Harris et al, 1987, Selby et al, 1990) and also in 25% of 
NIDDM patients 5-10 years after their diagnosis (Selby et al, 1990).
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The pathogenesis of diabetic nephropathy is not completely clear. The relative 
contributions of hypertension, dietary protein, glucose control, dyslipidemia and other 
factors in the initiation and continuation of renal injury are not fully known. Strict blood 
pressure control and protein restriction are important treatment strategies in both early 
and established diabetic kidney disease (Carella et al, 1994). More than 25% of all cases 
of end-stage renal disease in the United Statesare due to diabetes mellitus (Krolewski et 
al, 1985).
Microalbuminuria independently predicts decrease in renal function (Mogensen, 1986) 
and atherosclerotic cardiovascular disease in diabetic patients (Messent et al, 1992). It 
occurs before overt nephropathy in both IDDM (Harris et al, 1987, Selby et al, 1990, 
Mogensen and Christensen, 1984) and NIDDM (Harris et al, 1987). Microalbuminuria is 
thus considered to be a predictor for the development of nephropathy (Harris et al, 1987, 
Selby et al, 1990, Mogensen and Christensen, 1984).
The Pittsburgh Epidemiology of Diabetes Complications Study (PEDCS) suggested that 
glycémie control, age or duration of IDDM, dyslipidemia, and possibly hypertension all 
may contribute to the development of microalbuminuria. In addition, PEDCS proposed 
that the adverse cardiovascular risk profile exist in subjects with overt nephropathy may 
begin to develop even before the discovery of microalbuminuria (Coonroo et al, 1993).
2.11 Obesity and Androgen Status
2.11.1 Obesity
Obesity is a major problem for developed nations, affecting approximately 10-50% or 
more of the adult population (Bray, 1985). A useful measure of obesity is the body mass 
index (BMI), which is the weight in kilograms divided by the height in meters squared
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(kg/m ) (Redmond, 1991). Obesity is associated with premature mortality, morbidity, 
and social disadvantage (Pi-Sunyer, 1991).
The reference range for BMI is 20 to 25 kg/m2 for men and 19 to 24 kg/m2 for women. 
Above 25 kg/m2 for men and 24 kg/m2 for women is considered ‘overweight’ and above 
30 kg/m2 for both men and women regarded as ‘obese’ (Egger, 1992). According data 
from the National Heart Foundation Risk Factor Prevalence Survey in Australia (No 3, 
1989), approximately 48% of men and 34% of women aged 20-69 years have a BMI 
more than 25 kg/m2 (Calvert, 1991).
The health risks of obesity increase with its severity and reach significance at a weight > 
20% above optimal weight in individuals. Mortality risk begins to increase when the 
BMI exceeds 30 in adults (Redmond, 1991).
2.11.1.1 Classification
Obesity can be classified into categories. The most common classification divides 
subjects into two categories: upper body (android) and lower body (gynoid) obesity 
(Kissebah et al, 1989). Subjects with upper body obesity present a higher waist / hip 
ratio (WHR), increased deposition of mesenteric or visceral adipose tissue, 
hyperinsulinemia, with greater insulin resistance, and dyslipidemia in comparison with 
subjects with lower body obesity (Kissebah et al, 1989).
Abdominal obesity may be calculated by subscapular / triceps skinfold ratio (Centrality 
Index) or waist / hip ratio (WHR). WHR has been suggested as an independent risk 
factor for several diseases (ie diabetes mellitus, hypertension, cardiac events stroke, 
dyslipidemia, varicose veins, and arthritis), and also for mortality. WHR of more than
0.9 in males and 0.8 in females should be taken as representing increased risk (Egger,
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1992). Kalkhoff et al (1983) suggested that women with WHR = 0.83-0.99 should be 
considered to have upper body segment obesity and women with WHR = 0.50-0. .73 
should be considered to have lower body segment obesity.
Recently, Fujioka et al (1987) have proposed that there are two different types of obesity 
with respect to metabolic and clinical features: one is the ‘visceral type’, characterised by 
marked fat accumulation in the abdominal cavity and an association with metabolic 
alterations such as glucose intolerance, hyperlipidemia, and the other one is the 
‘subcutaneous type’ in which fat accumulates predominantly in the subcutis and is rarely 
associated with metabolic disorders.
Both men and women with abdominal subcutaneous or visceral obesity tend to have 
large fat cells, increased LPL activity, increased lipolysis, and low antilipolytic effect of 
insulin.
High plasma sex steroid, glucocorticoid, catecholamine, and growth hormone 
concentrations are associated with the amount of visceral fat, and the association may be 
somewhat different in men and women (Bouchard, 1994)
2.11.1.2 Pathophysiology of Obesity
The causes of obesity are multiple. Energy expenditure is an important factor in 
determining weight gain or loss. Daily energy expenditure can be divided into three 
major components: basal metabolic rate, which represents 50-70% of daily energy 
expenditure, the thermic effect of food which represents about 10%, and the energy cost 
of physical activity which represents 20-40% of daily energy expenditure (Ravussin and 
Swinbum, 1992).
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Dietary factors play an important role in the regulation of body weight. Diets high in fat, 
sugar, or both are the most effective promoter of obesity in animal investigations 
(Sclafani, 1986, Lucas and Scla fani, 1990).
In addition, the endocrine system plays an important role in the etiology and maintenance 
of obesity. Abnormalities in insulin secretion and function are probably the most 
important factors in metabolic changes in the obese subjects (Heber, 1994).
2.11.1.3 The Role of Obesity in the Pathogenesis of Diabetes Mellitus
The relationship between obesity and insulin resistance and NIDDM is very complex. 
Most patients with NIDDM are obese. Fujioka et al (1987) have reported that the 
fasting plasma glucose and area under the plasma glucose concentration curve after oral 
glucose loading (plasma glucose area) were significantly greater in obese than non-obese 
patients.
Subjects with excess intra-abdominal (visceral) fat have more insulin resistance related to 
obesity (Bjomtorp, 1989). Abdominal obesity is considered as a risk factor for the 
development of insulin resistance and its metabolically related abnormalities (Bjorntorp, 
1990).
2.11.2 Androgen Status
Sex-hormone-binding globulin (SHBG) is a steroid-binding globulin which binds to 
oestradiol and testosterone. In normal women, about 65% of the circulating testosterone 
is tightly bound to SHBG, while most of the remaining hormone is loosely bound to 
albumin. Only 1-2% of the total testosterone is free. It is generally accepted that
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testosterone bound to SHBG is not readily available to intracellular androgen receptors 
in target tissues and thus has little biologic activity (Goldfien and Monroe, 1994).
Women with overall or central obesity exhibit a lower plasma SHBG (Lindstedt et al, 
1991, Haffner et al, 1991). SHBG shows a much higher affinity to testosterone than 
oestradiol and therefore any changes in SHBG concentrations cause a greater change in 
the free testosterone fraction than the free oestradiol fraction (Reed et al, 1993).
Some studies have reported that low plasma levels of SHBG and central obesity are 
correlated with higher plasma concentrations of free testosterone (Haffner et al, 1989). 
Thus, a low plasma concentration of SHBG results in hyperandrogenicity in women 
(Rosenfield, 1975).
Preziosi et al (1993) found a significant and negative relationship between SHBG and 
insulin level in healthy pre-menopausal and post-menopausal women. This relationship 
was independent of age, BMI, subscapular skinfold, and fasting and 2-h plasma glucose.
Studies have shown that excess sex steroid and glucocorticoid concentrations in the body 
may be associated with regional fat distribution (upper body segment) and related 
metabolism disorders and have suggested that this relationship may be causal (Kissebah 
et al, 1989). Hyperandrogenicity may decrease insulin sensitivity in pre-menopausal 
women (Evans et al, 1983).
Tikkanen and Nikkila (1987) have reported that sex steroids demonstrate significant 
effects on lipoprotein metabolism. Steroids with androgenic activity increase hepatic 
triglyceride lipase activity and decrease plasma HDL2-C levels. This phenomenon was 
also reported in obese women with a high abdominal adiposity (Despers et al, 1989).
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2.12 Haemostatic Disorders
Diabetes mellitus is a common endocrine disease which exhibit an increased risk of 
atherosclerosis. The classic risk factors predict only 30% of all cardiovascular events 
(Heller et al, 1984). Several prospective epidemiological investigations suggest that 
plasma fibrinogen concentration is an independent cardiovascular risk factor (Meade et 
al, 1986, Kannel et al, 1987, Yarnel et al, 1991, Resch et al, 1992).
2.12.1 Fibrinogen
The Framingham Study has reported that fibrinogen levels independently are associated 
with cardiovascular disease and increase with age in both women and men (Kannel et al, 
1987, Wilhelmsen et al, 1984).
Plasma fibrinogen concentration seems to be related to hyperlipoproteinemia, 
hypertension, smoking, and several life style factors such as dietary habits (Koenig and 
Ernst, 1992). Several studies have reported that the fatty acid composition of the dietary 
lipids is an important factor in the athero-thrombotic process (Berg-Schmidt et al, 1990, 
Grundy and Denke, 1990). Cigolini et al (1994) examined the fatty acid composition of 
adipose tissue as an objective index of dietary fat intake in healthy men and they found 
no correlation between fibrinogen level and adipose tissue fatty acids.
Baxter et al (1988) suggested hyperfibrinogenemia may be an important risk factor for 
peripheral arterial disease in men. Cigolini et al (1994) suggested that
hyperfibrinogenemia may be considered as an integral part of syndrome X and that it may 
contribute along with impaired fibrinolytic activity to a ‘procoagulanf state.
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The exact mechanism underlying hyperfibrinogenemia and risk of CHD is not clear. 
There are several hypotheses. Hyperfibrinogenemia can adversely influence platelet 
aggregability and plasma viscosity, and thus predispose (perhaps) to thrombosis. In 
addition, atherosclerosis can cause hyperfibrinogenemia as fibrinogen is an acute-phase 
protein (Heinrich et al, 1994).
2.12.2 Factor VII
Factor VII is a vitamin K-dependent glycoprotein with a molecular weight of 50,000 
dalton composed of a single polypeptide chain, synthesized in the liver. The 
physiologically important activator of factor VII is factor Xa which, in the presence of 
calcium and phospholipids, rapidly converts factor VII to factor Vila. In the presence of 
thromboplastin, factor V ila activates factor IX and factor X very rapidly. The coagulant 
pathway proceeds, ending in the production of thrombin (Vander et al, 1994 d). Figure 
9-1 shows the classical view of the intrinsic and extrinsic pathways of the clotting 
cascade in humans (Vander et al, 1994 d).
Factor VII levels increase with age in both men and women, and may be higher in 
women. Factor VII levels increase in late pregnancy, with use of oral contraceptives, 
obesity, and in post-menopausal women (Bloom and Thomas, 1987, Poller et al, 1990).
Factor VII coagulant activity is also increased in hyperlipidemia (Miller et al, 1985), 
diabetes (Fuller et al, 1979), and with high dietary fat intake (Miller et al, 1986).
High levels of factor VTIc have been shown to be associated with ischaemic heart disease 
in men (Meade et al, 1986, Wilhelmsen et al, 1984). Increased factor VII levels have 
been reported in NIDDM patients with microalbuminuria and cardiovascular disease 
(Stehouwer et al, 1992).
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INTRINSIC PATHWAY EXTRINSIC PATHWAY
Figure 2-4 Classical view o f two independent pathways (intrinsic and extrinsic), leading 
to the generation o f thrombin (Vander et al, 1994 d)
Ceriello et al (1988) suggested that the plasma factor VII levels may be directly raised by 
high blood glucose in diabetic and normal subjects. On the other hand, Schernthaner et 
al (1989) showed that an altered haemostatic status (high plasma fibrinogen and factor 
VII) may not be completely corrected by better glycaemic control.
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2.12.3 Von Willebrand Factor (vWF)
vWF is a complex glycoprotein synthesized by vascular endothelium (Bloom et al, 1973) 
and megakaryocytes (Nachman et al, 1977).
The initial response to blood-vessel damage is vasoconstriction and this is facilitated by 
formation of a platelet plug, then blood coagulation in the damaged blood vessels. vWF, 
secreted by the endothelial cells, is necessary for platelet aggregation (Vander et al, 1994 
d).
High plasma levels of vWF, indicating endothelial cell dysfunction, have been found in 
diabetic patients with retinopathy (Stehouwer et al, 1992, Porta et al, 1987, Coller et al, 
1978). In addition, Silveira et al (1992) have suggested that abnormal degradation of 
vWF occurs in kidneys in IDDM patients with and without nephropathy.
The role of vWF in the pathogenesis of diabetic nephropathy is not clear. It is probably a 
marker of endothelial dysfunction, without being directly involved in the pathogenesis of 
diabetic nephropathy. Alternatively, vWF may stimulate adhesion of platelets to exposed 
subendothelium in the kidney (Stehouwer et al, 1991).
Cross-sectional studies have suggested that raised plasma factor VIII and vWF level is 
associated with clinical coronary artery disease (Sugrue et al, 1985). However, Myreng 
et al (1986) and Hamsten et al (1986) have reported no correlation between plasma vWF 
level and either clinical or angiographical findings of coronary artery disease.
Chetty et al (1988) found that race is a major determinant of vWF and factor VIII. 
Black people in the USA have higher factor VIII and vWF levels than whites.
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Numerous studies have suggested that coagulation disorders in diabetic patients, which 
seem to be caused by hyperglycaemia (Ceriello, 1993), give rise to a thrombotic 
tendency.
High levels of plasma fibrinogen (Coller et al, 1978, Ganda and Arkin, 1992), factor VII 
(Ceriello et al, 1988), factor VIII, vWF (Osterman and Va-deLoo, 1986), factor X 
antigen and low activity of factor X in plasma (Ceriello et al, 1990) have been reported in 
diabetic patients and thought to be due to hyperglycaemia.
Figure 2-5 shows the pathway linking hyperglycaemia and a tendency to thrombosis in 
diabetic patients. Hyperglycaemia may influence thrombosis by two mechanisms; either 
by a mechanism connected with non-enzymatic glycation or by an increased oxidative 
reaction (Ceriello, 1993).
Figure 2-5 Pathway linking hyperglycaemia and thrombosis in diabetes mellitus. 
(+ = increased and -  = decreased, Adapted from Ceriello, 1993).
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2.13 Dietary Habits and Other Lifestyle Factors
2.13.1 Dietary Habits
Recently, there has been much interest in elucidating the underlying links between 
NIDDM and genetics, obesity, nutrition, physical activity, and other factors. Diet plays a 
significant role in determining plasma concentrations of TG, cholesterol, TG-rich 
lipoproteins, and also HDL-C.
The relationship between lipids and lipoproteins and atherosclerosis also encourages 
investigators to pay more attention to dietary factors related to disease.
2.13.1.1 Dietary Fat and Blood Lipids and Lipoproteins
The type and amount of fat in the diet influences blood lipid and lipoprotein 
concentrations. Keys et al (1965) have shown that dietary polyunsaturated fatty acids 
decrease and saturated fatty acids increase total plasma cholesterol concentrations. 
However, the mono-unsaturated oleic acid and saturated stearic acid are neutral. Many 
researchers have reported that monounsaturated fatty acids have no significant influence 
on serum cholesterol concentrations (Thomson et al, 1967, McGandy and Hegsted, 
1975).
Grundy and Denke (1990) recently reported that only saturated fatty acids with chain 
lengths of 12, 14, and 16 carbon atoms in the diet increase total plasma cholesterol levels 
mainly by elevating the LDL levels, and the other fatty acids (such as stearic acid) have 
less effect on plasma LDL levels. Both polyunsaturated and monounsaturated fat reduce 
LDL levels when replacing saturated fat (Grundy and Denke, 1990).
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The plasma TG concentrations change with diet. Postprandially, the plasma TG 
concentration increases due to the appearance of chylomicrons and their remnants in 
plasma. The concentration of TG depends on both the amount and the type of fat in the 
diet. Saturated fat in the diet produces a longer postprandial plasma triglyceride than 
polyunsaturated fat. The type and amount of fat in the diet also influence the fasting 
levels of TG, mainly by increasing the concentrations of VLDL (Norum, 1992).
The fasting TG concentration in plasma decreases when monounsaturated fat is 
substituted for carbohydrates (Grundy, 1986). Polyunsaturated fatty acids (n-6 type) 
also decrease the fasting TG concentrations in plasma (Chait et al, 1974).
Diet affects LPL activity. In the fasting state the LPL activity increases in muscle, 
however, in the postprandial state, the activity increases in adipose tissue. The activity 
of LPL seems to be mediated by insulin and the insulin sensitivity of the muscle and 
adipose cells (Kiens et al, 1989).
Dietary unsaturated fatty acids tend to cause larger chylomicrons than saturated fatty 
acids intake (Ockner et al, 1969 and Ockner and Jones, 1970). Larger chylomicrons are 
cleared from plasma faster than smaller chylomicrons.
Saturated fatty acids in the diet increase the plasma VLDL concentrations. However, 
dietary fish oil decreases the plasma VLDL concentration resulting a small effect on 
plasma cholesterol (Harris, 1989, Sullivan et al, 1986). The main effect of marine fish oil 
on plasma lipids is a reduction in plasma TG level (Sanders, 1987, Schmidt et al, 1993). 
The proposed mechanisms for the VLDL-lowering effect of fish oil might be due to 
reduced plasma FFA concentrations resulting from decreased peripheral lipolysis of TG 
(Singer et al, 1990), increased oxidation of fatty acids in the liver, or because saturated
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and monosaturated fatty acids stimulate VLDL synthesis and n-3 polyunsaturated fatty 
acids do not have this effect (Harris et al, 1990, Dixon et al, 1991). In addition dietary 
marine fish oil tends to increase HDL-C (Schmidt et al, 1993).
LDL concentration is increased by using saturated fats in the diet, probably through 
effects on hepatic LDL receptors (a decrease in LDL receptor activity and thus a 
reduction in the LDL catabolism rate), but the mechanism is not clear (Norum, 1992). 
Dietary fatty acids do not appear to alter the rate of plasma cholesterol synthesis. 
Alteration in the plasma cholesterol concentrations may be due to an increase in the 
output of faecal neutral sterols and of faecal bile acids (Durrington, 1995).
On the other hand, saturated fat in the diet tends to produced smaller VLDL particles 
than polyunsaturated fat. It seems that smaller VLDL particles are more prone to 
convert to LDL particles than large VLDL particles are. This may be a possible 
mechanism underlying increased LDL levels by using saturated fat (Norum, 1992).
Bonanome et al (1992) have found that a diet rich in monounsaturated fatty acids 
(MUFA) compared with polyunsaturated fatty acids increases the resistance of plasma 
LDL to oxidative modification, independent of their content of antioxidant. This effect 
might lower the atherogenicity of these lipoproteins.
Thus, a low fat, monounsaturated fatty acid-rich diet is as effective as a low fat, 
polyunsaturated fatty acid rich diet in lowering total and LDL-C, but both also lower 
HDL-C concentrations (Wahrburg et al, 1992). Wahrburg et al (1992) suggested that 
the monounsaturated fatty acid-rich diet may be more advantageous than the 
polyunsaturated fatty acid-rich diet because it does not lower plasma apoA-I 
concentration as much as the polyunsaturated fatty acid rich diet.
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Because of the anti-atherogenic effect of HDL-C, the effect of dietary fat on HDL-C has 
been investigated intensively. Diets low in fat cause both low plasma HDL and LDL 
concentrations, however a diet high in saturated fat results in high HDL and LDL 
concentrations. Dietary polyunsaturated fat, but not monounsaturated fat, leads to lower 
HDL-C levels (Grundy and Denke, 1990).
Animal studies have suggested that a diet rich in cholesterol and saturated fat (an 
atherogenic diet) enhances the plasma CETP activity (Stein et al, 1990, Quinet et al, 
1990). Increased CETP activity may result in decreased levels of HDL-C and increased 
levels of VLDL-C and LDL-C (Grundy and Denke, 1990).
Trans-isomers of fatty acids, formed by the partial hydrogenation of vegetable oils to 
produce margarine and vegetable shortening, increase the LDL-C / HDL-C ratio. As a 
result, consumption of partially hydrogenated vegetable oils may contribute to the 
occurrence of coronary heart disease (Willett et al, 1993).
2.13.1.2 Dietary Cholesterol and Blood Lipids and Lipoproteins
Fungwe et al (1992) have reported that increasing dietary cholesterol intake increase the 
concentrations of TG and cholesteryl ester in liver and plasma in rat. This is 
accompanied by reduced fatty acid oxidation and increased incorporation of exogenous 
fatty acid into hepatic TG and increased secretion of VLDL (Fungwe et al, 1992).
Interestingly, Fungwe et al (1994) have recentiy suggested that dietary cholesterol 
stimulates the biosynthesis of FFA, while the addition of TG to the diet stimulates 
production of cholesterol.
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Dietary cholesterol intake causes elevation in the plasma total cholesterol and LDL-C 
(Erickson et al, 1964, Hegsted et al, 1965). Studies have shown that the serum 
cholesterol response to dietary cholesterol tends to plateau at high cholesterol intakes 
(Keys, 1984, Hegsted, 1986).
Riccardi et al (1987) suggested that the most effective dietary change to reduce plasma 
cholesterol concentrations in human is to decrease the consumption of saturated fat and 
cholesterol.
2.13.1.3 Dietary Carbohydrate and Blood Lipids and Lipoproteins
A high carbohydrate diet increases plasma TG concentration but not that of cholesterol. 
The effects of dietary carbohydrates depend on the type of carbohydrate. Intake of 
sucrose or fructose within the range usually found in the population does not have any 
elevating effect on plasma triglycerides in most normal and diabetic subjects (Truswell,
1994). While the plasma TG levels increase, HDL-C levels decrease (Gonen et al, 1981, 
Brinton et al, 1990).
In human, increased fasting TG levels are observed with very high carbohydrate intake, > 
35% of energy from sucrose or > 20% of energy from fructose, more commonly in men 
and in conjunction with saturated fat intake (Truswell, 1994).
The Lipid Research Clinics Study Prevalence Programme reported that there is a positive 
correlation between dietary cholesterol intake and the serum HDL-C in school-age white 
boys (Glueck et al, 1982). However, another study reported that serum HDL-C 
concentration was relatively unaffected by increases in dietary cholesterol (Mahley et al,
1978).
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2.13.1.4 Dietary Fibre and Blood Lipids and Lipoproteins
Wheat bran and cellulose (insoluble polysaccharides) do not decrease plasma cholesterol 
concentration. In contrast, pectin, guar gum, oat bran, psyllium husk, bean (legumes), 
fruit and vegetables decrease plasma cholesterol and LDL-C concentrations (Schneeman 
and Tietyen, 1994, Riccardi and Rivellese, 1991). There is a negative correlation 
between plasma total cholesterol concentrations and dietary fibre intake (Kirby et al, 
1981).
In general, evidence that fibre in fruits and vegetables has some hypocholesterolemic 
effect is better than for most of the cereals so far studied. One aim of a lipid-lowering 
diet must be to decrease saturated fat consumption and increase fibre intake (Durrington,
1995). Therefore, in practice, the consumption of legumes, vegetables, and fruit should 
be encouraged (Riccardi and Rivellese, 1991).
The mechanisms by which dietary fibre acts as a hypoglycemic and hypolipidemic agent 
are not clear. Several mechanisms have been proposed including increasing the faecal 
excretion of bile acids and decreasing the rate of lipid absorption in the large intestine 
(Schneeman and Tietyen, 1994).
The ability of dietary fibre to delay food digestion and nutrient absorption clearly has an 
important effect on lipid and carbohydrate metabolism (Riccardi and Rivellese, 1991).
2.13.1.5 Effect of Dietary Factors on Carbohydrate Metabolism and Insulin 
Resistance
Diet is an environmental factor that has changed in those populations with changing 
prevalence of non-insulin (type II) diabetes (Kawate et al, 1979), suggesting that diet is a
causative factor for diabetes.
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The San Luis Valley Diabetes Study has suggested that high fat /  low-carbohydrate diets 
are correlated with the onset of NIDDM in humans (Marshall et al, 1991). Thus, fat 
consumption significantly predicts NIDDM risk in subjects with IGT after controlling for 
obesity and markers of glucose metabolism (Marshall et al, 1994).
Several hypotheses have been proposed on the mechanisms relating high fat intake to the 
etiology of NIDDM. A diet rich in fat causes obesity (Dreon et al, 1988, Romieu et al,
1988) and increased body fat and altered fat distribution (Storlien et al, 1986). These 
abnormalities lead to altered glucose metabolism (Leibel et al, 1989). Impaired fat 
oxidation and / or glycogen storage accompanying a diet rich in fat may increase FFA 
concentration in blood and lead to insulin resistance (Randle, 1989).
Another possible explanation for the correlation between fat consumption and NIDDM 
can be impaired insulin action due to altered cell membrane composition and (possibly) 
altered signal transduction across the cell membrane (Olefsky et al, 1988, Storlien et al,
1989) .
Animal studies have revealed that a high fat diet leads to the induction of insulin 
resistance and hyperinsulinemia (Storlien et al, 1986). In addition, The Normative Aging 
Study has suggested that a diet high in saturated fatty acids is an independent factor for 
both fasting and postprandial insulin concentrations (Parker et al, 1993). Diets with high 
saturated fat content decrease insulin response and insulin resistance in isolated rat 
adipocytes (Van Amelsvoort et al, 1988, Chattaway et al, 1990).
Dietary treatment of diabetes remains a controversial area and the ideal diet remains to 
be defined. The specific diet and approach chosen will depend on the patient, the degree
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of obesity and the extent of metabolic compensations and complications present (Griver 
and Henry, 1994).
The American Diabetes Association (1987) has recommended a the suitable diet for 
diabetic patients should provide 55-60% of energy as carbohydrates and < 30% as fat. 
The high amount of complex carbohydrates may cause an increase in insulin sensitivity. 
Smith (1994) suggested the diet for diabetic people should contain food with low 
glycemic index and be high in dietary fibre, particularly soluble fibres. Diet containing
food with low glycemic index and high in dietary fibre appears to increase insulin 
sensitivity and may well reduce the problem of increased TG and decreased HDL-C levels.
2.13.2 Alcohol Consumption
Ethanol is a source of energy and it also has potent pharmacologic and biochemical 
properties that may influence other aspect of nutrition and metabolism (Mitchell, 1990).
Ethanol is metabolized in the liver to form acetaldehyde, which in turn is oxidized to 
acetate. Acetaldehyde (in excess) may cause liver damage by decreasing mitochondrial 
functions. In heavy alcohol consumers, alcohol becomes a preferred fuel for the liver and 
displaces fat as a source of energy. Oxidation of fatty acids is decreased and the 
production of TG is increased. If this processes continues a fatty liver may develop 
(Lieber and Pignon, 1989).
2.13.2.1 The Effect of Alcohol Ingestion on Lipids and Lipoproteins
The interaction of ethanol with lipid metabolism is complex. Alcohol intake may affect 
all lipid components of the plasma.
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A number of studies have reported that alcohol consumption increases plasma TG levels 
(Ostrander et al, 1971, Castelli et al, 1977). The consumption of enough ethanol to give 
a blood concentration over 1 g/L and mild intoxication results in a rise in TG 
concentration in the plasma of normal subjects (Lieber and Pignon, 1989). Ethanol 
consumption leads to an increase in VLDL synthesis and limitation of alcohol may 
markedly decrease plasma TG concentrations (Ginsberg et al, 1974, NIH Consensus 
Conference, 1984).
There is a positive correlation between alcohol intake and HDL-C levels in population 
studies (Moore and Pearson, 1986). Several studies have found alcohol consumption 
may lead to increase in both HDL2 (the putative atherogenic protective fraction) and 
HDL3 (Lieber, 1987), however other researchers have reported that only the HDL3 
fraction is increased (Haskell et al, 1984). ApoA-I and apoA-II are increased by alcohol 
(Camargo et al, 1985). Studies have reported that alcohol-related HDL-C elevation may 
be due to increased hepatic apoA-I synthesis (Taskinen et al, 1987, Okamoto et al,
1988).
Sillanaukee et al (1993) have reported that moderate to heavy intake of alcohol had no 
effect on HDL2 but increased the HDL3 fraction. The mechanism of elevated VLDL, 
HDL2, and HDL3 levels after ethanol intake was described by Lieber (1987). 
Overproduction of VLDL particles by the liver occurs, resulting from increased activities 
of synthetic enzymes and ready availability of precursors such as TG, cholesterol, and 
apolipoproteins. At the same time, HDL3 synthesis will increase in association with 
moderate alcohol intake. The degradation of VLDL and chylomicrons by LPL is 
associated with conversion of HDL3 to HDL2. As a result, an increased synthesis of
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VLDL by the liver and increased LPL activity will cause increased HDL2 levels (Lieber, 
1987).
A reduction in LDL-C level may be seen in alcohol drinkers (Taskinen et al, 1982). The 
modification of LDL-apoB by acetaldehyde (the first metabolite of ethanol) increases 
the catabolic rate of LDL particles in the rat, resulting in lower LDL-C levels 
(Savolainen et al, 1987, Kesaniemi et al, 1987). It can be an explanation for decreased 
LDL-C concentrations in alcohol users.
2.13.2.2 The Effect of Alcohol Ingestion on Insulin Sensitivity
Women drinking a moderate amount of alcohol had lower plasma insulin concentrations 
and higher HDL-C levels than non-drinking women (Razay et al, 1992).
In addition, Facchini et al (1994) reported that light to moderate alcohol intake is 
correlated with increased insulin-mediated glucose uptake, lower plasma glucose and 
insulin levels in response to oral glucose, and a higher HDL-C level. The changes in 
insulin and glucose metabolism may contribute to the lower risk of coronary heart 
disease described in light to moderate drinkers.
2.14 Smoking
Smoking may be an important contributors to both glucose level and diabetes risk 
(Bjorntorp, 1988, Pederson, 1989). Smoking is a risk factor for ischaemic heart disease 
(IHD) (Meade et al, 1987).
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2.14.1 Effects of Smoking on Lipoprotein Metabolism
Epidemiological studies have shown that smoking is associated with a number of 
abnormalities in plasma lipoproteins particularly decreased HDL-C (Criqui et al, 1980, 
Wilson et al, 1983). The correlation between smoking and decreased HDL-C was also 
confirmed by using multivariate analysis (Craig et al, 1989, Maede et al, 1991, Muscat et 
al, 1991). However, some researchers rejected the independent effect of smoking on 
HDL-C after correction for lifestyle factors (lack of exercise, obesity, alcohol intake, etc) 
(Wallentin and Sundin, 1985, Manttari et al, 1991).
Plasma HDL-C rises within 2-8 weeks to the normal range after smoking cessation 
(Fortman et al, 1986, Stamford et al, 1986, Moffatt, 1988). Some investigators consider 
it uncertain whether increased HDL-C level is due to stopping smoking or dietary 
changes (Quensel et al, 1989, Maida and Howlett, 1990). Quensel et al (1989) believe 
that the changes in HDL result from increased dietary fat and carbohydrate intake after 
stopping smoking.
Smokers have been reported to have lower plasma concentration of HDL2 (Shennan et 
al, 1985), HDL3 (Haffner et al, 1985, Moriguchi et al, 1990), and HDL2 and HDL3 
(Robinson et al, 1987).
Craig et al (1989) also have found that apo A-I concentration is low in smokers. In 
addition, plasma levels of TG (Simons et al, 1984), VLDL (Freedman et al, 1986) and 
LDL-C have been reported to be higher in smokers compared with non-smokers (Craig 
et al, 1989, Freedman et al, 1986, Muscat et al, 1991).
Dullaart et al (1991) have reported that the CETP activity is elevated in ID DM patients 
who smoke. The concentrations of tissue LPL are elevated in smokers and this seems to
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be associated with their lower body weight (Brunzell et al, 1980 and Chajek-Shaul et al, 
1987). LCAT activity is decreased in smokers (Haffner et al, 1985, Moriguchi et al,
1990), however hepatic lipase activity is increased (Moriguchi et al, 1990).
2.14.2 Smoking and Diabetes Mellitus
Cigarette smoking favours the development and progression of diabetic nephropathy. 
Several large prospective cohort studies have reported that the relative risk for all-cause 
mortality is approximately twice as high for smoking compared to non-smoking diabetic 
patients. Stopping smoking is probably the most cost-effective risk factor intervention 
for diabetic patients (Muhlhauser, 1994).
2.14.3 Smoking and Fibrinogen Levels
Data from several studies have suggested that the plasma levels of fibrinogen are higher 
in smokers than non-smokers (Balleisen et al, 1985, Kannel et al, 1987) and this may be 
one reason why smokers are more prone to ischaemic heart disease (Meade et al, 1987).
2.15 Physical Activity
Sedentary lifestyle is related to increased coronary atherosclerosis and physical activity 
decreases the risk of coronary atherosclerosis (Paffenbarger et al, 1986).
Physical activity tend to be associated with lower body fat, lower blood pressure, and 
beneficial effects on glucose, insulin, lipids, and lipoproteins (Bush, 1991).
2.15.1 Effects of Physical Activity on Lipids and Lipoproteins
It is well accepted that physical activity improves lipoprotein metabolism (Huttunen et al, 
1979, Berg and Keul, 1985).
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Researchers have reported decreased LDL levels in human (Wood et al, 1977, Goldberg 
et al, 1984, Hurley et al, 1986). Plasma TG concentration is reduced in both sexes 
(Wood et al, 1977, Farrell and Barboriak, 1980). Endurance exercise decreases VLDL- 
TG and LDL-C levels (Thompson et al, 1988, W ood et al, 1988). These changes are 
due to increased LPL activity and plasma TG clearance (Thompson et al, 1988). 
Moreover, exercise increase the plasma concentration of HDL-C fractions (Gordon and 
Rifkind, 1989, McHenry et al, 1990).
Exercise programs with moderate intensity seem to modify the effects of a hypocaloric, 
fat-restricted diet on HDL-C (Taylor and Ward, 1993).
2.15.2 Effects of Physical Activity on Carbohydrate Metabolism
In low to moderate intensity exercise, rapid adjustment in the supply of energy is the 
result of a fall in plasma insulin, and steady or increased glucagon production to maintain 
euglycemia. Hepatic glucose synthesis in moderate exercise is regulated mainly by the 
glucagon /  insulin ratio (Purdon et al, 1993).
In contrast, intense exercise is related to a marked stimulation of glucose synthesis with 
resulting hyperglycemia, marked increases in plasma catecholamines, and moderate 
hyperglucagonemia. The hyperglycemia increases in recovery and is accompanied by 
hyperinsulinemia (Purdon et al, 1993).
King et al (1988) have reported that the reversal of increased insulin action that occurs 
within a few days after stopping exercise is due to a decrease in insulin sensitivity, not to
a decrease in insulin secretion.
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2.15.3 Therapeutic Exercise for GDM Patients
Besides diet and insulin therapy, exercise is important in the treatment of people with 
diabetes (Wasserman and Vranic, 1987).
Exercise is known to increased glucose utilization by several mechanisms, and regular 
exercise has been recommended since early time as an addition therapy (Bung et al,
1993).
Bung et al (1993) suggested that in the absence of ominous fetal heart rate changes or 
significant alterations in uterine activity following the exercise sessions or diabetes- 
related peri- and neonatal morbidity, regular physical activity appears to be a safe 
therapeutic method for the fetus of GDM mothers.
2.16 Obstetrics and Family Medical History
Subjects with GDM may present more frequent obstetric complications, affected both 
baby and mother (Beydoun, 1987). They also are more likely to have a positive family 
history of diabetes mellitus (Henry and Beischer, 1991).
2.16.1 Obstetrics History
Obstetric complications are more likely to occur in diabetic pregnancies and may increase 
both mortality and morbidity (Beydoun, 1987).
Women with GDM exhibit more frequent and severe obstetric complications. Cousins 
(1987) reported that subjects with GDM had a higher frequency of maternal 
complications such as polyhydramnios (5.3%), preeclampsia (10%), chronic hypertension
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(9.9%), pyelonephritis (4%), and delivery by cesarean section (20.4%) than women with 
non-GDM pregnancies.
The fetus of the diabetic mother runs an increased risk of major congenital 
malformations, complications related to macrosomia, intra-uterine growth retardation, 
and biochemical abnormalities resulting from fetal hyperinsulinemia (Barret, 1987). The 
Third International Workshop Conference on GDM (1991) reported that the infant of the 
mother with GDM is also more likely to develop these morbidities.
Fetal macrosomia is a potentially dangerous complication of diabetic pregnancy, may be 
caused by hyperinsulinemia, a response to fetal hyperglycaemia following maternal 
hyperglycaemia. This and other complications can be prevented by strict control of 
maternal blood glucose levels, particularly in late pregnancy (Barret, 1987).
2.16.2 Oral Contraceptive
The most widely used contraceptive method is the combined-type oral contraceptive 
containing an estrogen and a progesterone steroid. Oral contraceptive intake causes 
alterations in glucose, lipid and protein metabolism (Molsted-Pedresen et al, 1991).
2.16.2.1 Effects of Oral Contraceptive on Lipids and Lipoproteins
Estrogen increases LDL receptor activity, so increasing the rate of clearance of both 
LDL and remnant particles (Knopp et al, 1993).
Estrogen also increases the amount of apoA-I in HDL particles by increasing synthesis 
and / or decreasing the catabolism of apoA-I, resulting in an increased number of HDL 
particles and increased plasma HDL-C levels including the HDL2 subfraction (Knopp et 
al, 1993). It also increases TG and VLDL-C levels. The mechanisms by which these
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changes occur are not clear but probably related to the effect on estrogen in reducing 
hepatic triglyceride lipase activity and inhibiting HDL catabolism (Miller and LaRosa,
1991).
The progestin component of oral contraceptives reduces glucose tolerance, increases 
insulin resistance, and tends to increase cholesterol concentration (Kjos et al, 1990).
Dyslipidemia characterised by elevated LDL and VLDL and also reduction of HDL 
particles has been reported during use of the combination-type oral contraceptive. This 
would increase the risk of atherosclerosis complications (Molsted-Pedersen et al, 1991).
2.16.2.2 Effects of Oral Contraceptive on Carbohydrate Metabolism
Exogenous oestrogen has an antagonistic effect to insulin (Spelsberg and Manson,
1993).
A combination of estrogens and progesterones has been reported to decrease insulin 
sensitivity at the cellular level in peripheral tissue (Skouby et al, 1987).
Eschwege et al (1990) reported that women who are using currently oral contraceptives 
have higher plasma glucose and insulin levels after a standard glucose challenge.
Rimm et al (1992) have found only a slightly increased in risk of NIDDM among women 
who have used oral contraceptives compared with those who have never used oral 
contraceptive. However, another study showed no increased risk of NIDDM in post­
menopausal oral contraceptive users (past or present) in comparison to those who had 
never used oral contraceptives (Manson et al, 1992).
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2.16.3 Family Medical History
A family history of diabetes and cardiovascular disease is often found in subjects who 
develop diabetes and cardiovascular disease.
Studies have suggested that genetic factors play a major role in the development of 
NIDDM (Newman et al, 1987, Fajan, 1989).
In the rare cases single genes alone can lead to NIDDM, but in the most cases it seems 
that NIDDM is results from combined defects of (3-cell function and insulin action, either 
of which can in principle have a genetic or environmental basis (McCarthy and Hitman,
1993).
2.16.3.1 Family History of Diabetes Mellitus
Several studies on populations at high risk for developing NIDDM have showed that 
history of diabetes in a first degree relative is a powerful predictive factor for the 
development of diabetes and impaired glucose tolerance preceding NIDDM is more 
prevalent in non-diabetic offspring of diabetic patients than in control subjects without a 
positive family history of diabetes (Leslie et al, 1986, Haffner et al, 1988, Eriksson et al,
1989).
Warram et al (1990) have reported that decreased glucose clearance may be 
demonstrated one or two decades before NIDDM is diagnosed. This decreased glucose 
clearance is accompanied by compensatory hyperinsulinemia, suggesting that the primary 
defect in development of NIDDM is in the peripheral tissue response to insulin and
glucose.
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2.16.3.2 Family History of Cardiovascular Disease (CVD)
Bell et al (1990) have reported that black women with GDM have a higher incidence of 
family history of CVD.
Diabetic patients have an increased chance to develop ischaemic heart disease (Barret- 
Conner et al, 1985) and black women have a 70% greater risk of CVD and mortality 
than white women (Johnson et al, 1986). However, the relationship of CVD and 




This chapter introduces the data collection techniques, levels of measurements, and 
statistical techniques for analyzing data.
3.2 Subjects
This is a cross-sectional study. The study was performed on 65 women who had had 
GDM in their last pregnancy (the GDM group), studied approximately one year after 
delivery, and 65 wom en who gave birth at the same time as the women with GDM and 
who did not have GDM  (the control group).
All women who have had GDM diagnosed and treated in the Mawarra Health Service 
(IAHS) in June 1992-January 1993 (80 subjects) were contacted and were offered a 
check which was centred on those factors thought to increase the chance of developing 
diabetes mellitus. O f the GDM  group, 65 agreed to join the study (81%).
A control group of 90 individuals was chosen at random from the list of women 
presenting for labour at the same time as the patients with GDM. Of women from the 
control group, 65 also agreed to join to the study (72%).
Subjects received a full description of the study and gave informed consent. All subjects 
received a detailed information sheet and consent form were signed by all participants.
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Those enrolled in the study were examined at the Outpatient Clinics, Illawarra Regional 
Hospital (Wollongong Campus), at the Medical Research Unit (MRU), and for 4 
subjects at their homes by the investigator. This study was approved by the University of 
Wollongong Human Research Ethics Committee (HR 92/213).
3.3 Experimental design
Subjects were examined after an overnight (~12 h) fast. All subjects received a clinical 
examination and were interviewed before blood and urine sampling.
3.3.1 Demographic information
Demographic information was obtained including age, country of birth, details of 
obstetric and medical history and family history of diabetes mellitus, coronary heart 
disease, other inherited disease, peripheral vascular disease (PVD) and kidney disorders, 
smoking status, alcohol consumption, medication and oral contraceptive use (Appendix
I).
3.3.2 Blood pressure measurement
Blood pressure measurement was done after 5 minutes rest in the sitting position, using a 
standard desk mercurial sphygmomanometer. Two blood pressure measurements were 
obtained and the mean was accepted as the blood pressure. Systolic blood pressure was 
defined by the appearance of sound, and diastolic blood pressure by the disappearance of 
sound.
Mean arterial pressure (MAP) was calculated by adding the sum of two thirds of the 
diastolic pressure and one third of the systolic pressure (Konen et al, 1993).
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The pulse pressure was calculated as systolic blood pressure minus diastolic blood 
pressure (Vander et al, 1994 a).
3.3.3 Blood sample taking
A blood sample (40 mL) was obtained from the left antecubital vein of seated subjects 
after approximately 5 minutes rest in the sitting position after blood pressure 
measurement.
A tourniquet was used but was released before collection of the blood sample to avoid 
artifactual increases in the concentration of plasma proteins and lipids.
Blood samples were divided into several types of tubes: (1) tubes containing di­
potassium EDTA (1 mg/mL), (2) 3 mL tubes containing 0.3 mL sodium citrate solution 
(109 mM, 3.2%), and (3) plastic tubes containing gel (SARSTEDT Momovette, Serum 
Gel S/7.5 mL)) for separation of serum.
All blood samples were mixed thoroughly and cooled immediately (by placing in fridge 
or ice box).
The plasma was separated from the blood samples collected in the EDTA tubes by 
centrifugation (2300 rpm for 20 minutes) and stored at 4°C for lipid studies. Other 
blood samples (citrated plasma and serum) had analyses performed in the Pathology 
Laboratories, Illawarra Regional Hospital.
Remaining plasma or serum samples were frozen at -85°C, in 2 mL snap-top plastic 
tubes within a few hours for further study.
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Some tests were carried out on fresh plasma and the others on frozen plasma (after 
approximately 5-6 months at -85 °C) as listed in Table-3-1.
Table 3-1 L a b o ra to ry  tests in this study
Fresh plasma or urine Frozen plasma
TC, TG, apoA-I, and apoB in plasma NEFA in plasma
VLDL isolation (Cholesterol, FC, TG, apoB, 
measurement)
Factor VII
IDL isolation (Cholesterol, FC, TG, apoB, 
measurement)
von Willebrand factor (vWF)
HDL isolation (Cholesterol and apoA-I 
measurement)
Lipoprotein (a)






TC = total cholesterol, TG = triglycerides, apo = apolipoprotein, NEFA = non-esterified 
fatty acids, CETP = cholesterol ester transfer protein.
3.4 Lipid Study
EDTA plasma was used for lipid studies. Blood was cooled rapidly, briefly stored at 
4°C, and standard lipid laboratory procedures were initiated within 0.5-2 hours after 
venipuncture.
3.4.1 Lipids and apolipoproteins in plasma
Total cholesterol, free (non-esterified) cholesterol (FC), and triglycerides were measured 
on a Cobas-Fara automated centrifugal analyzer (Roche Centrifugal Analyzer, France).
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Total cholesterol concentrations in plasma and different lipoproteins were measured by 
CHOD-PAP method (a standard enzymatic colorimetric method) based on Siedel et al, 
1983 and Kattermann et al 1984) (Appendix II) with reagents supplied by Boehringer 
Mannheim, Germany (Q C materials: Precinorm L, Cat No: L 781827 and Precipath Cat 
No: L 128574). Cholesterol was determined by enzymatic hydrolysis with subsequent 
determination of the liberated cholesterol (Test principle is presented in Appendix II) by 
colorimetry. The reaction product was read optically at 546 nm and compared to a 
known standard curve. Six reference points (254, 508, 1016, 2032, 4065, and 8130 
(imol/L) and 2 quality controls, one low (range 3635-5585 fimol/L) and one high (7350­
11250 |imol/L) for total cholesterol (Roche Control Serum Lipid Cat No 2023624) were 
used.
Boehringer-Mannheim Diagnostic kits for lipid standards, calibrators, and controls are 
traceable to Centers for Disease Control (CDC) (Myers et al, 1994).
As reference ranges 750-1070 ^imol/L (calibrator or standard) for free cholesterol (FC), 
the Boehringer Mannheim standard (Preciset Cat No: 125512) was used.
TG concentrations in plasma and lipoproteins were measured by Triglyceride GPO-PAP 
(a standard enzymatic colorimetric method) based on Wahlefeld (1974) and Trinder 
(1969) (Appendix II) with reagents supplied by Boehringer Mannheim, Germany (Q C 
materials: Precinorm L, Cat No: L 781827 and Precipath Cat No: L 128574). Enzymatic 
hydrolysis of triglycerides was determined with subsequent determination of the liberated 
glycerol by colorimetry. The reaction product was read optically at 500 nm and 
compared to a known triglyceride standard curve.
Quality Control Values: Precinorm L (1650 |imol/L)
Precipath L (4650 pmol/L)
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ApoB, and apoA-I concentrations were measured in fresh plasma on a Cobas-Fara by 
Apolipoprotein B, T Antiserum (standard immunoturbidimetric method) (Roche 
Diagnostics, France) (Appendix II). Turbidity of the antigen-antibody reaction was 
measured at 340 nm. As quality control (QC) for apo B and apo A-I, the apolipoprotein 
T Control (art. 0730696, Roche Diagnostics, France) was used.
Reference Values: ApoA-I ApoB
Male 1.15 -1.90 g/L 0.70-1.60 g/L
Female 1.15-2.20 g/L 0.60-1.50 g/L
Lipoprotein (a) concentration in plasma was measured by an immunoturbidimetric 
method based on Levine et al (1992) by using SPQ TM kit, SPQ Calibration / Control: 
includes Standards 1-5 and Controls Levels 1 and 2, (INCSTAR Corportion, Stillwater, 
Minnesota, USA) on a Cobas-Fara analyzer. The immunoturbidimetric method is based 
on the formation of insoluble antigen-antibody complexes, light scattering is measured, 
following an 10 minutes incubation of sample and reagents, compared to a known 
standard curve at 340 nm.
A calibration curve is produced by a series of standards with known concentrations of 
lipoprotein (a) and using the instrument’s data reduction capability or manually plotting 
the change in absorbance versus concentration.
Reference Values: Control Level 1 19 mg/dL
Control Level 2 46 mg/dL
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3.4.2 Non-esterified fatty acids (NEFA)
Concentrations of non-esterified fatty acids in plasma were measured by the Wako 
enzymatic method with reagent from Wako Pure Chemical Industries, Osaka, Japan.
Oleic acid 1.0 mM was used as the NEFA standard solution (Wako Pure Chemical 
Industries, Ltd, Japan).
The method relies upon the acylation of co-enzyme A (Co-A) by the fatty acids in the 
presence of added acyl Co-A synthetase. The acyl Co-A is oxidized by added acyl Co-A 
oxidase with generation of hydrogen peroxide. Then, hydrogen peroxide in the presence 
of peroxidase permits the oxidative condensation of 3-methyl-N-p hydroxyethylene 
aniline (MEHA). MEHA condenses with 4 amino antipyrine to form a purple colored 
product which can be measured colorimetrically at 550 nm.
Reference Values: Plasma NEFA Concentration
0.20-1.08 mEq/L
3.4.3 Isolation of VLDL and IDL
VLDL and IDL were isolated from fresh plasma by sequential ultracentrifugation after 
progressively raising the solvent density according to Havel et al (1955). KBr solutions 
were made in 100 ml of deionized water and contained 0.02% sodium azide.
1.0 mL normal saline (0.15M NaCl, density 1.006 g/mL) was added to 4 mL of fresh 
plasma in a quick-seal polyallomer ultracentrifuge tube (100.4, Beckman Instruments 
Inc, USA).
Normal saline was added very carefully on top of plasma to avoid mixing (a syringe was 
used) and then the tube was sealed.
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A Beckman TL-100 tabletop ultracentrifuge with a fixed angle, TLA-100.4 rotor 
(Beckman, USA) was used. The sample was subjected to ultracentrifugation for 25 
minutes, 100,000 rpm, at 4°C. The VLDL fraction was isolated as the supernatant by 
tube slicing.
Crystalline KBr was used to raise the solvent density. The amount of KBr to be added 
was calculated by the following formula (Hatch and Lees, 1968) :
KBr (g) = Vi ( df- dj) / l-(v x  df) Vi = initial volume (mL)
df = density final (g/mL) 
dj = density initial (g/mL 3-2) 
v = value from Table 3-2
Table 3-2 R eq u ired  so lid  K B r f o r  making d ifferen t den sity  so lu tion s in 100  m L d is tilled
(de-ion ized) w a ter  (Hatch and Lees, 1968)
Final density of KBr 
solution (g/ml)
V KBr (g) added to 100 ml 
distilled water
1. 1.019 0.2875 2.68722
2. 1.055 0.2923 7.9523
3. 1.063 0.2936 9.1582
4. 1.07 0.2943 10.2175
5. 1.09 0.2966 13.2997
6. 1.10 0.2977 14.8692
7. 1.12 0.2993 18.0509
8. 1.13 0.3003 19.6772
9. 1.14 0.3042 21.4325
10. 1.125 0.2997 18.8583
11. 1.21 0.3052 33.2959
12. 1.25 0.3084 40.6834
13. 1.27 0.3096 44.4951
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The infranatant was collected in a cylinder and the volume was measured. The sample 
was then adjusted to a density of 1.19 g/mL by adding solid KBr, according to the 
formula in Table 3-2. After adjustment, the sample was poured into a quick-seal 
centrifuge tube and filled by KBr solution density 1.019 g/mL. The IDL fraction was 
isolated as the supernatant after centrifugation at 65,000 rpm for 16 hours at 4°C. The 
infranatant was frozen immediately at -85°C.
Estimation of total cholesterol (TC), triglycerides (TG), and free cholesterol (FC) 
concentrations were carried out on fresh VLDL and the IDL fraction.
Cholesterol ester (CE) was calculated in both VLDL and IDL as the difference between 
total cholesterol and free (non-esterified) cholesterol. Apo B concentration was 
measured immunoturbidimetrically.
3.4.4 Isolation of HDL
ApoB-containing lipoproteins were precipitated with dextran sulfate-Mg2+ (Wamick et 
al, 1982) and HDL-C and HDL-apoA-I concentrations were measured in the 
supernatant. The procedure for isolation of HDL from plasma lipoproteins is described 
in detail in Appendix II.
3.4.5 Isolation of all lipoproteins for determination of HDL and LDL particle sizes
Plasma samples were adjusted to density 1.25 g/mL for isolation of all lipoproteins.
0.5 mL. fresh plasma was added to 0.1985 g KBr in a T L-100.1 Beckman centrifuge 
tube. It was mixed well and subjected to ultracentrifugation in a TLA -100.1 rotor at 
100,000 rpm for 16 hours at 4°C.
Chapter Three Materials and Methods 80
After ultracentrifugation, 50|iL  (yellow-top layer) was recovered and collected in a snap- 
top plastic tube and stored at 4°C for electrophoresis of lipoproteins. It was diluted 1:4 
with TBS buffer (Appendix II) for electrophoresis.
Electrophoresis was carried out on a M icrograd II Electrophoresis Apparatus (Gradipore 
Ltd Australia) using non-denaturing gradient gels (3-30% and 3-13%, Gradipore Ltd 
Australia) and a 24 slot comb. 3-30% gel and 3-13% gels were used for identification of 
HDL and LDL sub-populations, respectively.
3.4.6 Determination of HDL particle size by electrophoresis
HDL sub-populations were identified by electrophoresis using non-denaturing 3-30% 
polyacrylamide gradient gels. Samples were applied in a volume of 10|iL containing 4 
parts by volume of the density = 1.25 g/mL fraction and 1 part of a solution consisting of 
sucrose and bromphenyl blue (Appendix II).
A reference protein mixture was used for calibrating particle size radius. Each gel 
contained the reference protein mixture in 3 lanes and 6 samples (Figure 3-1). The 
reference protein mixture used for calibrating particle size radius included thyroglobulin 
(8.5 nm radius), apo-ferritin (6.10 nm radius), lactate dehydrogenase (4.08 nm radius), 
and bovine serum albumin (3.55 nm radius) (High molecular weight (HMW) Calibration 
Kit, Pharmacia LKB, Biotechnology AB, Uppsala).
Figure 3-1 Pattern of sample loading in 3-30% gel for identifying
HDL sub-populations
aaHMW a  1 a2 a3 aHMW  a4 a5 a6 aHMW a  a
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Samples were electrophoresed at 170 V (constant voltage), 10°C for 17 hours in a buffer 
containing 90 mM Tris base, 80 mM boric acid, 3 mM Na2EDTA and 3 mM sodium 
azide (pH = 8.35).
Gels were fixed in 10% sulfosalicylic acid (Appendix II) for 0.5 hour immediately after 
electrophoresis. After fixation, gels were stained for 3 hours in Coomassie Brilliant Blue 
dye (R-250) (Appendix II) and then destained in 5% acetic acid (Appendix II). Gels were 
rotated during fixing, staining, and destaining procedures,. Each gel was then put in a 
small plastic bag with a few mL of 0.02% sodium azide solution (Appendix II) and 
sealed.
Stained gradient gels were scanned with an Ultrascan XL Enhanced Laser Densitometer 
(LKB Bromma Sweden) at wavelength 663 nm. The migration distances (peak Rf 
values) of the reference proteins of known radius were measured and a standard curve of 
particle radius (nm) against Rf was constructed. The particle radius of the samples was 
determined by reference to the standard curve.
The software package (LKB 2400 Gel Scan XL, Bromma) determined the peaks, and 
calculated position (mm), and relevant area under the curve as a % of the total % for 
each protein.
Gradient gel electrophoresis resolves human HDL into five subfractions. Two of the 
subfractions (HDL2b and HDL2a) correspond to HDL2 and three of the subfractions 
(HDL3a, HDL3b, and HDL3c) correspond to HDL3 isolated by ultracentrifugation 
(Converse and Skinner, 1992). HDL sub-populations were identified according to the 
size ranges suggested by Nichols et al (1987).
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3.4.7 Determination of LDL particle size by electrophoresis
The procedure for identifying LDL particle size by electrophoresis is identical with that 
for HDL, except that 3-13% non-denaturing polyacrylamide was used and calibration 
was performed using 19 nm (radius) calibrated latex microspheres (carboxylated latex 
beads, Duke Scientific Palo Alto, CA) as well as the HMW calibration kit (Pharmacia 
LKB, Biotechnology AB, Uppsala, Sweden) for construction of the standard curve. The 
calibration mixture was applied at the beginning of gels and after loading three samples 
(Figure 3-2).
Figure 3-2 Pattern of samples loading in 3-13% gel for identifying
LDL particles
AAHMWABeadsAlA2A3AHMW/\BeadsA4A5A6AA
Fixation, staining and destaining procedures were the same as with 3-30% gels and the 
same equipment was used for scanning.
3.4.8 HDL radiolabelled in the cholesteryl ester moiety
Radiolabelled HDL3 was prepared in the density range of 1.13-1.21 g/mL by using 
tritium [3H] cholesterol ester as described by Albers and Tollefson (1984) (procedure in 
Appendix II). One preparation of radiolabelled HDL3 was used for all CETP activity 
assays.
3.4.9 Cholestryl ester transfer protein activity (CETP activity)
CETP activity was measured in plasma (thawed after storage at -85°C for 6 months) by 
using the Abbey and Nestel method (1993). The assays were done in duplicate. All 
assays contained as quality controls a positive control (a plasma sample from a normal
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healthy person) and a control for the estimation of non-specific transfer (not mediated by 
CETP).
The CETP assay was done three times with and without (5,5-dithiobis [2-nitrobenzoic 
acid]) but the results were not statistically different. As a result DTNB was not used 
routinely for this assay. The procedure is presented in Appendix II.
3.4.10 LDL-C Calculation
LDL-C was calculated according the modified Friedewald equation.
The m odified  F riedew a ld  equation:
LDL-C (mmol/L) = Total cholesterol (mmol/L) - HDL-C (mmol/L) - TG (mmol/L) / 
2.18
TG is an estimate of the concentration of cholesterol in VLDL particles in fasting 
plasma. This is based on the assumption that all the plasma TG is associated with VLDL 
and that the molar ratio of TG to cholesterol in VLDL is 2.18:1 (Samman and Truswell, 
1993).
There are three restrictions in the use of the method presented by Friedewald et al for 
estimating plasma LDL concentrations.
Firstly, it is not applicable to the fed state, when the ratio of TG to cholesterol in VLDL 
and chylomicrons is likely to be higher, so that the standardised molar ratio of TG to 
cholesterol in VLDL is not 2.18:1, and if the formula is used in these circumstances, it 
results in overestimation of VLDL-C and hence an underestimation of the LDL-C 
concentration. All participating subjects in this study were in the fasting state.
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Secondly, the technique gives erroneously high results in patients with type III 
hyperlipoproteinemia, because the Friedewald equation assumes that IDL-C is negligible. 
The lipid results did not suggest type HI hyperproteinemia in any subjects.
Thirdly, LDL-C can not be accurately estimated when the plasma triglyceride 
concentration is more than 4.5 mmol/L (Samman and Truswell, 1993). None of the 
subjects had a plasma triglyceride concentration more than 4.5 mmol/L.
3.4.11 LDL-apoB Calculation
LDL-apoB values were calculated according to this formula:
LDL-apoB = total apoB - (VLDL-apoB + IDL-apoB).
3.5 Tests related to carbohydrate metabolism
Fasting blood glucose, fasting blood insulin and HbAlc were measured by standard 
procedures described as follow:
3.5.1 Fasting blood glucose (FBG)
FBG was determined by a colorimetric method based on Trinder, 1969 and Curme et al, 
1978 on an Ektachem 700 XR analyzer (Kodak, NY, USA) using the Kodak Ektachem 
Clinical Chemistry Slide (GLU).
The Kodak Ektachem Clinical Chemistry Slide (GLU) is a dry, multilayered analytical 
element coated on a clear polyester support. Kodak Ektachem Calibrators 1, 2, and 3 
were used as calibrator. Kodac Ektachem Control was also used (Range for serum =
1.11-34.69 mmol/L).
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A 10 (iL drop of patient blood is deposited on the slide. It diffuses into the underlying 
reagent layer. The oxidation of glucose in the sample is catalyzed by glucose oxidase to 
form hydrogen peroxide and gluconate.
This reaction is followed by an oxidative reaction catalyzed by peroxidase in the presence 
of chromogens (4-aminoantipyrine + 1,7-dihydroxynaphthalene) to produce a red dye. 
The intensity of the red dye is measured by reflected light (wavelength = 540 nm) 
(Kodak Ektachem Clinical Chemistry Products’ manual, 1992).
Expected Values in Serum:
Male (18-44 yr) 4.2-6.1 mmol/L 
Female (18-64 yr) 3.6-5.8 mmol/L
3.5.2 Fasting blood insulin (FBI)
FBI was measured by microparticle enzyme immunoassay (MEIA) based on Travis 1980 
method on an Abbot IMX analyzer (Abbott Diagnostics, Chicago, USA). In the IMX 
insulin assay, an antibody-insulin complex is formed by incubating the patient’s serum 
sample with coated microparticles. Then the anti-insulin:alkaline phosphatase conjugate 
is added to the antibody-insulin complex and binds to it. The substrate (4- 
methylumbelliferyl phosphate) is added to the complex and the end product of the 
reaction (the fluorescent product) is measured by the MEIA optical assembly (Abbott 
Diagnostic, 1994). The IMX insulin assay shows no cross-reactivity with proinsulin 
(Abbott Diagnostic, 1994).
The IMX Insulin Calibrators contain insulin (human) prepared in buffer at six different 
concentrations (0.000, 0.003, 0.010, 0.030, 0.100, and 0.300 mU/mL).
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The IMX Insulin Controls contain insulin (human) prepared in buffer to yield the 
following concentration ranges.





HbAlc was determined by high performance liquid chromatography (HPLC), on a 
Pharmacia Mono S HR 5/5 column (Pharmacia LKB Technology, Almeda, CA) (Bio­
Rad Haemoglobin A le  Micro-column Test Instruction Manual, 1990).
Lyphocheck Glycated Haemoglobin BioRad (Cat No C-555) level 1 and 2 were used as 
quality control material.
Expected levels
> 10% Poor degree of glucose control
9-10% Fair " " "
8-9% Good " " "
7-8% Excellent " " "
< 6% (4.2-5.9 %) Non-diabetic level
3.6 Haematological Tests
3.6.1 Fibrinogen
Fibrinogen was determined in fresh citrated plasma (one part citrate solution, 0.106 
mol/L sodium citrate + nine parts blood) by the Corrivea and Fritsma method (1988).
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Principle of test: In the presence of a high concentration of thrombin, the thrombin 
clotting time is inversely proportional to the fibrinogen concentration of plasma.
The reference range for fibrinogen is 2.0-4.0 mg/L at all ages, including full-term and 
premature newborn.
ARP or Uniplasmatrol Normal is used as control plasma. Calibration: CSL Human 
Thrombin (dried) 2500 U is mixed with 5 mL of distilled water to give a resulting 
concentration of 500 U/mL. 4 mL Owems buffer is added to 1 mL of thrombin 500 
U/mL to make a final concentration of thrombin of 100 U/mL. Six different dilutions 
(1:5, 1:7.5, 1:10, 1:15, 1:20, and 1:30) are assayed directly on the MLA and the 
corresponding thrombin times used in the construction of a standard curve.
3.6.2 Factor V n
Factor VII activity assay was performed on the MLA 1000C automated coagulation 
analyzer (Baxter Diagnostics, MLA 1000C) on citrated plasma. This assay is based on 
Seegers and Walz, 1986, Bajaj et al, 1981. Factor VII activity was measured by a 
clotting method utilizing the prothrombin time test (Baxter Diagnostic, MLA 1000C 
operator’s manual, USA, 1988).
Immuno ads orbed Factor VII Deficient Plasma (human) with different concentrations 
(1:10, 1:20, ..., 1:160, 1:320) was used in the construction of a standard curve. Factor 
Assay Reference Plasma (Cat No B4234-30) and Ci-Trol Coagulation Control Level 1 
(Cat No B4224-10) also were used. The result was calculated as % of activity. Factor 
VII activities over 100% is considered as higher than normal.
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Note: There are several different methods available to evaluate plasma factor VII level 
such as factor VII coagulant activity (measurement of factor VII activity via a clotting 
method utilising the prothrombin time test), activated factor VII (factor Vila) 
(quantitation of activated factor VII levels in plasma by using a tissue factor mutant 
selectively deficient in promoting factor VII activation), and factor VII antigen (factor 
VIIAg) (Baxter Diagnostic, Manual, 1988, Morrissey et al, 1993, respectively). We 
used factor VH coagulant activity method, because this method is commonly used in the 
region pathology laboratories.
This method is traceable to Centers of Disease Control (CDC).
3.6.3 Von Willebrand Factor (vWF) antigen
vWF antigen was measured in frozen citrated plasma by the ELISA method based on 
Cejka (1982) using Dakopatts rabbit’s anti-human von Willebrand Factor (Cat No. 
A082). Dakopatts rabbit anti-human von Willebrand Factor conjugated with horseradish 
peroxidase (Cat No. P 226) supplied by Bio Scientific Pty Ltd was used in the 
construction of a standard curve.
Principle of method: Dilutions of patients and pool reference plasma are incubated in 
micro wells that have been coated with antibody to human vWF antigen raised in rabbits. 
The vWF antigen in the diluted samples and reference plasma is bound by the 
immobilized antibody. The microwells are then washed and a second antibody to human 
vWf antigen conjugated to horseradish peroxidase is added and the samples incubated.
A peroxidase substrate (TMB) was added after post-incubation washing. The substrate 
developed colour in the presence of conjugated enzyme. The absorbency of each well 
was read at 450 nm using the MR 5000 microtitre plate reader.
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The vWf antigen concentration of the unknown patient sample is determined by reading 
off the standard curve the value corresponding to each patient’s absorbance.
3.7 Hormonal Tests
3.7.1 Total testosterone
Total testosterone was determined in fresh serum using a solid phase 125I 
radioimmunoassay based on testosterone-specific antibody immobilized to the wall of a 
polypropylene tube (Coat-A-Count, Total testosterone, Diagnostic Products Corporation 
Los Angeles, CA).
125I-labelled testosterone competes for a fixed time with testosterone in the patient 
sample for antibody sites. The tube is then decanted, to separate bound from free, and 
counted in a gamma counter. The amount of testosterone present in the patient sample is 
determined from a calibration curve (DPC manual, 1995).
Human serum-based calibrators (TTC3-8) having testosterone concentrations ranging 
from 0.2-16 ng/mL (which is equivalent to 0.7-55 nmol/L or 20-1600 ng/dL) were used. 
These were provided by Diagnostic Products Corporation (DPC).
Reference Values: 4-1600 ng/dL = 0.7-55 nmol/L.
3.7.2 Sex hormone binding globulin (SHBG)
SHBG was measured in fresh serum using the Farmos SHBG IRMA test procedure 
based on the principles of a non-competitive ‘liquid-phase’ immunoradiometric assay Sex 
Hormone Binding Globulin [125I] Immunoradiometric Assay Kit (Farmos Group Ltd, 
Oulunsalo, Finland).
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SHBG Standards (A-F) contain 6.25, 12.5, 25, 50, 100, and 200 nmol SHBG/L (Farmos 
Group Ltd, Finland) were used. SHBG standard was made from human pregnancy 
serum diluted in bovine serum.
Two SHBG controls (low and high) were used and expected values are as follows:
Reference Values: Quality Control L (Low) Quality Control H (high)
9.0-12.2 nmol/L 81.0-106 nmol/L
3.8 Albumin in Urine
The amount of albumin in urine was measured by rate nephelometry (micro ALBUMIN 
(MA), Reagent, P/N 441450) on a Beckman Array 360 analyzer. The method measures 
the rate of increase in light scattered from particles suspended in solution as a results of 
complexes formed during an antigen-antibody reaction (Beckman MA micro ALBUMIN 
manual, 1990).
It is recommended that pooled urine or commercially available nephelometric quality 
control material with known concentrations of albumin be included in each set of 
determinations. In this test, pooled urine with known concentration of albumin was 
used.
Expected Value for Albumin in Urine: < 20 mg/dl
3.9 Anthropometry
All anthropometric measurements were carried out in accordance with the WHO 
standards (WHO, 1987).
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Subjects stood clad in underclothes for the anthropometric measurements. The 
following measurements were made: height against a fixed scale, weight using a 
calibrated digital balance, hip circumference at the widest point of the hip by a new fabric 
tape measure, and waist circumference at the level of the umbilicus without compression 
of the skin by a fabric tape measure.
All skinfolds were measured on the right side of the body using a Harpendon calliper. 
Those were made at four sites on all subjects, at the biceps, triceps, subscapular, and 
suprailiac areas (Dumin and Wormersley, 1974).
Biceps skinfold was measured above the center of the cubital fossa, at the midpoint of 
the biceps muscle.
Triceps skinfold was measured halfway between the inferior border of the acromion 
process and the tip of the olecranon process and in line with the point on the elbow and 
the acromion process.
Suprailiac skinfold was measured above the superior iliac crest in the midaxillary line. 
Subscapular skinfold was measured just below the tip of the scapula.
Table 5-5 Body fat % calculation (Siri, 1956)
Age bracket (years):
20-29 D = 1159.9-71.7 Log (XI)
30-39 D = 1142.3-63.2 Log (XI)
40-49 D = 1133.3-61.2 Log (XI)
where: D = body density
XI = sum of biceps, triceps, subscapular, and suprailiac skinfold 
thicknesses
Body fat percentage was determined according to the formula:
% Body Fat = [(4950/D)-4.5] x 100
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Body mass index (BMI) as a measure of body adiposity was calculated as BMI = weight 
(kg)/ height (m)2 (Quetelet, 1869).
The ratio of waist to hip circumferences (W/H ratio) was calculated as a measure of 
central or abdominal adiposity and the skinfold ratio (subscapular /  triceps ratio) was 
employed as a measure of upper-body fat (Cassano et al, 1992).
Body fat % was calculated by using Siri’s equation (1956).
3.10 The Dietary and Health Questionnaire Booklet
The booklet was explained completely to subjects. The subjects was asked to fill it 
carefully (at home) and return it by post as soon as possible.
Dietary intake was assessed using a self-administered, semi-quantitative food frequency 
questionnaire. This questionnaire has been used frequently in previous dietary intake 
studies in Australia and has been shown to have high repeatability (Baghurst et al, 1988). 
This questionnaire was open-ended both with respect to the foods included and the usual 
serve size of the respondent. Subjects were instructed to indicate how often they usually 
have each of the foods and beverage (ie never, rarely, or so many times per day, per 
week, and per month). For most of the foods listed in the questionnaire, standard serve 
sizes were assumed (Baghurst et al, 1988).
In addition to these food frequency questions, there were a number of questions dealing 
with their health, family medical history, current medication, their dietary changes, 
physical activity, smoking, age, occupation status, income, country of birth, and marital 
status (Appendix III).
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Daily nutrient intake was calculated using a modified version of the Frequan computer 
program (a computerized dietary analysis system for use with diet diaries or food 
frequency questionnaires, CSIRO Division of human Nutrition, Adelaide) (Baghurst and 
Record, 1984).
% energy intake Calculation for different macronutrients:
* % Energy intake from total carbohydrate intake =
(Total carbohydrate (g) x  16 x 100 )/ Total energy intake (KJ)
* Energy intake from total fat intake =
(Total fat intake (g) x  37 x 100) / Total energy intake (KJ)
* Energy intake from protein intake =
(Protein (g) x  17 x  100) /  Total energy intake (KJ)
3.11 Data collection - validity
Every study in medicine must involve an interaction between the observer and the patient 
or object being observed. Measurement bias is a factor that every researcher must be 
wary of (Daly et al, 1991). To avoid this problem, the study protocol was piloted twice 
on volunteers by the researcher and her colleagues. Quality control was checked for 
each run of tests.
Data were extracted from demographic forms and all dietary questionnaires were coded 
by the researcher. The coded dietary questionnaires were sent to CSIRO and were 
analyzed by staff at the Division of Human Nutrition, CSIRO, Adelaide.
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Then all results were entered on a spreadsheet associated with the JMP statistical 
package (SAS Institute Inc) on a Macintosh Quadra 650 computer. The data were 
checked several times to detect any mistakes and then statistical analysis was carried out.
3.12 Statistical Analysis
Statistical analysis were performed using the ‘JM P’ statistical package (SAS Institute 
Inc, NC, USA, Version 3). All statistical comparisons were two tailed. Variables were 
tested for normality (a Gaussian distribution) using the Shapiro-Wilk W test (because n < 
2000). Several variables were not distributed normally and data transformation, 
commonly to the logarithm, was used to reduce skewness.
A significant cut-off level for the p value of 0.05 was used for all statistical analysis. The
0.05 level means that an obtained result that is significant at the 0.05 level should occur 
by chance only 5 times in 100 trials. The 0.05 level corresponds fairly well to two 
standard deviations from the mean of a normal probability distribution.
Student’s t-test (unpaired) was employed to assess the significance of differences in 
group means. The data were presented as mean ± standard deviation.
The chi-square (Pearson) test was used in this research for determining the relationship 
between nominal variables.
Cross-correlation used to determine the possible correlations between variables.
Simple and multiple regression analysis is a method of analyzing the variability of a 
dependent variable on one or more independent variables. These statistical techniques 
were used in this study.
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The advantage of multiple regression over other techniques used is that it shows the 
combined effects of a set of independent variables and the separate effects of each 
independent variable controlling for the others.
The P coefficient of each independent variable and the coefficient of multiple 
determination (denoted by r2), which are two statistics that often accompany the report 
of the multiple regression, are used in this research for describing the relationships 
between the response variable (Y) and independent factors (Xs) in different models.
We chose nine variables (age, fasting insulin concentration, BMI, family history of 
diabetes mellitus, use of an oral contraceptive pill, smoking, fat and alcohol intake, and 
exercise) as independent variables for multiple regression analysis in this study. Subjects 
as a whole were entered in the models and identified as a variable named groups (coded 
as 1 = GDM subjects and 0 = control subject).
Nine different models were determined for BMI, fasting insulin, total cholesterol, total 
triglyceride, and NEFA concentrations, CETP activity (%) in plasma, serum SHBG 
concentration, systolic blood pressure, and the concentration of albumin in urine. The 
result is presented in Table 4-9 in Chapter four.
In multiple regression analysis, there is a nominal variable (X = independent variable) for 
a interval variable (Y = response variable) model. The model translates this specification 
into a linear model as follows. The nominal variables define a sequence of ‘dummy’ 
variables, which have only values 1, 0, and -1. For example, suppose you want to lit the 
response Y to a nominal variable group with three levels. The linear model is written
yi — Po + Pi Xn + P2X2i + £i
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The first dummy variable is labeled group [1-3] in the report, which denotes that group = 





if group = 1 
if group = 2 
if group = 3




if group = 1 
if group = 2 
if group = 3
The last level does not need a dummy variable because in this model its level is found by 
substracting all the other parameters. Therefore, the coefficients sum to one across all 
the levels.
The estimates of the means for the three levels in terms of this parameterization are
M-i = Po + Pi
fii-po + P2 
M-3=Po — Pi — P2
Solving for P yields
p0 = ((J.J+ (i2 + p.3) / 3 = |d (the average over levels) 
p2 = H2 “  H
p3 -  Pi -  P2 = Us -  M-
Thus, if the indicator coding is each level minus the previous level, the parameter coding 
is each level minus the mean of all levls (JMP Package Manual, 1994).
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Each model will be fully described in their own sections.
Subgroups determination:
We determined several subgroups. We used a cut-off point of fasting insulin 
concentration > 1 1 , BMI > 25 kg/m2 for overweight persons, NEFA > 0.6 mmol/L, and 
family history of diabetes mellitus as positive (+) and negative (-) to determine the 
subgroups. ).
Subjects who had plasma NEFA levels > 0 .6  mmol/L, positive family history of diabetes, 
and BMI > 25 kg/m2 determined as subgroup (A).
Subjects who had plasma NEFA levels > 0 .6  mmol/L, positive family history of diabetes, 
and BMI < 25 kg/m2 determined as subgroup (B).
The GDM group with fasting plasma insulin < 10 IU/L were distinguished from those 
with fasting insulin > 10 IU/L and named as hyperinsulinémie subgroup or subgroup C.
Each subgroup were compared with the residual GDM group and residual control group 
using Student’s t test.
CHAPTER FOUR
RESULTS
4.1 Comparison o f Study and Control Populations
The overall response rate was 81.25% in the GDM group and 72.22% in the control 
group (Table 4-1). The uncorrected chi square test indicated that there is no significant 
difference between the response rate in the GDM and the control groups (Table 4-1).






4.1.1 Demographic Data of the Study
The results showed there is no significant difference in age between the GDM and the 
control groups (Table 4-2 and Figure 4-1).
Subjects who had had GDM were more likely to have a positive history of diabetes in 
their first degree relatives (mother, father, sister, and brother) (Table 4-2). The 
frequency of familial diabetes mellitus in the maternal side (17%) was not significantly 
more than paternal side (18.5%) between the GDM subjects (Table 4-3).
The GDM individuals also were more likely to have a positive history of cardiovascular 
disease (CVD) in their first degree relatives (Table 4-2).
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One G D M  subject had had five abortions’, when she was excluded from the data, no 
significant differences were found in parity, number o f  deliveries, number o f  abortions, 
and history o f  stillbirth betw een G D M  and controls (Table 4-2).
Table 4-2 Demographic Data
Variable Number GDMs Controls P
Age M ean 31.52 31.39
Std D ev 4.95 4.22
Fam ily history o f  D M N o history 21 (32.3% ) 43 (66.2% )
First degree relative 25 (38.5% ) 8 (12.3% ) **
Second degree relative 19(29.2% ) 14(21.5%)
Fam ily history o f N o  history 38 (58.5% ) 42 (64.6% )
CVD
First degree relative 24 (36.9% ) 10(15.4% ) **
Second degree relative 3 (4.6% ) 13 (20% )
O bstetrics history Parity 2.35 ±  1.6 2.71 ±  1.3
D elivery 1.95 ±  1.15 2.32 ±  1.13
Abortion 0.23 ±  0.72 0.32 ± 0 .6 2
Stillbirth 0.08 ± 0 .2 1 0.05 ± 0 .2 1
Last baby weight 3410 ±  567 3304 ±  514
Pre-pregnancy BM I M ean 24.81 22.31 **
Std D ev 5.20 2.83
Current BM I M ean 26.05 22.75
**
Std D ev 5.50 2.90
W H R M ean 0.85 0.82
*
Std D ev 0.007 0.007
B ody Fat % M ean 38.8 35.1
**
Std D ev 4.81 3.73
Std D ev  = Standard deviation, BM I = Body mass index, W HR -  W aist /Hip Ratio, * -  
p < 0 .05, ** = p < 0.01, blank space = N o significant.
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The m ean birth-weight w as slightly greater in babies o f  GDM  subjects than in babies o f  
control subjects but the difference was not significant (Table 4-2 and Figure 4-2).
W om en w ho had had G D M  were more likely to be fatter, both pre-pregnancy and one 
year after delivery, than controls. The G D M  subjects have also a significantly greater 
W H R and B ody fat % than controls (Table 4-2, Figures 4-3, 4-4, 4-5, 4-6).
Figure 4-1 Means comparison o f age in GDM and control subjects (the difference
between means is not significant)
Figure 4-2 Means comparison o f  baby birth-weight between GDM and controls 
(the difference between means is not significant)
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Figure 4-3 M eans comparison o f  pre-pregnancy BM I in GDM and control subjects 
(the difference between means is significant)
Figure 4-4 M eans comparison o f  BM I in GDM and control subjects (the difference
between means is significant)
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Figure 4-5 M eans comparison o f WHR in GDM and control subjects 
(the difference between means is significant)
Figure 4-6 M eans comparison o f  body fa t  % in GDM and control subjects 
(the difference between means is significant)
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Table 4-3 Frequencies offamily history o f diabetes mellitus in the GDM and control
group
Frequency of DM in relatives GDM Controls
N o  p ositive  fam ily history 21 (32.3% ) 43 (66.2% )
M other 11 (16.9% ) 2 (3 .1 % )
Father 12(18 .5% ) 3 (4.6% )
Sister 2 (3 .1 % ) 2 (3 .1 % )
Brother 0 (0.0% ) 1 (1.5% )
Grandmother (m other side) 11 (16.9% ) 2 (3 .1 % )
Grandmother (father side) 0 (0.0% ) 1 (1.5% )
Grandfather (m other side) 1 (1.5% ) 2 (3 .1 % )
Grandfather (father side) 2 (3 .1 % ) 2 (3 .1 % )
U ncle  (m other side) 2 (3.1% ) 2 (3 .1 % )
U ncle  (father side) 0 (0.0% ) 2 (3 .1 % )
A unt (m other side) 0 (0.0% ) 0 (0.0% )
A unt (father side) 1 (1.5% ) 1 (3.1% )
Cousin (mother side) 0 (0.0% ) 2 (3.1% )
Cousin (father side) 2 (3 .1 % ) 0 (0.0% )
4.1.2 Physiological Data of the Study
Plasm a cholesterol concentrations were significantly higher in the G D M  group than in 
the control group (Table 4-4 and Figure 4-7). The G DM  subjects had significantly  
higher plasm a TG  levels than controls (Table 4-4 and Figure 4-8).
The plasm a apoB levels  w ere significantly higher in the G D M  group than in the control 
group (Table 4-4  and Figure 4-9), but there w as no significant difference betw een the 
G D M  and control group m eans o f  plasm a apo A-I concentrations (Table 4-4).
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Plasm a N E F A  concentration after an overnight fast was significantly higher in the G D M  
subjects than in the control subjects (Table 4-4 and Figure 4-10).
Characteristics o f  VLDL in subjects outlined in Table 4-4. V LDL-TG  concentration 
w as significantly higher in the G D M  group than in control group. Difference between  
means for other aspects o f  VLDL com position were not significant betw een the tw o  
groups (Table 4-4  and Figure 4-11).
Characteristics o f  the EDL fraction are outlined in Table 4-4. IDL-C, IDL-FC, and IDL- 
TG (but not IDL-CE and IDL-apoB concentrations) were significantly higher in the 
G D M  group than in control group (Table 4-4 and Figure 4-12).
Calculated LDL-C levels were significantly higher in the GDM  subjects than in controls 
(Table 4-4  and Figure 4-13). Calculated LDL-apoB w as significantly greater in G D M  
subjects than in control subjects (Table 4-4 and Figure 4-14).
LDL-I particle sizes were smaller in G DM  group than in the control group (Table 4-4  
and Figure 4-15). LDL-II and LDL-III also were smaller in the G D M  group than in the 
control group but not significantly smaller (Table 4-4).
There is no difference betw een plasma HDL-C level in G DM  subjects and in controls 
(Table 4-4). H D L -apoA -I also was not significantly lower in the GDM  than in control 
group (Table 4-4). H D L 2 area % / H D L 3 area % ratio (using electrophoresis scans) did 
not show  any significant difference betw een the GDM  and the control groups (Table 4 ­
4).
H D L 2 and H D L 3 sub-population com ponents (H D L 2b, H D L 2a, H D L3a, H D L 3b, and 
H D L 3c) w ere compared betw een tw o groups (G D M  and controls) using unpaired
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Student’s t test. H D L 3b and H D L 3c w ere significantly sm aller in G D M  subjects than in 
controls but not other sub-population com ponents (Table 4-4, and Figures 4-16 , 4-17).
There is no significant difference in the Lp(a) levels betw een G D M  and control subjects 
(Table 4-4). Plasm a CETP activity % (C ETP.A  %) w as significantly higher in the 
G D M  group versus the control group (Table 4-4  and Figure 4-18).
Table 4-4 Summarized data from lipoprotein metabolism related tests o f study
V a ria b le s i G D M C o n tro ls p va lu e
Plasm a Cholesterol (m m ol/L) 4.94  ± 0 .9 5 4 .44  ± 0 .8 8 **
Plasm a TG (m m ol/L) 1.07 ± 0 .5 0 0.87 ± 0 .3 9 *
Plasm a apoB (g/L) 1.05 ± 0 .2 4 0.88 ± 0 .2 2 **
Plasm a apo A -I (g/L) 1.50 ± 0 .2 7 1.54 ± 0 .2 5
N E F A  (m m ol/L) 0.68 ± 0 .2 2 0.54 ± 0 .2 3 **
VLDL-C Ounol/L) 518.3 ±  30.6 489.4  ± 3 2 .6
V LD L -T G  (|im ol/L ) 446.8  ± 3 3 .7 8 326.58 ± 3 3 .7 7 *
VLDL-FC (|jinol/L) 204.6  ±  16.2 184.0 ±  16.30
VLDL-CE (fim ol/L) 333.6 ±  28.1 305.5 ± 2 8 .2
V LDL-apoB (g/L) 0.136  ±  0.12 0.109  ± 0 .0 7
IDL-C (jim ol/L) 91 .82  ±  6.56 67.03 ± 6 .5 1 **
ID L-TG  (Mmol/L) 130.06 ±  10.39 82.63 ±  10.39
**
IDL-FC (Mmol/L) 42 .02  ± 2 9 .5 27.59  ± 2 0 .1
**
IDL-CE (ttm ol/L) 49.81 ± 3 .9 6 39.50 ± 3 .9 3
IDL-apoB (g/L) 0.028 ± 0 .0 1 2 0.025 ± 0 .0 1 0
LDL-C (m m ol/L) 3.32 ± 0 .9 4 2.79 ± 0 .7 5 **
LD L-apoB (g/L) 1.05.3 ±  0 .236 0.882 ± 0 .2 1 8 * *
L D L-I size (nm) 30.7 ± 0 .9 8 31.4 ± 0 .9 9
*
LDL-II size (nm ) 29.4 ± 0 .9 9 29.7 ±  1.00
LDL-III size (nm) 28.2 ±  0 .16 28.5 ± 0 .1 3
LD L-C  / H D L-C  Ratio 2.55 ±  0.12 2.06 ± 0 .1 2
**
H D L-C  (m m ol/L) 1.32 ± 0 .0 4 1.38 ± 0 .0 4
TG = triglyceride, apo = apolipoprotein, * = p < 0 05, ** = p < 0.01, blank space = N o  
significant.
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Table 4-5  (continued)
V ariables GDM C ontro ls p value
H D L -apoA -I (g /L ) 1.39 ± 0 . 0 3 1.41 ± 0 . 0 3
H D L 2 (%) /  H D L 3 (% ) 0.81 ± 0 . 0 9 0.97 ± 0 . 1 0
H D L 2b s ize  (nm ) 10.91 ± 0 . 0 4 11.0 ± 0 . 0 4
H D L 2a s ize  (nm ) 9 .28  ± 0 . 0 4 9.34 ± 0 . 0 4
H D L 3a s ize  (nm ) 8 .46  ± 0 . 0 3 8.54 ± 0 . 0 3
H D L 3b size  (nm ) 7.92 ± 0 . 0 1 7.98 ± 0 . 0 1 **
H D L 3c s ize  (nm ) 7.59 ± 0 . 0 2 7 .66  ± 0 . 0 2 **
Plasm a Lp (a) (m g/dl) 19.64 ±  16.8 23.71 ± 2 2 . 9
CETP activity (%) 19.51 ±  1.07 15.78 ±  1.06 *







Figure 4-7 M eans comparison for plasma cholesterol concentration between GDM and  
control groups (difference between means is significant\ p  = 0.0021)
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Figure 4-8 M eans comparison for plasma triglyceride concentration between GDM and  
control groups (difference between means is significant, p  = 0.0153)
Figure 4-9 Comparison between mean values o f  plasma apoB concentrations in GDM  
and confrol groups (difference between means is significant, p  = 0.0000)
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Figure 4-10 Comparison between mean values o f  plasma NEFA concentrations in GDM  





Figure 4-11 Means comparison fo r  VLDL composition levels between GDM and  
controls (there is only a significant difference between means o f  VLDL-TG)









Figure 4-12 M eans comparison fo r  1DL-C, IDL-TG, and IDL FC concenfrations 
between the GD M  subjects and controls (means are significantly different)
Figure 4-13 Comparison o f  means o f  plasm a LDL-C concentration between GDM and 
confrol subjects (there is a significant difference between means, p  = 0.0006)
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Figure 4-14 Comparison o f  means o f  LDL-apoB between GDM  and control subjects 
(there is a significant difference between means, p  = 0.0000)
Figure 4-15 Comparison o f  means ofLDL-1 (size) between GDM and control subjects 
(there is a significant difference between means, p  = 0.0006)
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Figure 4-16 M eans comparison o f  HDL3 b (diameter) between GDM and control groups 
(there is a significant difference between means, p  = 0.0188)
Figure 4-17 M eans comparison o f  HDL3c (diameter) between GDM and control groups 
(there is a significant difference between means, p  = 0.0028)
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Figure 4-18 M eans comparison for plasma CETP activity % between GDM and controls 
(there is a significant difference between means, p  -  0.0190)
The fasting b lood  glucose concentration w as not significantly higher in G D M  subjects 
than in controls (Table 4-5).
Fasting insulin  level w as significantly higher in G D M  patients than in controls (Table 4 ­
5 and Figure 4-19). In addition, the ratio o f  fasting insulin level / fasting g lucose level (as 
a marker o f  insulin resistance) w as significantly higher in G D M  subjects (Table 4-5 and 
Figure 4-20).
G lycosylated  haem oglobin  (H b A lc ) levels w ere similar in the G D M  and control groups 
(Table 4-5).
The m ean p lasm a fibrinogen concentration, factor VII coagulant activity (factor V ile), 
and vonW illebrand factor (vW F ) activity (%) were slightly higher in the G D M  than in 
controls but did not differ sign ificantly  (Table 4-5).
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The tw o groups (G D M  and Controls) had significantly different plasma SHBG  
concentrations (Table 4-5 and Figure 4-21).
The G D M  group w ith a low er concentration o f  SH BG  had a slightly but not 
significantly higher plasm a testosterone concentration than the control group (Table 4 ­
5)-
The testosterone / SH B G  ratio w as significantly greater in G D M  than in control 
subjects (Table 4-5 , Figure 4-22).
B oth systo lic  and diastolic blood pressures were significantly higher in the G D M  group 
than in the control subjects (Table 4-5 and Figures 4-23, 4-24). M ean arterial pressure 
(M A P) w as significantly higher in G DM  subjects than in controls (Table 4-5 and Figure 
4-25). H ow ever, the pulse pressure was similar in G DM  subjects and in controls (Table 
4-5). The amount o f  albumin in urine (m g/L) was significantly greater in G D M  subjects 
than in controls (Table 4-5 and Figure 4-26).
Figure 4-19 Means comparison for fasting blood insulin between GDM and control 
groups (there is a significant difference between means, p  = 0.0008)
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Table 4-5 Summarised data from other physiological tests o f the study
Variables G D M Controls p value
F.blood glucose (m m ol/L) 4 .59  ± 0 .4 4 4.55 ± 0 .4 0
Fasting b lood insulin (IU/L) 7.53 ± 5 .2 3 5.14 ±  1.96 **
Insulin /  G lucose Ratio 1.20 ± 0 .4 1 1.02 ± 0 .2 7 **
H b A lc  (%) 5.30 ± 0 .6 2 5.28 ± 0 .5 0
Fibrinogen (g/L) 3.11 ± 0 .8 4 2.96 ± 0 .7 3
Factor VII activity (%) 100.1 ±  19.5 93.95 ± 2 1 .9
vW F (%) 80.38 ± 3 0 .3 77.25 ± 2 7 .3 1
SH BG  (nm ol/L) 45.05 ± 2 9 .0 2 57.69 ± 3 3 .3 *
T estosterone (nm ol/L) 1.04 ± 0 .5 5 0.91 ± 0 .3 5
T estosterone / SH BG  Ratio 0 .034 ± 0 .0 2 9 0.021 ± 0 .0 1 5 **
Systolic BP (m m H g) 110.15 ±  1.55 105.08 ±  1.55 *
D iastolic BP (m m H g) 76.67 ± 5 .9 4 72.77 ±  5.45 **
M A P (m m H g) 87.23 ± 7 .7 6 83.43 ± 7 .0 1 **
P ulse pressure (m m H g) 34.35 ± 9 .2 5 32.31 ± 9 .3 2
Albumin in urine (m g/L) (Log) 1.10 ±  0.05 0.95 ± 0 .0 5 *
F =  fasting, M A P = main arterial pressure, * = p < 0.05, ** = p < 0.01, blank space =
N o  significant.
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Figure 4-20 M eans comparison for insulin /  glucose ratio between GDM and control 















Figure 4-21 M eans comparison fo r  plasma SHBG level between GDM and control 
subjects (there is a significant difference between means, p  = 0.0239)
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Figure 4-22 Means comparison for Testosterone /  SHBG ratio between G D M and  








Figure 4-23 Means comparison o f  systolic blood pressure in GDM subjects and controls 
(there is a significant difference between means, p  = 0.0225)
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Figure 4-24 M eans comparison o f  diastolic blood pressure in GDM subjects and  
controls (there is a significant difference between means, p  = 0.0026)
Figure 4-25 M eans comparison o f  mean arterial pressure (MAP) in GDM subjects and 
controls (there is a significant difference between m eansp  = 0.0045)














Figure 4-26 M eans comparison for microalbuminuria between GDM and control 
subjects (there is a significant difference between means, p  = 0.0171)
Table 4 -6  show s the m ean values o f  measured dietary factors in this study. 
Poly-unsaturated fat and vitam in E intakes w ere significantly greater in G D M  subjects 
diet than in controls (Figures 4-27 , 4-28).
Other dietary variables w ere not significantly different betw een G D M  and controls.
The mean o f  alcohol consum ption w as not statistically different betw een the G D M  
group and controls (Table 4-6).
4.1.3 C ategorical D ata of the Study
There w as no significant difference in use o f  an oral contraceptive betw een  the G D M  
and control groups (Table 4-7).
Sm oking status w as not significantly different betw een G D M  and control subjects
(Table 4-7).
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There is no statistically significant difference between different measures of exercise 
(frequency, duration, and intensity) between the GDM and control groups (Table 4-7).
Table 4-6 Dietary data o f the study
Variables GDM Controls p value
Total Energy Intake (KJ) 9568 ±  2622 9603 ±  3273
Total D ietary Fat (g) 89 ± 2 4 88 ± 3 5
% Energy Intake (Total fat) 35.4 ± 4 .3 33.8 ±  5.5
Saturated Fat (g) 35.3 ±  11 38.4 ±  19
% Energy (Saturated fat) 14 ± 2 .6 14.3 ± 3 .2
Unsaturated Fat (g) 47 ±14 44 ±  17
% Energy (Unsaturated fat) 18.5 ±  3 17 ±  3
Polyunsaturated Fat (g) 16.3 ± 8 14 ±  6 *
% Energy (Polyunsaturated fat) 6.4 ± 2 .5 5.5 ± 2 .0
M onounsaturated Fat (g) 30.2 ±  8.6 30.0 ± 13
% Energy (M onounsaturate fat) 12 ±  1.5 12 ± 2 .0
Protein (g) 98 ± 3 1 101 98 ± 40
% Energy (Protein) 97.6 ± 2 .9 100.9 ± 4 .0
Total Carbohydrate (g) 266.3 ± 74 275.2 ± 9 7
% Energy (total carbohydrate) 44,7 ± 5.6 45.4 ± 5.5
C om plex Carbohydrate (g) 130 ±  34 122 ± 3 8
% Energy (Comp, carbohydrate) 22.5 ± 4 21.6 ± 5
Sugars (g) 130 ± 4 7 138 ± 47
% Energy (Sugars) 22.5 ± 5 21.6 ±4
Fibre (g) 25 ± 7 25 ±9
Water (g) 2486 ± 690 2306 ± 7 5 5
Retinol (m eg) 659 ± 5 2 2 555 ± 4 2 7
p-carotene (m eg) 3144 ± 1628 3443 ± 1772
Vitamin D  (m eg) 2.63 ± 1.3 2.45 ±1.3
Vitamin E (mg) 10.6 ± 4 .3 8 9.0 + 4.19 *
Vitamin C (mg) 174 ± 7 8 172 ±  80
Thiamine (mg) 1.45 ± 0 .5 1.37 ±  0.5
Riboflavin (mg) 2.35 ± 0 .7 2.34 + 0.8
* = p < 0.05, blank space = No significant.
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Table 4 -6  (continued)
Variables GDM Controls p value
Vitam in B -6  (m g) 1.88 ± 0 .6 1.84 ± 0 .7
N icotin ic  A cid (m g) 21 .9  ±  6.6 21.11 ± 6 .1
Vitam in B -12  (m g) 4 .4  ± 2 .1 4.37  ± 2 .2
F olic A cid  (m eg) 253 ± 8 0 252 ±  10
Biotin  (m eg) 22.55 ±  8 23 .10  ±  10
Pantothenic A cid (m g) 6.6 ±  1.7 5.8 ± 2 .3
Sodium (m g) 2865 ± 7 1 3 2657  ±  790
Chloride (m g) 4793 ±  1340 4641 ±  1735
Potassium  (mg) 3582 ± 9 9 6 3 9 0 6 ±  110
M agnesium  (m g) 331 ± 8 8 330 ± 9 5
Calcium (mg) 1089 ± 3 7 6 1064 ± 4 0 4
Phosphorus (m g) 1582 ± 5 2 1 1560 ± 6 0 9
Iron (m g) 14 ±  4 14 ±  5
Zinc (m g) 13.4 ±  4.3 13.8 ± 6 .1
Copper (m g) 1.9 ±  0.6 2.0 ± 0 .7
Sulphur (m g) 785 ± 2 8 7 826 ±  423
A lcohol (g) 2 .06  ± 3 .6 2.64 ± 3 .5
D ata is presented as mean ±  standard deviation. There is no significant difference  
betw een  tw o groups in the above dietary variables.
Chapter Four R esults 121
Figure 4-27 Means comparison for dietary polyunsaturated fat between GDM and 
controls (there is a significant difference between two groups, p  -  0.0433)
Figure 4-28 M ean comparison for dietary vitamin E  between GDM and confrols ((ther 
is a significant difference between two groups, p  = 0.0386)
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Table 4-7 Summarized categorical data o f the study
Variable Category GDMs Controls p value
Oral contraceptive 1 = Current use 28 (22% ) 2 0 (1 5 % )
2 = Former or Never use 37 (28% ) 45 (35% )
Smoking 0 = Non smoker 38 (29% ) 36 (28% )
1 -  Smoker 10(8% ) 14(11% )
2 = Ex-smoker 17(1 3 % ) 15 (12% )
Freq o f  E xercise 0 = Not at all 18(1 4 % ) 1 6(12% )
1 = Less than once a week 1 7 (13% ) 11 (9% )
2 = Once or twice a week 14(1 1 % ) 17(13% )
3 = Three times a week 1 6 (12% ) 20(16%)
Dura o f  E xercise 0 = Not at all 18(14% ) 16(12% )
1 = Less than 20 minutes 16(12% ) 12(9% )
2 = 20-30 minutes 19(15% ) 14(11% )
3 = More than 30 minutes 12 (9% ) 2 2 (1 7 % )
Inten o f  Exercise 0 = No exercise 18 (14% ) 16(12% )
1 = None of exercise session 6 (5% ) 4(4% )
2 = Some of exercise session 30 (23% ) 33 (26% )
3 = Most or all of exercise 
session
11 (11% ) 10(8% )
L D L  P henotype A 44 (72% ) 37 (62% )
B 17(28% ) 23 (38% )
Freq — frequency, D ura =  duration, Inten — intensity. There is no significant difference 
b etw een  the G D M  and control groups in the above variables.
4.1.4 Cross-correlation Between Different Variables
Table 4-8  show s correlation coeffic ien ts betw een  different variables in the G D M  group 
in this study. The underlined values have significant correlation (p < 0.05).
Age show ed only a negative and significant correlation with concentration o f  albumin in
urine in the G D M  group.
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Total cholesterol concentration w as p ositive ly  and significantly correlated with plasma 
TG, apoA -I, apoB , L D L -C , V L D L -T G  concentrations, and CETP activity in plasma. 
Plasm a cholesterol w as also p ositive ly  and significantly correlated w ith factor V ile, 
diastolic b lood  pressure, and markers o f  obesity  (BM I, body fat %), but the correlation 
betw een plasm a cholesterol concentration and W H R  did not reach significance level. 
Total cholesterol level w as also significantly and positively  correlated with pre­
pregnancy BM I. Plasm a cholesterol concentration w as not significantly related to  
plasma insulin level, fasting blood glucose, H b A lc , exercise, smoking, cholesterol intake 
or total fat intake (T able 4-8).
Fasting plasm a insulin, apo B concentrations, factor V ile , BM I, body fat %, and CETP  
activity in plasm a w ere positively  and significantly related to plasm a TG concentration. 
Plasma TG  level w as negatively and significantly correlated with H D L-C  and LDL1 
particle size  (Table 4-8).
Plasma apo A-I concentration was significantly related to plasma H D L-C , N E FA , 
SH BG  concentrations and alcohol consum ption. Plasm a apoB level w as positively  and 
significantly related to L D L-C , ID L-C , and V L D L -T G  concentrations and CETP  
activity in plasm a as one m ight expected and negatively to H D L-C . Plasm a apoB level 
also w as p ositively  correlated w ith fasting insulin level, factor VII, BM I, and body fat 
% (Table 4-8).
Plasm a N E F A  concentration w as negatively and significantly correlated with blood  
pressure, alcohol intake, and am ount o f  albumin in urine. Plasm a N E F A  concentration 
w as also negatively  correlated with CETP activity in plasm a (Table 4-8).
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H D L-C  w as negatively and significantly correlated with plasm a TG, apoB, VLDL-TG , 
IDL-C concentration, and CETP activity in plasma. There is a positive and significant 
association betw een H D L -C  level and alcohol consumption. H D L 3c w as positively  and 
significantly correlated w ith H b A lc  (Table 4-8).
Data show ed a relationship betw een LDL-C concentration and V LD L-TG  level and 
CETP activity in plasm a, as one might expect. LDL-C also is correlated with fasting 
plasm a insulin level, BM I, and body fat %. There are several dietary factors which are 
negatively related to LDL-C. A  negative linear relationship w as betw een LDL-I 
(particle size) and a set o f  variables including plasm a TG and apoB, VLDL-TG , IDL, 
insulin concentrations, BM I, and body fat %, how ever LDL-I had a positive correlation 
w ith H D L -C  (Tables 4-8).
Statistical analysis show ed that V LD L-TG  was positively  correlated with CETP 
activity in plasm a, fasting plasm a insulin concentration, BM I, and body fat %, while 
there w as a negative correlation between V LD L-TG  and LDL1 particle size (Table 4-8). 
IDL-C has positive correlation with CETP activity in plasma, BM I, and body fat. 
There w as a positive correlation betw een IDL-C level and fasting plasma insulin level, 
but it w as not significant (Table 4-8).
Plasm a Lp (a) concentration w as negatively and significantly correlated with  
concentration o f  albumin in urine (Table 4-8).
Plasm a C ETP.A  % w as related to total cholesterol, TG, apoA-I, apoB, VLDL-TG , 
ID L-C , LD L-C  and N E F A  concentrations. CETP activity in plasma w as correlated 
positively  and significantly with fasting insulin level, BM I, body fat. The relationship
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b etw een  C ETP activity in plasm a and alcohol intake w as negative and significant (Table 
4-8). -
There is a p o sitiv e  and significant association  betw een  fasting blood glucose level and 
factor Vile. Fasting insulin concentration w as p o sitiv e ly  and significantly with total 
cholesterol, TG , apoB , L D L -C , V L D L -T G , testosterone concentrations, CETP activity  
in plasm a, factor V ile , b lood pressure, microalbuminuria, and obesity. There is a 
negative and significant association betw een  plasm a insulin level and LDL1 particle size  
(Table 4-8). _
Plasm a fibrinogen level w as p o sitiv e ly  and significantly associated  with obesity , 
diastolic b lood  pressure, and negatively and significantly with fiber intake. Plasma 
fibrinogen level also w as correlated p ositive ly  with IDL-C. There is a positive and 
significant correlation betw een factor V ile  and BM I. Factor V ile  w as positively  and 
significantly correlated with plasm a cholesterol, TG, apoB, glucose, insulin  
concentrations. V on willebrand factor w as p ositively  and significantly associated w ith  
total fat intake (Table 4-8).
SH B G  level in serum w as negatively and significantly correlated with fasting apoA -I, 
insulin , testosterone concentrations and obesity. Serum testosterone concentration w as  
positively  and sign ificantly  associated  w ith fasting insulin level, and obesity (Table 4-8).
B lood  pressure w as p ositively  and significantly correlated with lipids and lipoprotein
(total ch olestero l, TG, N E F A , and LD L -C  levels), insulin concentrations, and B M I
(Table 4 - 8).
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M arkers o f  ob esity  (B M I, W H R , and body fat %) w ere significantly associated w ith  
plasm a lip ids and lipoproteins (p lasm a cholesterol, TG, apoB, V L D L -T G , IDL-C , and 
L D L -C  levels), insulin, fibrinogen, factor V ile , and testosterone concentrations, blood  
pressure, and CETP activ ity  in plasma. O besity  also w as negatively and significantly  
correlated w ith  plasm a SH B G , LD L particle s ize  (Table 4-8).
The concentration o f  albumin in urine w as significantly and p ositive ly  correlated w ith  
plasm a N E F A  and insulin concentrations, how ever, The concentration o f  albumin in 
urine w as sign ificantly  and negatively correlated with age (Table 4-8).
There is  on ly  a significant and p ositive  correlation betw een  baby w eight and pre­
pregnancy B M I (T able 4-8).
A lcohol consum ption  w as p ositive ly  and significantly associated with plasm a apoA -I, 
N E F A , H D L -C  concentration. The correlation betw een alcohol consum ption and CETP  
activity in plasm a w as negative and significant (Table 4-8).
The am ount o f  fibre in d iet w as negatively and significantly correlated w ith both  
systo lic  and d iastolic b lood  pressure, plasm a fibrinogen concentration, and BM I.
D ietary fibre intake w as a lso  correlated w ith plasm a total cholesterol, apo B , and LD L- 
C concentrations, but the correlation did not reach the sign ificance level (Table 4-8).
D ietary fat intake w as not correlated w ith  any o f  biochem ical tests except vW F . 
D ietary fat intake and all other dietary factors w ere correlated with W HR, but not other
variables (T able 4-8).
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Table 4-8 Cross-correlation beh\ een different variables in this study
r  .---- ;-----
C o r r e l a t i o n s__________________ /




A p o  A - I 0.0758 0.4416 -0.0294
ApoB 0.1428 0.8571 0.4769 0.2231
NEFA 0.1038 0.0367 0.1142 0.2335 0.0278
HDL-C 0.1541 0.0597 -0.2996 0.6166 -0.2512 0.1292
LDL-C 0.0582 0.9983 0.3015 0.4398 0.8499 0.0392 0.0635
VLDL-TG 0.1213 0.3242 0.7365 -0.0204 0.5042 -0.0860 -0.3485
ID L -C 0.0700 0.1821 0.6313 0.0073 0.3395 -0.0700 -0.2762
Lp(a) 0.1022 0.0781 0.1176 0.0120 0.0564 -0.1396 0.1206
CETP 0.0407 0.3997 0.4108 -0.2282 0.5930 -0.2372 -0.4782
HDL3b 0.0555 0.0197 -0.0149 0.2140 -0.0251 0.0023 0.2175
H D L3c 0.0402 -0.0876 -0.0078 0.0207 -0.1331 -0.0271 0.1729
HDL2/HDL3 0.0309 -0.0430 -0.0750 0.1864 -0.1365 0.0554 0.2995
LDLI 0.0182 -0.1588 -0.2261 -0.0410 -0.2109 -0.1316 0.2479
FBG 0.0307 0.0702 0.0702 0.0550 -0.0033 0.1705 0.1975
Insu lin 0.1315 0.2247 0.4143 -0.0936 0.2798 0.1070 -0.1288
Hb A1 c 0.0089 0.0393 0.0517 -0.0798 0.0457 -0.1080 0.063“
F ib 0.0268 0.1183 0.2160 0.0492 0.1647 0.0677 0.056“
F a cV II 0.1259 0.2230 0.2346 0.0641 0.2692 -0.1794 0.0457
vWF 0.1119 -0.0691 0.1307 -0.0357 -0.0605 0.1274 -0.0345
SHBG -0.0116 -0.0231 -0.0749 0.3637 0.0398 0.0355 0 .16K
T e s to s 0.0956 0.0816 0.0765 -0.1383 0.0004 0.0373 -0.0327
SBP 0.1157 0.2218 0.2078 0.1253 0.2653 0.3467 • 0.026C
DBP 0.1448 0.2970 0.2106 0.1098 0.3470 0.3325 . -0.004C
PB Ml 0.1082 0.2823 0.2418 0.0340 0.3235 0.0383 -0.1237
BM I 0.0895 0.3723 0.3808 -0.0164 0.4178 0.0094 -0.1 982
WHR 0.1389 0.0933 0.1901 0.0190 0.0260 0.0588 -0.0043
B . F a t % 0.0787 0.3479 0.3120 0.0738 0.3331 0.1052 -0.148C
A lb u -0.2380 0.1067 0.1432 0.0417 -0.0243 0.4049 -0.0792
Baby W (q) 0.0030 0.1338 0.0492 0.0396 0.0794 0.0959 -0.0147
A lco h o l 0.0607 0.0405 0.0868 0.3363 0.0103 0.2801 0.2556
F ib e r 0.1425 -0.1655 -0.0424 -0.0664 -0.1759 -0.0148 0.0213
Na 0.0986 0.0889 0.0267 0.0042 0.1363 0.1163 0.0180
E n e r . ln 0.0886 0.1581 -0.0743 0.0637 0.1964 0.0183 0.0050
F a t. In 0.1013 0.1160 0.0404 0.0142 0.1968 0.0319 0.0454
C h o i.In 0.0330 0.1372 0.0328 -0.0647 0.1818 0.0184 0.0002,
S Fa t 0.0574 -0.1121 0.0428 -0.0590 0.1491 0.0251 -0.0068
U S Fat 0.1584 0.0382 0.0725 0.0201 0.1279 0.0269 0.0660
C a rb .In 0.0271 0.1654 0.0935 0.0950 0.1671 0.0493 0.0885
P r o te in 0.0822 0.2204 0.0453 0.1500 -0.2593 -0.0487 0.0129
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Table 4-8 (Continued)
V a r ia b le  LD L-C  VLD L-TG  ID L -C  Lp(a) CETP
A g e  
T C  
TG






ID L -C 0.1304 0.6469
Lp(a) 0.0739 0.0602 0.0528
CETP 0.3872 0.4892 0.3800 0.0085
HDL3b 0.0208 0.0215 -0.0646 0.1025 -0.0809
H D L3c -0.0868 -0.0127 -0.1252 0.0113 -0.1161
HDL2/HDL3 -0.0455 -0.1674 -0.0577 0.0643 -0.1906
LDLI -0.1549 -0.2290 -0.2151 0.0713 -0.2098
FBG 0.0670 0.0353 -0.0085 -0.0689 -0.0929
In su lin 0.2165 0.3331 0.1945 0.1154 0.2679
Hb A1 c 0.0387 0.0476 -0.0358 -0.0500 0.0810
F ib 0.1027 0.0785 0.2260 0.1236 0.0228
Fac V II 0.2096 0.2301 0.1122 0.1384 0.1598
vWF -0.0762 -0.0779 0.0835 0.0592 -0.0769
SHBG -0.0267 -0.0972 0.0715 -0.0128 -0.0939
T e s to s 0.0821 0.0813 -0.0034 0.0289 0.0780
SBP 0.2256 0.1483 -0.0163 0.1655 0.0506
DBP 0.3010 0.1963 0.0019 -0.0004 0.0925
PB MI 0.2804 0.3142 0.1571 0.0388 0.2322
B M i 0.3655 0.4064 0.2265 0.0806 0.2994
WHR 0.0883 0.0775 0.0878 0.1311 0.1410
B . F a t % 0.3376 0.3246 0.2472 0.0155 0.2747
A lb u -0.1 110 0.0476 0.1107 -0.2740 -0.1821
Baby W (q) 0.1375 0.1200 -0.0520 0.0694 0.0770
A lco h o l 0.0362 -0.0493 0.0115 0.1998 -0.2699
F ib e r -0.1 690 -0.0529 -0.0402 0.0421 -0.0492
Na 0.0910 0.0199 0.0343 0.1005 -0.0256
E n e r.In 0.1528 0.0446 •0.0905 0.1102 0.0114
F a t.I  n 0.1135 0.1290 0.0578 0.1155 0.0324
C h o i.In 0.1351 0.0104 0.0813 0.0450 0.0012
S Fat 0.1111 0.0582 0.0309 0.0996 0.0335
U S F a t 0.0326 0.0874 0.0897 0.1152 -0.0103
Ca rb . ln -0.1570 0.0090 0.1049 0.1296 0.0356
P r o te in -0.2188 0.0163 0.0615 0.0514 0.0044
Fib = fibrinogen, Albu =  albumin, W = weight, S = saturated, US -  un-saturated, Carb
carbohydrate.
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Table 4-8 (Continued)
V a r ia b le  H D L3b
A g e  
T C  
TG











H D L3c 0.4685
H D L2/H D L3 -0.2054 0.0323
LDLI -0.0599 0.1678 0.1329
FBG -0.0746 0.0301 0.0105 0.1813
In s u lin -0.0043 -0.1601 -0.1295 -0.2641 0.1668
H bA1 c -0.0525 0.2698 0.0736 0.0534 0.1612
F ib -0.0440 0.0577 0.0360 -0.0046 0.0984
Fac VII -0.0744 0.0137 -0.2216 0.0556 0.2610
vW F -0.1519 0.1820 -0.0499 0.0006 0.1389
SHBG 0.1007 0.0113 0.0616 0.1879 -0.1457
T e s to s -0.1523 -0 .1523 . 0.1506 -0.0735 0.1605
SBP -0.0367 -0 .1330 -0.0166 -0.2799 0.0348
DBP -0.0304 -0.0258 0.0265 -0.1735 0.1910
PB Ml -0.0350 -0.1728 -0.1634 -0.2525 0.0188
B M I -0.0098 -0.1681 -0.1747 -0.2466 0.0090
WHR -0.0807 -0 .0842 -0.0531 -0.11 60 0.0209
B . F a t % -0.0427 -0.1948 -0.1817 -0.2571 0.0655
A lb u -0.1812 -0 .0388 0.0053 -0.1381 0.1199
Baby W (g) -0.0724 -0 .1249 0.0514 -0.1403 0.1663
A lc o h o l 0.1695 0.0429 0.1294 0.0505 • 0.1169
F ib e r 0.1412 0.0993 0.0437 0.1422 -0.1367
Na -0.0430 0.0094 0.0286 0.0176 0.0177
E n e r .In -0.0854 0.0797 0.0735 0.1130 0.0486
F a t . In -0.0629 0.0720 0.1168 0.0971 0.0303
C h o i. In -0.1209 -0.0968 0.1386 0.0387 0.0829
S F a t -0.0971 0.0822 0.1254 0.1268 0.0289
U S F a t -0.0462 0.0401 0.0243 0.0986 0.0295
C a rb . In -0.0946 0.0989 0.0422 0.0636 0.0949
P r o te in -0.0707 0.0258 0.0503 0.1162 0.0426
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Table 4-8 (Continued)
V a r ia b le  In s u lin  Hb A1 c F ib  F a c V I l vW F
A g e  
T C  
TG










H D L 3 c
H D L2 /H D L3
LDLI
FBG
In s u lin
Hb A1 c 0.0424
F ib 0.0214 0.1154
F a c  V II 0.2211 0.0785 0.1857
vW F 0.0116 0.2208 0.1915 0.0448
SHBG -0.3736 -0.0427 -0.0393 -0.1452 -0.0448
T e s to  s 0.3107 0.0403 0.0709 0.0206 0.0992
S B P 0.3205 0.0822 0.1921 0.0359 0.0565
DB P 0.2177 0.0014 0.2527 0.0053 0.0204
P B M l 0.5511 0.0972 0.1379 0.1345 0.0180
B M I 0.5713 0.1051 0.2428 0.2419 0.0675
WHR 0.2175 0.0858 0.1555 0.0242 0.0519
B . F a t % 0.4782 0.1398 0.2575 0.1743 0.0631
A l b u 0:2601 0.0338 0.1047 0.1882 0.0615
B aby W (g) 0.0137 0.0844 0.0936 0.0907 0.0785
A lc o h o l 0.0601 0.0921 0.1254 0.1126 0.0422
F ib e r -0.1736 -0.0875 -0.2502 -0.0723 0.0889
N a 0.0337 -0.0152 0.0008 0.0817 0.1527
En e r . I  n 0.0583 -0.0041 0.1250 0.1148 0.1756
F a t . I  n 0.0067 -0.0066 0.1118 0.0779 0.2270
C h o l. In 0.0944 -0.1413 0.1072 0.0223 0.1845
S F a t 0.0115 -0.0281 •0.0439 0.0439 0.2144
U S F a t -0.0501 0.0350 0.0297 0.0556 0.1854
C a rb . In 0.0896 0.0405 0.1721 0.1908 0.0860
P r o te in 0.0319 0.0404 0.1602 0.1204 0.1942
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Table 4-8 (Continued)
V a r ia b le  SHBG
A g e  
T C  
TG










H D L 3 c
H D L2 /H D L3
LDLI
FBG
in s u lin
Hb A1 c
F ib
F a c  V II 
vW F
SHBG
T e s to s -0.3881
S B P -0.1327
DBP -0.1030
P B M I -0.3226
B M I -0.3617
WHR '-0.1939
B . F a t % -0.3073
A lb  u -0.0010
B aby W (g) -0.0512
A lc o h o l 0.1960
F ib e r 0.0679
Na -0.0542
E n e r . ln -0.0752
F a t . I  n -0.0639
C h o i. In -0.1449
S F a t -0.1075
U S F a t -0.0589
Ca r b . In -0.0578
P r o te in -0.1367
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Table 4-8 (Continued)
V a r ia b le  B M I
A g e  
T C  
TG

















F a c V ll
vWF
SHBG






B . F a t % 0.7990
A lb u 0.0540
Baby W (g) 0.2165
A lco h o l 0.0358
F ib e r -0.2565
Na 0.0898
E n e r . ln 0.0798
F a t. In 0.0948
C h o i.In 0.0163
S F a t 0.0608
U S F a t 0.1054
C a rb . ln 0.0568
P r o te in 0.0799
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Table 4-8 (Continued)
V a r ia b le  A lc o h o l F ib e r
A g e  
T C  
TG











H D L2/H D L3
LDLI
FBG
In s u lin
Hb A1 c
F ib
F ac V II 
vWF 
SHBG 
T e s to s  
S B P  
DBP 
P B M I 
B M l 
WHR 
B . F a t %
A Ib u
Na Ene r . ln
Baby W (g) 
A lc o h o l
F ib e r -0.0503
Na -0.0499 0.5736
E n e r .In -0.0930 0.6341 0.8775
F a t . In -0.0779 0.4900 0.8126 0.8949
C h o i. In -0.1615 0.2802 0.4913 0.6180
S F a t -0.1550 0.4293 0.7788 0.8934
U S F a t -0.0295 0.4976 0.8173 0.8674
C a rb . ln -0.1043 0.6344 0.7737 0.9235
P r o te in -0.1963 0.6137 0.7706 0.8706
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Table 4-8 (Continued)




A p o A - I
A p o B
N E F A
H D L-C
L D L -C
V L D L -T G
ID L - C
L p (a )
C E T P
H D L 3 b
H D L 3 c
H D L 2 /H D L 3
LD LI
FBG
In s u lin
H b  A1 c
F ib
F a c  V II 
vW F  
SH B G  
T e s t o s  
S B  P 
D B P  
P B  M I 
B M I 
W H R  
B . F a t % 
A lb u
B a b y  W  (g) 
A lc o h o l 
F ib e r  
N a
E n e r . In  
F a t . I  n 
C h o i. I  n 
S F a t 
U S F a t 
C a r b . In  
P r o t e in
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Most of the correlations between plasma lipoprotein and lipoprotein constituents could 
be predicted with a knowledge of the physiology of plasma lipid and lipoprotein 
metabolism.
Note: Other correlations indicated that relationships could be further explored by two 
techniques, multiple regression analysis of a group of apparently related variables, and 
subgroup analysis (eg of a subgroup with particularly well-developed insulin resistance 
syndrome).
4.1.5 M ultiple Regression Analysis
Multiple regression was used to investigate relationships between BMI, fasting insulin, 
total cholesterol and triglyceride, NEFA, and SHBG concentrations, CETP activity in 
plasma, systolic blood pressure, and microalbuminuria and their possible determinants.
Age, Groups (1= GDM group and 0 = control group), fasting plasma insulin 
concentration, BMI, family history of diabetes mellitus, use of a contraceptive pill, 
alcohol, fat, and protein intake, and exercise were chosen as independent variables in 
different multiple regression model. The results are presented in Table 4-9.
The multiple regression model for BMI showed that group (as 1 -  GDM subjects and 0 
= controls) and fasting insulin concentrations are significant determinants of BMI in this 
study (Table 4-9).
The multiple regression model for fasting insulin concentration indicated that BMI is the 
most important determinant in the variance of fasting insulin concentration in this
investigation (Table 4-9).
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Regression analysis showed that group (as 1 -  GDM subjects and 0 = controls), BMI, 
family history of diabetes, and exercise are the significant determinants for the total 
cholesterol levels (Table 4-9).
Table 4-9  R esults fro m  the m ultiple r e c e s s io n  an a lyses
BMI Insulin TC TG NEFA CETP SHBG SBP Albu
N 130 130 130 130 130 130 130 130 130
Adj R2 0.28 0.24 0.17 0.24 0.16 0.12 0.35 0.18 0.12
Intercept 25.33 -2.65 3.57 0.063 0.59 2.299 4.22 85.56 1.53
Age -0.10 -0.02 -0.003 0.01 -0.002 -0.0003 0.01 0.01 -0.02*
Groups [0-1] -1.03* -0.66 -0.23* -0.03 -0.07* -0.10 0.13* 0.48 0.05*
Insulin 0.48* (-) 0.01 0.04* 0.01 0.03 -0.003 0.62* 0.03*
BMI (-) 0.39* 0.05* 0.02 -0.004 0.01 -0.03* 0.73* -0.01*
FH.DM [0-2] 0.08 0.55 0.14 0.02 -0.14 0.11 0.03 -0.36 -0.03
FH.DM [1-2] -0.25 0.36 -0.22* 0.04 -0.0003 -0.07 -0.05 0.01 0.03
C.Pill [0-2] -0.18 0.38 -0.12 0.14 -0.05 0.08 -0.23* -3.41 -0.04
C.Pill [1-2] -0.11 -0.19 0.15 -0.01 0.05 0.01 0.39* 2.34 0.09
Smoking [0-2] -0.23 0.01 -0.01 0.013 0.02 0.08 -0.11 0.50 -0.03
Smoking [1-2] -0.08 0.03 -0.06 0.05 0.05 -0.012 0.17* 0.05 0.10
Alcohol 0.32 0.03 0.28 0.15 0.20* -0.25* 0.15 5.21* 0.02
Fat in -0.01 -0.001 -0.002 0.0001 0.001 -0.0004 -0.001 -0.03 0.001
Fre.Exer [0-3] 0.67 0.72 0.31* -0.06 -0.05 0.13 0.08 0.41 0.02
Fre.Exer [1-3] 0.29 0.32 0.16 0.10 0.004 -0.06 0.02 -2.22 0.02
Fre.Exer [2-3] 0.02 -0.77 0.01 -0.06 0.02 0.07 -0.10 3.23 -0.05
The regression coefficients and their significant level of the relevant variables in the 
regression model are presented. N = number of observations, FH.DM = family history 
of diabetes mellitus, C.Pill = contraceptive pill, in = intake, Fre = frequency, Exer = 
exercise, Dur = duration, Int = intensity, (-) = not included in the model, albu = 
Albuminuria. “Note: the explanation of [ ] is in Chapter Three”.
In the final regression analysis, fasting insulin concentration was shown significantly
associated with plasma TG concentration (Table 4-9).
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Multiple regression analysis showed that group (as 1 = GDM subjects and 0 = controls) 
and alcohol consumption are significant independent variables in the plasma NEFA 
levels (Table 4-9).
CETP activity (%) in plasma was significantly associated with alcohol consumption in 
the multiple regression analysis (Table 4-9).
The multiple regression model for serum SHBG concentration indicated that group (as 
1= the GDM subjects and 0 = controls), BMI, use of an oral contraceptive, and smoking 
are the significant determinants for serum SHBG model (Table 4-9).
Fasting insulin concentration, BMI, and alcohol consumption were significantly 
associated with systolic blood pressure in the multiple regression analysis (Table 4-9). 
Regression analysis showed that age, group (as 1 = GDM subjects and 0 = controls), 
fasting insulin concentration, and BMI are the most important determinants of the 
amount of albumin in urine (Table 4-9).
4.2 Sub-population Analysis:
4.2.1 The Definition of Subgroups
The multiple regression models suggested that sub-populations with sub-clinical or 
overt disease may exist.
The populations (both GDM and controls) were categorised according to three factors: 
plasma NEFA concentration, family history of diabetes, and BMI. The frequencies are 
presented in Table 4-10).
In addition, another subgroup was determined according to fasting insulin concentration 
(hyperinsulinemic subgroup or subgroup C). Data suggested that a number of subjects
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in the GDM group might have the insulin resistance syndrome. The defining feature of 
the insulin resistance syndrome was taken to be fasting hyperinsulinemia. On initial 
analysis of fasting plasma insulin concentrations, it was clear that there was a group of 
GDM women who had a higher plasma insulin than the control group. The control 
group had a mean fasting plasma insulin 5.14 IU/L (range 1.1-9.8, 95% within range 
1.36-9.54).
The GDM group with fasting plasma insulin < 10 IU/L were distinguished from those 
with fasting insulin > 1 0  IU/L. There were 65 women in the control group, 52 in the 
GDM group with fasting insulin <10 IU/L who were assessed not to have developed 
insulin resistance and 13 (ie 20% of the GDM group) who were assessed as having 
insulin resistance.
Table 4-10 Frequencies for different subgroups
Subgroups GDM Control
h.NEFA , (+) FH , OW 14 0
h.NEFA , (+) FH 15 8
h.N EFA , OW 3 5
(+) FH , OW 8 3
h.NEFA 6 8
(+) FH 7 11
OW 7 4
None 5 26
h.NEFA = high plasma NEFA level, FH - family history, OW = overweight.
4.2.2 Subgroup (A) Results
Sub-group (A): Sub-population includes subjects who are overweight and have high 
plasma NEFA concentrations and a positive family history of diabetes.
There were no differences in age between the subgroup (A) and residual GDM group
and controls (Table 4-11).
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The subgroup (A) had slightly higher plasma cholesterol and apoB than residual GDM 
subjects, but significantly higher than controls (Table 4-11).
The subgroup (A) tended to have higher plasma TG, VLDL-TG, and IDL-C 
concentrations than the residual GDM or control groups. There was a tendency for the 
subgroup (A) to have a slightly higher LDL-C than the residual GDM group, and a 
significantly higher LDL-C than controls (Table 4-11).
All three subgroups were similar in the HDL-C concentrations. HDL particle sizes and 
the HDL2 /HDL3 ratio were similar in the three groups (Table 4-11).
The subgroup (A) tended to have slightly smaller LDL-I then the residual GDM group 
and significantly smaller than the control group (Table 4-11).
The subgroup (A) also tended to have slightly higher CETP activity in plasma then the 
residual GDM group, but CETP activity in plasma was significantly higher in the 
subgroup (A) than controls (Table 4-11).
Fasting blood glucose means were similar in the three groups. However, fasting insulin 
levels were significantly higher in the subgroup (A) than other two groups (Table 4-11).
The mean systolic and diastolic blood pressures were slightly higher in subgroup (A) 
compared with the residual GDM subjects, and significantly higher in subgroup (A) 
than controls (Table 4-11).
The subgroup (A) showed a greater concentration of albumin in urine than both the 
residual GDM group and controls. The subgroup (A) had slightly greater amount of
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albumin in their urine than the residual GDM group and significantly greater than the 
control group (Table 4-11).
The subgroup (A) tended to be fatter before they became pregnant (as described by pre­
pregnancy BMI) than both the residual GDM and control groups (table 4-11).
Table 4-11 C om parison  o f  subgroup (A) Math the residual G D M  popu la tion  an d  controls
(Continuous Data)
V a ria b le Subgroup (A)
(n -  14)
R.GDM
(n -  51)
Pi C o n tro ls
(n = 65)
P2
Age 32.1 ± 6.1 31.4 ± 4 .7 31.4 ± 4.2
TC 5.2 ± 1.0 4.9 ± 0.9 4.4 ± 0.8 * *
TG (log) 1.06 ± 0.02 1.04 ± 0.02 * * 1.04 ± 0.02 * *
ApoB 1.12 ± 0.2 1.03 ± 0.3 0.88 ± 0.2 *  *
VLDL-TG (log) 6.3 ± 0.6 5.8 ± 0.7 * 5.6 ± 0.7 *  *
IDL-C (log) 4.7 ± 0.5 4.2 ± 0.6 * 4.1 ± 0.6 * *
HDL-C (log) 1.05 ± 0.01 1.05 ± 0.01 1.06 ± 0.02
LDL-C 3.5 ± 1.0 3.3 ± 0.9 2.8 ± 0.7 *  *
HDL3b Size 7.92 ± 0.10 7.92 ± 0.11 7.97 ± 0.11
HDL3c Size 7.62 ± 0.16 7.59 ± 0.16 7.65 ± 0.13
HDL2 /H D L 3 ‘ 0.85 ± 0.18 0.91 ± 0.19 0.92 ± 0.21
LDL-I Size 30.34 ± 0.83 30.88 ± 1.06 31.39 ± 1.00 *
CETP.A (log) 3.0 ± 0.49 2.8 ± 0.60 2.6 ± 0.66 *
FBG (log) 1.54 ± 0.08 1.50 ± 0.10 1.50 ± 0.09
Insulin 10.9 ± 6.5 6.6 ± 4.5 * * 5.1 ± 2.0 * *
SBP 114.5 ± 12.1 109.6 ± 12.7 105.5 ± 11.7 * *
DBP 76.9 ± 5.5 76.0 ± 6.0 73.2 ± 5.4 *
Microalb (log) 1.16 ± 0.33 1.09 ± 0.37 0.9 ± 0.38 *
P.BMI 26.8 ± 5.2 24.1 ± 4.5 * 22.3 ± 2.8 * *
Baby weight 3573 ± 547 3366 ± 569 3304 ± 5 1 3
Alcohol in (log) 0.34 ± 0.40 0.28 ± 0.36 0.40 ± 0.41
Sodium intake 7.95 ± 0.34 7.96 ± 0.26 7.87 ± 0.37
Fat intake 103.5 ± 57.5 93.14 ± 31.0 90.78 ± 28.4
Data presented as mean ± standard deviation. R.GDM = the residual GDM group, P! = 
p values of comparison of subgroup (A) Vs the residual GDM group, P2 = p values of 
comparison of subgroup Vs controls, in = intake, log = Natural logarithm (base e), * = p 
< 0.05, ** = p < 0.01, and blank space in the P x and P2 columns = No significant 
difference.
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The babies o f  the subgroup (A ) m others tended to be slightly heavier than the babies o f  
the other tw o  groups. Fat, alcohol and sodium  consum ption were similar in three 
groups.(T able 4-11). There w ere no significant differences betw een use o f  an oral 
contraceptive, sm oking, and exercise betw een the subgroup (A ) and other tw o groups 
(Table 4 -12).
Table 4 -12  C om parison  o f  su bgrou p  (A) w ith  re s t o f  the G D M  p o p u la tio n  a n d  controls





Pj C o n tr o ls  P2
(n = 65)
C.Pill Current use 7 (50%) 22 (43%) 21 (32%)
F or N use 7 (50%) 29 (57%) 44 (68%)
Smoking Non-sm oke 9 (64%) 29 (57%) 36 (55%)
Smoker 0 (0%) 10 (20%) 14 (22%)
Ex-sm oke 5 (36%) 12 (24%) 15 (23%)
Fre.Exer 0 5 (36%) 13 (26%) 16 (25%)
1 3 (21%) 14 (27%) 12 (19%)
2 2 (14%) 12 (24%) 17 (26%)
3 4 (29%) 12 (24%) 20 (31%)
Dur.Exer 0. 5 (36%) 13 (26%) 16 (25%)
1. 4 (29%) 12 (24%) 13 (20%)
2. 3 (21%) 16 (31%) 14 (22%)
3. 2 (14%) 10 (20%) 22 (34%)
Int.Exer 0- 5 (36%) 13 (26%) 17 (26%)
1- 0 (0%) 6 (12%) 5 (8%)
2- 7 (50%) 23 (45%) 33 (51%)
3- 2 (14%) 9 (18%) 10 (15%)
R .G D M  = rest o f  the G D M  group, Pi -  p values o f  com parison o f  subgroup (A ) versus 
rest o f  G D M  group, P 2 =  p values o f  com parison o f  subgroup versus controls, F =
former, N  =  never, Sm oke = smoker, 0 = N ot at all, 1 = L ess than once a w eek, 2 = Once 
or tw ice  a w eek , 3 = Three tim es a w eek, 0. =  N ot at all, 1. = L ess than 20 m inutes, 2. =  
2 0 -3 0  m inutes, 3. = M ore than 30 m inutes, 0- = N o  exercise, 1- = N on e o f  exercise 
session , 2- =  Som e o f  exercise session , 3- = M ost or all o f  exercise, and blank space in 
the P i and P 2 colum ns = N o  significant difference.
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4.2.3 Subgroup (B) Results
Sub-group (B): Sub-population includes subjects w ho have high plasma N E F A  
concentrations and positive fam ily history o f  diabetes.
There w ere no significant difference for age betw een subgroup (B ) and other tw o groups 
(the residual G D M  and control groups) (T able 4-13).
The subgroup (B ) had slightly low er plasm a cholesterol than the residual G D M  group, 
but not significantly. Plasm a cholesterol m eans w ere similar betw een the subgroup (B) 
and controls (Table 4-13).
The subgroup (B ) had significantly low er plasm a TG, V LD L-TG , and IDL-C  
concentration than the residual G D M  group. T hose three variables were similar 
betw een the subgroup (B) and controls (Table 4-13).
There w as a tendency for the subgroup (B ) to have a slightly low er LDL-C than the 
residual G D M  group, and a similar mean o f  LDL-C concentration with controls (Table 
4-13).
A ll three subgroup were similar in the H D L -C  concentrations. H D L 3c particle sizes  
were significantly smaller in the subgroup (B ) than the control group, but were not 
sign ificantly  sm aller compared w ith the residual G D M  subjects (Table 4-13).
The H D L 2 /  H D L3 ratio w ere sim ilar in the three groups. LD L-I particle size also were 
sim ilar betw een  three groups (Table 4 -13).
The subgroup (B ) also tended to have slightly  low er CETP activity in plasma then the 
residual G D M  and control groups, but not sign ificantly low er (Table 4-13).
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Fasting blood g lu cose means were similar in the three groups. H ow ever, fasting insulin 
levels w ere significantly low er in the subgroup (B ) than the residual G D M  group, and 
slightly low er than the control group (Table 4-13).
The m ean systo lic  and diastolic blood pressures w ere slightly higher in the subgroup (B) 
compared w ith the residual G D M , but the subgroup (B ) tended to have significantly 
higher d iastolic b lood  pressure than the control group (Table 4-13).
Subgroup (B ) tended to have similar SH BG  concentration with the control group and to  
have significantly higher SHBG concentration than the residual G D M  group (Table 4 ­
13).
T estosterone concentration were significantly low er in the subgroup (B ) than in the 
residual G D M  group, but there is no significant difference betw een testosterone  
concentrations in the subgroup (B) and controls (Table 4-13).
The subgroup (B ) showed significantly greater concentration o f  albumin in urine than 
the controls, but the difference betw een means for concentration o f  albumin in urine 
betw een the subgroup (B) and the residual G D M  were not significant (Table 4-13).
The subgroup (B ) tended to be slimmer before they became pregnant (as described by  
pre-pregnancy B M I) than both the residual G D M  and control groups. The difference 
betw een m eans o f  the residual G D M  group and subgroup (B ) w as significant (Table 4 ­
13).
The babies o f  the subgroup (B ) mothers tended to be slightly lighter than the babies o f
the other two groups (Table 4-13).
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Fat, alcohol and sodium  consum ption w ere sim ilar in three groups.(Table 4-13).
Table 4 -1 3  C om parison  o f  su bgrou p  (B) w ith  the res id u a l G D M  pop u la tio n  a n d  residu a l
co n tro ls  ( C ontinuous D ata)




p, R .C o n tro ls
(n = 57)
p 2
Age 29.7 ± 4.4 32.1 ±  5.0 31.5 ±  4.0
TC ±  1.1 5.0 ± 0.9 4.4 ± 0.8
TG 0.84 ±  0.4 1.13 ±  0.5 * 0.87 ± 0.4
ApoB 0.10 ±  0.3 1.1 ± 0.3 0.88 ± 0.2
VLDL-TG (log) 5.47 ± 0.7 6.01 ± 0.6 *  * 5.55 ± 0.7
IDL-C (log) 3.9 ± 0.6 4.4 ± 0.60 * * 4.1 ± 0.60
HDL-C (log) 1.06 ± 0.01 1.05 ± 0.01 1.06 ± 0.01
LDL-C 3.11 ± 1.12 3.38 ± 0.88 2.79 ± 1.12
HDL3b Size 7.92 ± 0.11 7.92 ± 0.11 7.97 ± 0.11
HDL3c Size 7.57 ± 0.14 7.60 ±  0.16 7.64 ± 0.13
HDL2 /  h d l 3 0.90 ± 0.15 0.89 ± 0.20 0.92 ± 0.21
LDL-1 Size 30.9 ± 0.95 30.7 ± 1.06 31.4 ± 1.00
CETP.A (log) 2.48 ± 0.73 2.94 ± 0.49 *  * 2.58 ± 0.66
FBG (log) 1.50 ± 0.14 1.51 ± 0.07 1.52 ± 0.09
Insulin 4.51 ± 2.39 8.45 ± 5.52 * * 5.15 ± 1.96
SBP 111.1 ± 10.9 110.5 ± 13.2 105.5 ± 11.7
DBF 77.1 ± 4.7 75.9 ± 6.1 73.2 ± 5.4 *
SHBG (log) 3.92 ± 0.63 3.59 ±  0.54 * 3.92 ± 0.50
Testostero (log) 1.03 ± 0.02 1.05 ± 0.02 * 1.04 ± 0.01
Microalb (log) 1.19 ± 0.37 1.08 ± 0.36 0.95 ± 0.38 *
P.BMI 22.03 ± 2.36 25.64 ± 5.5 * 22.31 ± 2.8
Current BMI 22.07 ± 2.20 27.15 ± 5.66 * * 22.75 ± 2.95
WHR 0.81 ± 0.05 0.86 ± 0.07 * 0.82 ± 0.06
Baby weight 3202 ± 530 3473 ± 567 3304 ± 514
Alcohol in (log) 0.24 ± 0.30 0.31 ± 0.38 0.40 ± 0.40
Sodium intake 8.07 ±  0.26 7.93 ± 0.28 7.87 ± 0.37
Fat intake 92.82 ± 32.9 96.14 ± 39.6 90.78 ± 38.4
R =  residual, Testostero = testosterone, M icroalb =  m icroalbuminuria , * = p < 0.05, ** 
= p < 0 .01 , blank space = N o significant. Data presented as mean ±  standard deviation. 
M ost (60% ) o f  subjects in the subgroup (B ) were using oral contraceptive pill, at time 
o f  study, com pared w ith other tw o  groups, but only the difference betw een the 
subgroup (B ) and controls w as sign ificant (Table 4 -14), log  =  natural logarithm (base e).
Chapter Four Results 145
Table 4 -1 4  C om parison  o f  subgroup (B) w ith  the residu a l G D M  popu la tion  a n d  residual
controls (C a tegorica l D ata)




Pi R .C on tro ls  P 2
(n -  57)
C.Pill Current use 9 (60%) 20 (40%) 16 (28%) *
F or N use 6 (40%) 30 (60%) 41 (72%)
Smoking Non-sm oke 7 (47%) 31 (62%) 29 (50%)
Smoker 6 (40%) 4 (8%) * 14 (25%)
Ex-smoke 2 (13%) 15 (30%) 14 (25%)
Fre.Exer 0 2 (13%) 16 (32%) 14 (25%)
1 1 (7%) 16 (32%) * 10 (18%)
2 7 (47%) 7 (14%) 17 (30%)
3 5 (33%) 11 (22%) 16 (28%)
Dur.Exer 0 . 2 (13%) 16 (32%) 14 (25%)
1. 2 (13%) 14 (28%) 11 (19%)
2. 5 (33%) 14 (33%) 13 (23%)
3. 6 (40%) 6 ( 12%) * 19 (33%)
Int.Exer 0 - 2 (13%) 16 (32%) 15 (26%)
1- 0 (0%) 6 (12%) 3 (5%)
2- 9 (60%) 21 (42%) 31 (54%)
3- 4 (27%) 7 (14%) 8 (14%)
R .G D M  = rest o f  the G DM  group, Pj = p values o f  comparison o f  subgroup B versus 
rest o f  G D M  group, P2 = p values o f  comparison o f  subgroup B versus controls, F = 
former, N  = never, Sm oke = smoker, 0 - Not at all, 1 = Less than once a week, 2 - Once 
or tw ice a w eek, 3 = Three tim es a week, 0. = Not at all, 1. = Less than 20 minutes, 2. = 
20-30  minutes, 3. = M ore than 30 minutes, 0- = N o exercise, 1- = N one o f  exercise 
session , 2- = Some o f  exercise session, 3- = M ost or all o f  exercise, * -  p < 0.05, and 
blank space in the and P2 colum ns = N o significant difference.
The subgroup (B ) tended to sm oke more than both other groups, but only the difference 
betw een subgroup (B) and the residual G D M  group was statistically significant (Table 
4-14).
The three com ponents o f  exercise (frequency, duration, and intensity) were similar 
betw een the subgroup (B) and controls. H ow ever, the subgroup (B ) tended to do more 
exercise  than the residual GDM  group (Table 4-14).
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4.2.4 Hyperinsulinemic subgroup (Subgroup C) Results
There w ere no d ifferences in age betw een  the three groups.
The insulin resistant group had significantly higher plasm a cholesterol level than the 
other tw o groups. The insulin resistant group tended to be m ildly hypertriglyceridem ic 
(range 0 .8 -2 .8  m m ol/L , median 1.4 m m ol/L), and as a group, they had higher plasm a TG  
values than residual G D M  or control groups.
Plasm a apoB, V L D L -T G , ID L-C , LD L-C , and N E F A  were higher in insulin resistant 
group then other tw o  groups.
There w as a tendency for the insulin resistant group to have a slightly low er H D L-C  
than the other tw o  groups, but this w as not significant. CETP activity w as significantly  
higher in the insulin  resistant group than in other tw o groups.
H D L 3 particle s izes w ere similar in three groups, how ever LDLI particle size slightly  
sm aller in the insulin resistant group than in the residual G D M  group and significantly  
sm aller than in controls (Table 4-15).
The m ean systo lic  and diastolic blood pressures w ere significantly higher in the insulin 
resistant group than in the other tw o groups (Table 4 -15).
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Table 4 -15  C om parison  o f  subgrou p  (C) w ith  re s t o f  the G D M  p o p u la tio n  a n d  con tro ls  
____________________ __________ (C ontinuous D a ta )______
V ariable Subgroup (C ) R .G D M p. C o n tr o ls P2
(" = 13) _(" = 52) (n = 65)
Age 30.9 ±  7,1 31.7 ±  4.3 31.39 ± 4.22
TC 5.4 ± 0.8 4.8 ±  1.0 * 4.39 ±  0.76 * *
TG 1.06 ± 0.02 1.04 ± 0.02 * * 1.03 ±  0.02 * *
ApoB 1.23 ±  0.22 1.01 ±  0.22 * * 0.88 ± 0.22 * *
NEFA 1.029 ±  0.008 1.028± 0.01 1.023 ± 0.01 *
VLDL-TG (log) 6.54 ± 0.49 5.72 ±  0.61 * * 5.55 ± 0.70 * *
IDL-C (log) 4.50 ± 0.58 4.28 ± 0.64 4.05 ± 0.60 *
HDL-C (log) 1.05 ± 0.02 1.06 ± 0.02 1.06 ± 0.01
LDL-C 3.78 ± 0.80 3.20 ± 0.95 * 2.79 ± 0.75 * *
HDL3b Size 7.93 ± 0.12 7.92 ± 0.10 7.97 ± 0.11
HDL3c Size 7.61 ± 0.19 7.59 ± 0.15 7.65 ± 0.13
HDL2 / h d l 3 0.86 ± 0.17 0.90 ± 0.19 0.92 ± 0.21
LDL-I Size 30.43 ± 0.83 30.85 ± 
1.06
31.39 ± 1.00 *
CETP.A (log) 3.22 ± 0.36 2.74 ±  0.60 * * 2.58 ± 0.66 * *
FBG (log) 1.54 ± 0.06 1.50 ± 0.10 1.52 ± 0.09
SBP 121.5 ± 6.9 108.0 ±  
12.3
* * 105.5 ± 11.7 * *
DBP 79.6 ± 5.2 75.4 ± 5.7 * 73.2 ± 5.4 * *
SHBG (log) 3.47 ± 0.72 3.71 ± 0.53 3.92 ± 0.50 *
Testoste (log) 1.05 ± 0.03 1.04 ± 0.02 1.04 ± 0.01 * *
Testoste /  SHBG 0.31 ± 0.07 0.28 ± 0.04 * 0.27 ± 0.04 * *
Microalb (log) 21.89 ± 10.6 17.02 ±
18.3
13.22 ± 14.2 *
P.BMI 31.06 ±  4.75 23.25 ±  
4 .02
* * 22.31 ± 2.83 * *
Current BMI 32.59 ± 4.53 24.32 ±  
4 .38
* * 22.8 ± 2.95 * *
Baby weight 3460 ± 488 3398 ± 589 3304 ± 514
Alcohol in (log) 0.24 ± 0.31 0.31 ± 0.38 0.40 ± 0.41
Sodium intake 7.93 ± 0.29 7.97 ±  0.28 7.87 ±  0.37
Fat intake 96.41 ± 40.3 95.11 ±  
37.7
90.78 ± 38.4
Testoste = testosterone, P.BMI = pre-pregnancy BMI, * = p < 0.05, ** -  p < 0.01, 
blank space = No significant difference. Data presentes as mean ± standard deviation.
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N o  study subject w as hypertensive: in the insulin resistant group the highest sy sto lic  
blood pressure w as 130 mm  Hg, in the residual G D M  group it w as 140 mm H g and in 
the control group it w as 130 mm  H g. T he h ighest d iastolic b lood pressure in the insulin  
resistant and the residual G D M  groups w as 90  mm H g and in the control group it w as  
80 m m H g. Fasting blood g lu cose  leve ls  w ere sim ilar in three groups.
The group w ith  insulin  resistance tended to be fatter than either the control or the 
residual G D M  group, w ith all being overw eight (BM I > 25) or obese (BM I > 30) (Table 
4-15). The m inim um  B M I in the insulin resistant group w as 26 .6 , and 9 o f  the 13 in 
this group (about 70% ) w ere obese. On the other hand, only one o f  the 65 control 
subjects w as ob ese  (B M I = 34) and 11 (17% ) w ere overw eight. O f the residual (non­
insulin  resistant) G D M  group 16 (31% ) w ere overw eight and 3 (6% ) w ere obese.
Pre-pregnancy B M I w as significantly higher in the insulin resistant group than other 
tw o groups (T able 4 -15).
The insulin resistant group show  a greater am ount o f  albumin in urine (Table 4-15).
A lcohol, sodium , and fat intake w ere not significantly different betw een three groups 
(Table 4-15).
There w ere no sign ificant differences betw een use o f  an oral contraceptive, smoking, and 
exercise  b etw een  the subgroup (C) and other tw o groups (Table 4 -16).
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Table 4 -1 6  C o m p a riso n  o f  su b g ro u p  (C) w ith  the re s id u a l G D M  p o p u la tio n  a n d  co n tro ls
(C a te g o rica l D a ta )




p , C o n tr o ls
(n = 65)
p 2
C.Pill Current use 7 (54%) 22 (42 %) 21 (32%)
F or N  use 6 (46%) 30 (58%) 44 (68%)
Smoking N on-sm oke 8 (62%) 29 (56%) 36 (55%)
Smoker 0 (0.0%) 10 (19 %) 14 (22%)
E x-sm oke 6 (46%) 13 (25%) 15 (23%)
Fre.Exer 0 5 (39%) 13 (25%) 16 (25%)
1 2 (15%) 14 (27%) 12 (19%)
2 3 (23%) 13 (25%) 17 (26%)
3 3 (23%) 12 (23%) 20 (31%)
Dur.Exer 0 . 5 (39%) 13 (25%) 16 (25%)
1 . 3 (23%) 13 (25%) 12 (19%)
2. 3 (23%) 16 (31%) 14 (22%)
3. 2 (15%) 10 (19%) 22 (34%)
Int.Exer 0- 5 (39%) 13 (25%) 17 (26%)
1- 1 (8%) 6 (12%) 5 (8%)
2- 6 (46%) 23 (44%) 33 (51%)
3- 1 (8%) 10 (19%) 10 (15%)
R .G D M  =  rest o f  the G D M  group, Pj = p values o f  com parison o f  subgroup C versus
rest o f  G D M  group, P 2 -  p values o f  com parison o f  subgroup C versus controls, F = 
former, N  =  never, Sm oke — sm oker, 0 =  N ot at all, 1 =  L ess than once a w eek , 2 =  O nce 
or tw ice  a w eek , 3 =  Three tim es a w eek , 0. = N ot at all, 1. — L ess than 20  m inutes, 2. =  
20-30  m inutes, 3. =  M ore than 30 m inutes, 0- = N o  exercise, 1- = N o n e  o f  exercise 
session , 2 - =  Som e o f  exercise  session , 3- = M ost or all o f  exercise, blank space in the P t 
and P2 co lum ns = N o  significant difference.
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DISCUSSION
The objective of this chapter is to discuss the finding of the present study on women with 
previous GDM one year after delivery compared with controls.
In this study, age was not significantly different between the GDM and control groups. 
GDM is most common in women over 30 years old (Wiess, 1988). This discrepancy 
may be due to sample size of this study.
5.1 Family Medical History in Women with Previous GDM
GDM subjects gave a history of diabetes mellitus (n = 25, 38.5%) and / or CVD (n = 24, 
36.9%) in their first degree relatives more often than in controls (n = 8, 12.3% and n = 
10,15.4%, respectively).
Haffner et al (1988) have suggested that fasting insulin concentrations are significantly 
higher in normoglycemic persons who have diabetic parents than in persons with no 
diabetic relatives. In addition, Eriksson et al (1988) have found that persons with 
positive family history of diabetes have decreased non-oxidative glucose disposal 
compared with persons with no family history of diabetes.
Weisser et al (1993) have reported that there is a correlation between insulin and blood 
pressure in subjects with a positive family history of diabetes or hypertension and this 
genetic influence may be related to insulin resistance.
Aerts et al (1990) have reported that 35% of patients with GDM are offspring of diabetic 
mothers versus only 5% of normoglycemic women, and GDM occurs more frequently in 
the offspring of diabetic mothers (35%) than in offspring of diabetic fathers (7%).
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A history of diabetes on the m other’s side has been reported to be a more important and 
frequent factor for developing diabetes in offspring than a history of diabetes in the 
father’s side. Our finding are in agreement with these reports.
Several metabolic abnormalities may occur in adulthood including NIDDM and obesity 
in the offspring of mothers with GDM  (Pettitt et al, 1988, Pettitt et al, 1987, 
respectively). Our finding in GDM subjects in this study is consistent with these 
findings.
Van Assche et al (1991) suggested that even mild diabetes mellitus induces an abnormal 
intra-uterine milieu that causes morphological and functional changes in fetal 
development with consequences for later life. Intra-uterine factors may be responsible 
for the transmission of diabetes mellitus from one generation to another. The incidence 
of NIDDM is much higher in the offspring of diabetic mothers than in normal mothers 
(Aerts et al, 1990).
GDM subjects had more frequently significant and positive family histories of CVD in 
comparison with control subjects. Bell et al (1990) previously reported a similar finding 
in GDM subjects.
Our findings also indicate that the GDM subjects are more likely to have a diabetic 
mother than controls and that the GDM subjects are more likely to have history of 
diabetes in the mother side in father side. The GDM subjects also are more likely to
have a first degree relative with CVD.
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5.2 Obstetrics History in Women with Previous GDM One Year after Delivery
Fetal risks accompanying diabetes in the mother include spontaneous abortion, prenatal 
death, and malformation (Crandall, 1987). In our study, there is a similar incidence of 
those and other complications in patient who have had GDM and controls.
This good outcome is possibly due to intensive diet management and insulin therapy to 
maintain euglycemia. Caesarean delivery was more common in GDM but not 
statistically different between two groups. Our finding is in agreement with similar 
findings by Goldman et al (1991).
GDM subjects did not have greater parity than controls; our findings in this agree with 
those of Molsted-Pedersen et al (1989).
Three GDM subjects had had GDM in previous gestations. They were obese, and they 
required insulin to achieve normoglycemia in their most recent and previous pregnancies. 
Gaudier et al (1992) reported that women with a history of GDM and BMI > 35 kg / m2, 
if they required insulin therapy during pregnancy, were at increased risk (52%) of 
recurrence of GDM.
5.3 Oral Contraceptive Use in Women with Previous GDM One Year after Delivery 
There is no significant difference in use of an oral contraceptive between the GDM and 
control groups.
In our study, current use of oral contraceptive was not significantly associated with 
plasma cholesterol, LDL-C, HDL-C, NEFA, and insulin concentrations. Our results are 
consistent with those of Kjos et al (1990) who reported that low-dose oral
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contraceptives in women with prior GDM did not seem to have any adverse effect on 
carbohydrate or lipid metabolism.
Current oral contraceptive use was positively and significantly correlated with plasma 
cholesterol, apoB, and apo A-I concentrations. Lussier-Cacan et al (1991) reported that 
apoB and apoA-I both were higher during oral contraceptive therapy.
The serum concentration of SHBG is known to be increased by estrogen, tamoxifen, 
phenytoin, or thyroid hormone administration and by hyperthyroidism and cirrhosis. 
SHBG also is decreased by exogenous androgen, glucocorticoids or growth hormone 
and by hypothyroidism. Only one GDM subject was excluded from analysis, because she 
was taking replacement thyroxine (Braunstein, 1994). There is a positive and significant 
correlation between oral contraceptive pill and SHBG in our study. SHBG is 
synthesized in the liver, and its synthesis is stimulated by estrogens and inhibited by 
androgen (Goldfien and Monroe, 1994).
Normal and healthy women taking oral contraceptive pills have a slightly increased risk 
of cerebrovascular and cardiovascular disease, and the risk is higher for the diabetic 
patients (Rapkin, 1987).
5.4 Obesity in Women with Previous GDM One Year after Delivery
In our study, subjects who have had GDM have significantly greater WHR, BMI, and 
body fat % than control subjects. WHR seems to be the simplest and most reproducible 
measure of central obesity (Haffner et al, 1987) and it is strongly associated with visceral 
fat mass (Ashwell et al, 1985).
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Factors affecting percent body fat include age, gender, level of energy balance, 
composition of the diet, level of physical activity, and a variety of social factors including 
smoking and alcohol intake (Bouchard et al, 1990). In this study, we examined these 
factors in GDM populations.
Metabolic disorders in obesity have been shown to be correlated with abdominal obesity 
(Kalkhoff et al, 1983, Larsson et al, 1984, Ohlson et al, 1985). In addition, Ashwell et al 
(1985) have found a strong correlation between the intra-abdominal fat:subcutaneous fat 
area ratio and WHR by using CT scanning at an umbilical level. Shimokata et al (1989) 
have reported that WHR is strongly affected by age and BMI. WHR has a positive 
correlation with age and BMI. Our data also indicates that WHR has a positive 
correlation with age and BMI, too.
Central obesity is positively associated with overall adiposity, particularly in females. In 
our study, GDM subjects also represent a higher BMI in company with higher WHR 
and body fat %.
Insulin resistance occurs in both NIDDM and obesity, and most NIDDM patients are 
obese. In fact, obesity precedes the development of NIDDM in more than 80% of cases 
in Pima Indians (Seely and Olefsky, 1993). In the present study, GDM subjects had 
higher BMI and higher insulin levels leading to dyslipidemia (Table 4-8).
Multiple regression analysis showed that fasting insulin concentration is the strongest 
determinant of BMI in the GDM subjects (Table 4-9).
WHR, BMI, and body fat % showed a positive and significant correlation with fasting 
plasma insulin level and insulin / glucose ratio. Baynes et al (1991) reported a similar 
result in both diabetic males and females. Hyperinsulinemia may develop through
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progressive development of insulin resistance, presumably due to post-receptor site 
alterations (Lillioja and Bogardus, 1988, Olefsky et al, 1988).
Women are resistant to insulin action at an average body fat % of 37.7% (in GDM 
subjects mean was 38.79 %), while men develop an equivalent condition at an average 
body fat % of 23.9% (Plaisted and Istfan, 1994).
In mildly hyperinsulinemic obese subjects, only a decrease in insulin sensitivity exists. As 
the hyperinsulinemia worsen, a post-receptor defect also occurs. Furthermore, there is a 
direct association between degree of insulin resistance or hyperinsulinemia and the 
magnitude of the post binding defect (Seely and Olefsky, 1993).
Glucose oxidation is lower in obese subjects than normo-weight controls, but lipid 
oxidation is 30% higher in obese subjects than controls in the fasting state. Thus, there 
is a negative correlation between glucose oxidation and lipid oxidation which may be 
explained by the glucose-fatty acid cycle (Seely and Olefsky, 1993).
The association between insulin and hypertriglyceridemia has been shown in Figure 5-1.
Insulin resistance causes increased insulin secretion, and increased flux of NEFA to the 
liver (where they stimulate TG synthesis), and increasing hyperinsulinemia (Durrington,
1995). Hyperinsulinemia, in turn, can be a cause of overproduction of hepatic TG and 
increased hepatic VLDL secretion, and as a result cause hypertriglyceridemia (Olefsky et 
al, 1974) (Figure 5-1).
GDM subjects in this investigation have a significantly higher plasma NEFA 
concentration than controls. NEFAs are thought to increase insulin resistance in muscle 
and liver and increase hepatic gluconeogenesis and lipoprotein synthesis and perhaps 
decrease hepatic removal of insulin (Bjomtorp, 1992). NEFAs are a determinant of
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VLDL production. High N EFA  levels may give rise to high plasma V L D L , LDL, apoB- 
100, and g lucose concentrations, and perhaps secondarily, hypertension (Bjom torp,
1992). A ll these variables have been show n to be raised when plasma N E FA  is raised in 
our investigation. A ll these variables w ere significantly and positively related to obesity 
among the G D M  group.




Increased hepatic VLDL 
secretion
Increased hepatic TG 
synthesis
Figure 5-1 Alternative hypothesis to explain the association between insulin and 
hypertriglyceridemia (Data from  Durrington, 1995 and Olefsky et al, 1974). TG — 
triglyceride, NEFA -  non-esterified fatty acid.
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Grundy and Barnett (1990) have suggested two basic mechanisms for the 
hypertriglyceridemia of obesity: overproduction of VLDL-TG and impaired lipolysis of 
the TG-rich lipoproteins. The high plasma TG concentrations in subjects (GDM) may be 
due to a reduction in VLDL catabolism, through the decreased plasma post-heparin LPL 
activity, and / or an increased VLDL synthesis (Despres et al, 1990 b).
Stromblad and Bjomtorp (1986) have reported that high FFA concentrations in portal 
blood are associated with reduced hepatic insulin clearance in rat with dietary-induced 
obesity.
In addition, Svedberg et al (1990) have demonstrated that elevated FFA levels inhibit 
insulin binding and degradation in isolated rat hepatocytes. Thus, central obesity and 
high FFA concentrations may increase insulin resistance and thus hyperinsulinemia.
BMI showed a significant and negative correlation with LDL particle size in this study. 
The correlation of abdominal obesity with denser and smaller LDL was reported 
previously (Harris-Peeples et al, 1989). BMI and WHR were positively associated with 
LDL-C but it did not reach significant level.
HDL-C may be decreased in obese subjects, either through direct clearance of HDL-C 
from circulation by the adipose tissue or through separation of the lipid from its apo A-I 
or its cholesterol ester (Grundy and Barnett, 1990). In the present study, BMI was not 
significantly correlated to HDL-C but WHR was significantly and negatively associated 
with plasma HDL-C concentration.
CETP was a significandy and positively correlated with BMI and body fat % in the 
GDM group. Increased CETP activity is associated with increased lipid exchanged 
between VLDL and HDL in abdominal obesity (Despres et al, 1992).
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There was a significant and positive correlation between BMI and systolic blood 
pressure, diastolic blood pressure, and mean arterial pressure. Previous studies have 
reported a similar correlation between obesity and both systolic and diastolic blood 
pressure in obese subjects (Van Gaal et al, 1988, Peiris et al, 1989).
Obesity is a strong predictor for the development of hypertension (Sowers et al, 1991). 
Although the mechanisms by which obesity cause hypertension are not fully understood, 
hypercaloric intake, hyperinsulinemia, insulin resistance, enhanced metabolic activity of 
visceral adipose tissue, enhanced sympathetic activity, and even the greater body mass 
present in obese patients are all thought to be involved mechanisms (Plaisted and Istfan,
1994).
5.5 Carbohydrate Metabolism in Women with Previous GDM One Year after 
Delivery
Data from a study on Nauruans indicated that subjects with higher post-load serum 
insulin levels, presumably indicative of insulin resistance, at base line tended to develop 
IGT or diabetes over a six year period (Sicree et al, 1987). It is generally accepted that 
insulin resistance plays an important role in the pathogenesis of NIDDM (Alzaid and 
Rizza, 1993).
Reduced glucose clearance, accompanied by compensatory hyperinsulinemia, is present 
one or two decades before NIDDM is diagnosed in the offspring of diabetic parents. It 
indicates that the primary defect is in the peripheral tissue response to insulin and 
glucose, not in the pancreatic cell (Warram et al, 1990). The same authors suggested 
that a low glucose clearance rate and hyperinsulinemia are the best predictors of the
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subsequent development of diabetes in the offspring of diabetic parents (Warram et al,
1990).
Several studies have showed that fasting hyperinsulinemia is a good predictor for the 
development of NIDDM in different populations such as in Nauruans (Sicree et al, 
1987), Pima Indians (Knowler et al, 1990, Saad et al, 1988, Lillioja et al, 1988), Mexican 
Americans (Haffner et al, 1990 b), Swedish women (Lundgren et al, 1990), the offspring 
of diabetic parents in America (Warram et al, 1990), and French policemen (Charles et 
al, 1991). The cellular mechanisms involved in the alteration of insulin function are still 
unclear (Knowler et al, 1993). It may be applicable for GDM subjects and say that high 
fasting insulin level is a predictor of the development of diabetes mellitus in these 
population.
The current hypothesis is that as a result of chronic insulin resistance, compensatory 
hypersecretion of insulin develops to maintain glucose homeostasis and that eventually 
diabetes mellitus develops when pancreatic hypersecretion fails (Haffner et al, 1990 b).
The present study showed that 20% of the GDM subjects had developed insulin 
resistance (as defined by fasting hyperinsulinemia) one year post-partum. They were 
overweight or obese and they tended to have mild dyslipidemia. They also tended to 
have a higher blood pressure, lower SHBG concentration, and microalbuminuria.
BMI was the unique determinant factor in the insulin multiple regression model (Table 4­
9).
There is considerable evidence to suggest that insulin resistance is caused (at least in 
part) by excess availability of fatty acids. Randle has suggested that elevated plasma 
FFA levels impair glucose metabolism. Increased uptake of free fatty acids and
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subsequent oxidation inhibits glucose oxidation and glycogen synthesis (Randle et al, 
1963).
Infusion of FFA into normal subjects using the insulin clamp technique to measure insulin 
resistance and indirect calorimetry showed that increased FFA concentrations may result 
in mild insulin resistance, reduction in glucose transport, and a reduction in both glucose 
oxidative and non-oxidative metabolism (Ferrannini et al, 1983, Yki-Jarvinen et al, 
1991).
Haffner et al (1992) have demonstrated that increased fasting insulin concentrations 
predict a cluster of metabolic disorders including dyslipidemia, hypertension, and 
NIDDM, and other have previously shown that fasting insulin predicts NIDDM (Saad et 
al, 1988, Haffner et al, 1990 a, Charles et al, 1991, Zimmet et al, 1992).
Subjects who have GDM have an increased risk of developing NIDDM later in life and 
more than 50% of these women develop NIDDM within 25 years (O’Sullivan, 1975). 
Women with GDM who need insulin treatment during pregnancy have a higher risk of 
later development of diabetes mellitus than those who have been controlled by diet alone 
(Henry and Beischer, 1991).
In our study, 17% (11 cases) of GDM patients have received insulin for control their 
blood glucose levels during pregnancy and 83% (54 cases) have been treated only by diet 
to achieve an acceptable level of glucose. GDM subjects who received insulin treatment 
during pregnancy had a higher BMI before and after pregnancy and dyslipidemia (higher 
plasma cholesterol and LDL-C).
None of the GDM subjects including those with insulin resistance were sufficiently 
hyperglycaemic to elevate glycosylated haemoglobin (as % of blood haemoglobin).
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As a result, the severity of insulin resistance appears to be predicted by factors such as 
antecedent glycemic control, level of fitness, age, obesity, body fat distribution, and 
hypertension (Alzaid and Rizza, 1993).
Our study showed that a subgroup of those women who have a history of GDM have 
hyperinsulinemia and mild hypertriglyceridemia. They tended to be fatter, to be 
dyslipidemic (higher plasma cholesterol and TG concentrations), to have a higher blood 
pressure, to have a greater amount of albumin in urine, and to have lower plasma SHBG 
concentrations, but not to be older.
Alterations in lipid metabolism associated with insulin resistance are outlined in Table 5­
1 (Frayn, 1993). In the present study all these changes were found in the GDM group, 
particularly those with insulin resistance.
Table 5-1 A ltera tion s in lip id  m etabolism  com m only a ssocia ted  with insulin resistance  
Elevated plasma TG concentration (particularly VLDL-TG)
Decreased plasma HDL-C concentration (particularly HDL2-C)
Elevation NEFA 
Small, dense LDL particles
5.6 Lipoprotein Metabolism in Women with Previous GDM One Year after Delivery 
Plasma cholesterol and apoB concentrations in the women with prior GDM tend to be 
significantly higher than in women with no history of GDM of the same age. Apo B 
level has been reported as a more effective marker for coronary artery disease than LDL 
or total cholesterol level (Levinson and Wagner, 1992). As shown in recent study, apo 
B level may be measuring the atherogenic potential of both VLDL and LDL (Grundy and
Vega, 1992).
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The plasma cholesterol concentration was not related to cholesterol intake and 
cholesterol intake was similar between two groups.
Elevated TG levels may result from overproduction or defective removal. The latter may 
be due to genetic or acquired deficiency of LPL or apoC-II (the activator of LPL), or an 
excess of apoC-IH which inhibits apoC-II activity and (3-VLDL uptake (Kashyap, 1991).
A clinically important aspect of HTG is that it signals the presence of other metabolic 
disorders (Vergani et al, 1990). In addition to HTG and low level of HDL, affected 
subjects frequently have one or more of the following: overweight, insulin resistance 
with fasting hyperinsulinemia and glucose intolerance, hypertension, and hyperuricemia. 
Different terms have been used to define this syndrome: ‘plurimetabolic syndrome’, 
‘overweight-hyperlipidemic-hyperuricemic syndrome’, ‘glucose intolerance-obesity- 
hypertension condition’, and ‘symptom complex’ (Vergani et al, 1990). The name most 
used now is ‘insulin resistance syndrome’. The syndrome is strongly related to coronary 
heart disease (Vergani et al, 1990).
According to Zavaroni and Reaven, an increase in the plasma triglyceride concentration 
and a decrease in the plasma HDL-C concentration are the expected results of insulin 
resistance and hyperinsulinemia (Vergani et al, 1990).
In the current investigation, GDM subjects have HTG, but not a low level of HDL-C 
compared with controls. In these subjects HTG seems statistically to be related with 
hyperinsulinemia, high plasma NEFA concentration, NEFA, and smoking. Interestingly, 
BMI and alcohol consumption were not strong predictors in the subjects. This lack of 
correlation might be due to considerable homogeneity in the subjects.
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Reaven and Greenfield have suggested that HTG associated with insulin resistance is 
related to plasma insulin concentration and / or free fatty acids (Reaven and Greenfield, 
1981). In impaired glucose tolerance states, subjects exhibit insulin resistance and a 
compensatory hyperinsulinemia. The hyperinsulinemia causes an increased rate of 
synthesis and secretion of VLDL-TG and perhaps HTG due to impaired clearance 
capacity (Nikkila, 1984). On the other hand, high plasma FFA concentration derived 
from VLDL metabolism give rise to hypertriglyceridemia (Galton and Krone, 11991).
Genetic studies have suggested that the high concentration of apoB in circulation can be 
a strong coronary risk factor (Douste-Blazy and Kloer, 1989). In human, apoBlOO is a 
protein constituent of VLDL, IDL, and LDL. Each of these lipoprotein particles 
contains but a single copy of apoBlOO (Innerarity, 1990). In our study, the GDM 
subjects exhibited a higher level of plasma apoB and LDL-apoB concentrations than 
controls, and they also had slightly higher levels of VLDL-apoB and IDL-apoB than 
controls but not to an exact that was statistically significant.
Plasma FFA (NEFA) concentration is a function of rates of both input and removal from 
the plasma concentration. Inflow of FFA is governed by the rate of lipolysis in adipose 
tissue and also the release of FFA during the hydrolysis of circulating TG-rich particles, 
particularly in the postabsorptive state (Taskinen et al, 1985). The rate of FFA removal 
is determined by both esterification (or re-esterification) and lipid oxidation. It has been 
generally accepted that plasma FFA concentration is controlled mainly by FFA 
production (ie by the rate of lipolysis), whereas the efflux rate of FFA is secondary to 
changes in plasma FFA concentration. This concept implies that the removal of FFA 
from plasma is not controlled independently (Taskinen et al, 1985).
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As is shown by simple regression, intensity of exercise is related positively to NEFA 
level. The activation of lipase and subsequent lipolysis and mobilization of FFA from 
adipose tissue is increased by the hormones epinephrine, norepinephrine, glucagon, and 
growth hormone. Because plasma concentrations of these hormones are increased 
during exercise, this mechanism for lipase activation provides the muscle with a supply of 
a potent energy substrate. Alterations in lipase activity may partly explain the enhanced 
utilization of fat observed with aerobic exercise training (McArdle et al, 1991 a).
The most substrates used by the heart for energy are glucose, fatty acids, and lactic 
acids. During exercise the myocardial metabolism of FFAs rises to approximately 70% 
of the total energy requirement (McArdle et al, 1991 a).
Emphasis has recendy been placed on abnormalities not only in lipid and apolipoprotein 
concentrations but also in lipid and apoprotein composition of different lipoproteins in 
diabetic as well as in non-diabedc individuals (Steinberg et al, 1989).
Compared with non-diabetic people, diabetic patients have decreased clearance of both 
VLDL-apoB and VLDL-TG, and increased production of VLDL-TG. Obese subjects 
have increased production of both VLDL-apoB and VLDL-TG and more VLDL of 
normal composition (Howard et al, 1987). Study on VLDL turnover showed that 
production of both VLDL-apoB and VLDL-TG were significantly correlated with insulin 
concentrations, and the rates of clearance of both were significantly correlated with 
plasma glucose levels (Howard et al, 1987).
In GDM subjects, it may be said that clearance of both VLDL-TG and VLDL-apoB are 
decreased and also the production of VLDL-TG is increased. It explains significant 
elevation in the level of VLDL-TG and a slightly higher (but not significantly higher)
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concentration of VLDL-apoB but not significant in the GDM group compared with 
controls. Saheki et al (1993) reported that VLDL from diabetic patients are a poor 
substrate for LPL compared with normal VLDL.
IDL particles are thought to be associated with increased atherosclerosis risk (Tatami et 
al, 1981, Steiner, 1981). This supposition is supported by the observation that particles 
with size and flotation similar to those of human cholesterol-enriched IDL have been 
associated with a predisposition to coronary atherosclerosis in the cholesterol-fed 
monkey and that elevated levels of IDL mass and IDL-C have been related to increased 
risk of coronary disease in human (Krauss, 1987).
On this basis, Fielding et al (1984) have suggested that the block to cholesteryl ester 
transfer to VLDL and LDL in NIDDM patients is mediated by their increased free 
cholesterol (FC) content and may be related to the increased risk of these patients for 
developing atherosclerosis.
In the GDM group as a whole, the plasma LDL-C and LDL-apoB concentrations were 
significantly greater in the GDM subjects than in controls.
Elevated levels of LDL-C might be secondary to either an increase in the synthesis rate 
of LDL-C or a decrease in the rate of its catabolism and clearance from plasma (Barter,
1994). A down-regulation of the B/E receptor may be involved in the decreased rate of 
LDL-C catabolism (Barter, 1994). On this basis, a defect in VLDL degradation possibly 
due to LPL activity disorders and an enhanced synthesis of VLDL from the liver can be a 
cause of HTG and combined HTG and hypercholesterolemia (Barter, 1994), and thus a
greater level of LDL-C in plasma.
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Deckelbaum et al have suggested that transformation of IDL and larger LDL to smaller, 
denser LDL subspecies can result from the combined effects of TG hydrolysis and lipid 
transfer (Musliner et al, 1991).
The factors that determine the size and composition of LDL are not fully known. 
Investigations have shown that genetic factors are involved in the size of LDL. Studies 
have demonstrated that environmental factors or other disease states may also influence 
the size and composition of IDL (Feingold et al, 1992). Firstly, age has a positive 
correlation with LDL phenotype B. Secondly, weight loss induced by exercise decreases 
the concentration of small, dense LDL, and thirdly, studies have recently found that in 
subjects with acquired immunodeficiency syndrome (AIDS) the prevalence of the LDL B 
phenotype B is increased 2.5 fold (Feingold et al, 1992).
Krauss and Burke (1982) suggested that the TG-enriched LDL found in the larger and 
less dense subfractions may give rise to smaller, dense LDL subspecies via lipolysis and 
loss of core TG and other lipids. However, in the smallest and most dense LDL 
subspecies, LDL-TG is increased, suggesting that another metabolic pathway is involved 
in their formation. Some of the smaller, denser subspecies may also conceivably be 
precursors of larger, less dense LDL subspecies formed as a result of transfers of lipid 
and protein components to and from these particles (Krauss and Burke, 1982).
McNamara et al (1987) have found that the presence of small LDL particle is associated 
with increased age, plasma cholesterol and TG concentrations, and lower HDL-C and 
apoA-I levels. On the other hand, Barakat et al (1990) have found that LDL particles 
are smaller and denser in patients with IGT and NIDDM. LDL size was correlated with 
plasma insulin concentrations independent of plasma TG level, age and BMI. In addition,
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this does not necessarily testify a causal relationship and it is difficult to identify the 
mechanisms that govern the alterations in LDL particle size. It may be a link between 
hyperinsulinemia and atherosclerosis (Barakat et al, 1990).
Smaller LDL particle size is prevalent in subjects with IGT and NIDDM but not in 
normoglycemic obese subjects whose plasma insulin concentrations are normal. It seems 
the presence of small LDL may be related to the degree of resistance of tissues to insulin 
action. LPL also may play a role in the alteration in LDL size (Barakat et al, 1990), 
because adipose tissue and lipoprotein metabolism are associated with insulin (Eckel, 
1989).
Feingold et al believe that whether HTG itself leads to the formation of small, dense 
LDL or whether those who inherit the LDL B phenotype are more susceptible to the 
development of HTG is unresolved (Feingold et al, 1992).
HDL consists of a heterogenous group of particles defined either by size or by their 
apolipoproteins (Silverman et al, 1993).
Data from this study suggests that HDL-C is not significantly lower in GDM subjects 
and also the HDL2 %:HDL3 % mass ratio (the HDL2 area %:HDL3 area % ratio 
measured after gel electrophoresis separate the HDL subfractions) is not increased, 
resulting in no evidence for impaired LCAT activity. Silverman et al suggested that 
transfer of CE via CETP, followed by lipolysis of TG by HPL, results in the conversion 
of HDL2 into HDL3 (Silverman et al, 1993).
It is thought both HDL2 and HDL3 are acceptors of phospholipid, FC, and apoCs from 
VLDL and chylomicrons, but the major acceptor particles are probably HDL3. With
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higher substrate concentrations the HDL3 decreases and may be completely transformed 
to the density of HDL2 (Nikkila et al, 1987).
Deckelbaum et al (19884) have reported that there is a positive correlation between 
plasma TG concentrations and TG content of HDL in normolipidemic and 
hypertriglyceridemic subjects.
TG-enriched HDL3 particles show a positive relationship with posprandial lipemia and 
the evidence suggests that they serve also as substrate for hepatic lipase and are 
converted to particularly small, dense HDL3 (Patsch et al, 1987).
Behr et al (1981) have reported that an immunologically mediated blockage of the effect 
of LPL (by influencing antibodies to LPL) in the chicken resulted in accumulation of TG- 
rich lipoproteins, a higher TG content of HDL, and the replacement of the larger HDL2 
by smaller, denser HDL3.
Largost (1992) have suggested that CETP promotes a reduction in the size of HDL3 
when HDL3 was incubated with purified CETP at 37°C for 24 hours. In addition, 
NEFAs have been reported to modulate the redistribution of particle size in HDL3 by 
CETP even in the absence of any other lipoprotein classes (Largost and Barter, 1991).
In hypertriglyceridemia, the fractional catabolic rate (FCR) for apoA-I is increased, and 
low plasma concentrations of apoA-I and HDL-C are presumed secondary to the 
increased FCR (Tribble and Krauss, 1993). In present study, GDM subjects were 
moderately hypertriglyceridemic in comparison with controls and their HDL-C and HDL 
apoA-I levels were slighdy lower than controls but not to a statistically significant extent.
In the GDM group Lp (a) concentration in plasma was not significantly different 
between GDM and control subjects. Plasma Lp (a) concentration was not associated
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with plasma cholesterol, TG, VLDL-C, IDL-C, LDL-C, apoB, smoking, blood pressure, 
and dietary factors, these being other risk factors for atherosclerosis, but it was 
significandy correlated with plasma insulin concentration and markers of obesity in this 
study. Lp (a) also was associated with amount of albumin in urine (Table 4-8). It seems 
likely that obesity and hyperinsulinemia are associated with higher plasma Lp (a) 
concentrations, but the underlying mechanisms are not clear. Steinmetz et al (1993) 
reported that Lp(a) and atherosclerosis are associated, but the underlying mechanism is 
not clear.
In conclusion, it can be said that a number of metabolic and pathophysiological 
mechanisms may modulate the concentration of Lp (a) and that these are not yet fully 
understood.
In this investigation, CETP activity % was higher in the GDM group than in control 
group. Studies have suggested that increased CETP activity may promote atherogenesis 
by stimulating enhanced transfer of CE to LDL in patients with low plasma HDL 
concentrations (Sparks et al, 1991).
The CETP mediated transfer of cholesteryl esters from HDL to apoB-containing 
lipoproteins can be potentially atherogenic, particularly in circumstances when plasma 
concentrations of apoB-containing particles are elevated, a circumstance perhaps in 
which the cholesteryl ester-rich apoB-containing lipoproteins are more likely to transfer 
cholesterol to peripheral cells in the arterial wall (Albers et al, 1990).
The activity of CETP has been shown to be positively related to adiposity (Dullaart et al,
1994). The data in this study suggest that there is a positive relationship between higher 
CETP activity and markers of obesity, BMI and body fat %. In addition, CETP activity
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showed a significant and negative correlation with exercise in the present study. It is 
possible that obese subjects may have greater plasma CETP activity because of their lack 
of physical activity, but that needs to be practically examined.
CETP plays a major role in modifying the composition of lipoproteins in the plasma 
compartment (Albers et al, 1990). For example, CETP facilitates the exchange of LDL 
cholesteryl ester for VLDL triglyceride. By this process, the TG-enriched LDL formed 
can then subsequendy undergo lipolysis, leading to the formation of smaller, dense LDL 
(Albers et al, 1990).
McPherson et al (1991) have reported that plasma CETP concentrations are elevated in 
patients with hypercholesterolemia, sometimes in combination with HTG and 
hyperchylomicronemia. Correction of the abnormal lipoprotein phenotype by dietary 
therapy caused significant reductions in plasma CETP concentrations in patients with 
hypercholesterolemia (McPherson et al, 1991).
In light of the above information, it seems a number of the GDM group demonstrate a 
syndrome of dyslipidemia compared with controls. The dyslipidemic syndrome in the 
GDM subjects includes hypercholesterolemia, hypertriglyceridemia, higher plasma apo B 
and NEFA concentrations, alterations in VLDL, IDL, and LDL compositions (ie higher 
VLDL, IDL-C, IDL-C, LDL-C, and LDL-apoB in the GDM subjects compared with 
controls), greater CETP activity in plasma, and denser and smaller HDL and LDL 
particles.
Approximately 37% of the GDM group in the current study have the dyslipidemic 
syndrome. The results showed that subjects with dyslipidemia had hyperinsulinemia and
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insulin / glucose ratio, greater BMI and body fat %, higher blood pressure (both systolic 
and diastolic), and lower plasma SHBG concentration.
Plasma cholesterol and LDL-C concentrations were positively associated with insulin 
levels in men but not in women (Haffner et al, 1988). Plasma insulin concentration has 
been reported to be associated with smaller and denser LDL particles which seem to be 
more atherogenic (Barakat et al, 1990). In this investigation, plasma insulin
concentration and insulin / glucose ratio, as a marker of insulin resistance, were 
positively correlated to plasma cholesterol and LDL-C concentrations in GDM subjects.
Gary et al (1988) have reported that insulin-mediated glucose disposal is negatively 
correlated with fasting TG concentration as well as VLDL-C, VLDL-TG, and LDL-C / 
HDL-C ratio. Laakso et al (1990) have found insulin resistance is associated with low 
HDL-C and high total TG and VLDL-TG levels in subjects with normal and impaired 
glucose tolerance and NIDDM. In our investigation, the GDM subjects with 
hypertriglyceridemia had higher fasting plasma insulin concentrations and insulin / 
glucose ratio, and VLDL-TG levels, they also had slightly lower HDL-C levels but not 
to a statistically significant extent.
Over all, it seems that abnormalities founded in this study in LDL composition and size 
can be due to HTG and a high activity of CETP in plasma (GDM subjects represent 
higher plasma TG levels and CETP activity compared with controls). These changes 
may be due to insulin resistance.
In addition, LDL composition was altered ( higher LDL-C and LDL-apoB levels) in 
women who had had GDM in comparison with controls. LDL phenotype was not 
significantly different in women who had had GDM than control women.
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As a result, based on the results of our study, it is possible to say that subjects with 
previous GDM exhibit a complex of lipid and lipoprotein disorders which can be risk 
factors for atherosclerosis. Subjects with history of GDM presented mild 
hypercholesterolemia, hypertriglyceridemia, higher apoB and NEFA levels, and greater 
CETP activity. Additionally, they had abnormal VLDL, IDL, and LDL compositions 
and they possessed denser and smaller LDL-I and HDL3b and HDL3c particles.
Subjects with dyslipidemia were overweight or obese and had hyperinsulinemia. It may 
be that the dyslipidemic syndrome in a number of the GDM subjects is secondary to 
insulin resistance.
Many studies recently have suggested that a profile of plasma apolipoprotein values may 
be useful in the evaluation of coronary heart disease risk, although the final goal should 
be to identify by means of their apolipoprotein components atherogenic and non­
atherogenic lipoprotein particles (Douste-Blazy and Kloer, 1989).
Thus, abnormalities in lipid metabolism may be very important in GDM patients and 
should be considered carefully by those caring for them. Lipids and lipoproteins should 
be checked in following these patients up and action taken where appropriate.
5.7 H y p era n d ro g e n ic ity  in  W om en  w ith  P re v io u s  G D M  O n e Y ear a fte r  D elivery
In the present study, GDM patients exhibited lower plasma SHBG levels than controls 
but the plasma levels of testosterone were not significantly elevated in GDM subjects. 
On the other hand, total testosterone / SHBG ratio (the free androgen index) was 
significandy higher in women with previous GDM than in women with history of a 
normal pregnancy (p = 0.0048).
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GDM subjects demonstrated a significant negative correlation between plasma SHBG 
concentration and the plasma level of testosterone. Rosenfield (1975) reported the same 
linkage between low level of SHBG and higher level of free testosterone in pre­
menopausal and post-menopausal women. It is considered a marker of 
hyperandrogenicity in women. A small increase in total testosterone in the blood (as 
exist in GDM subjects) accompanied by a decrease in the concentration of SHBG may 
result in a significant increase in circulating biologically active hormone (Goldfien and 
Monroe, 1994).
Studies have reported an inverse relationship between body weight and the plasma 
SHBG concentration (Demoore and loosens 1970), BMI and upper body obesity in pre­
menopausal women (Haffner et al, 1989). In our study, we found an inverse relationship 
between the plasma SHBG concentration and WHR, BMI, and body fat % in the GDM 
patients.
Evans et al (1983) reported that abdominal obesity causes low SHBG and high free 
testosterone levels in women. In addition, Kirschner et al (1990) demonstrated that sex 
hormone production and metabolism are different in women with upper body 
(abdominal) and lower body obesity. Women with upper body obesity exhibit higher 
androgen production rates, higher testosterone and estradiol (E2) levels and lower 
SHBG levels. However, women with lower body obesity make increased amounts of E2 
from peripheral aromatization.
Use of an oral contraceptive was strongly related to the plasma SHBG concentration. 
Estrogen therapy is one of the factors which increased SHBG synthesis (Goldfien and 
Monroe, 1994). The mechanism of this effect will be discussed later in this Chapter.
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Data from the present investigation showed that SHBG has significant and positive 
correlations with plasma apoA-I and HDL-apoA-I concentrations but the relationship 
between SHBG and HDL-C was not significant.
Previously, Haffner et al (1989) reported that SHBG is positively correlated with HDL­
C in pre-menopausal women and Longcope et al (1990) found that SHBG is significantly 
related to HDL-C and apoA-I in women. The numbers of subjects in our study may not 
have been great enough to demonstrate statistical significance for the relation of SHBG 
and HDL-C.
Longcope et al (1990) suggested that the positive associations between SHBG and 
HDL-C, HDL2, and apoA-I are related to the fact that these proteins are synthesized in 
the liver, and their syntheses may be stimulated through similar mechanisms.
Insulin is known as a regulator of SHBG production in v itro  and in v ivo  (Peiris et al,
1993). Insulin is capable of suppressing SHBG production in a hepatic cell line and may 
also promote hepatic secretion of TG-rich VLDL (Longcope et al, 1990). It is possible 
therefore that hyperinsulinemia in the GDM patients decreases the production of SHBG 
and has an independent effect on lipoprotein synthesis.
Lindstedt et al (1991) have suggested that low plasma SHBG concentration is a strong 
independent risk factor for the development of NIDDM in women.
Whether the low plasma SHBG concentration or the high testosterone /  SHBG ratio we 
have found in women who have had GDM  can be regarded in any way as a causative
factor for GDM is uncertain.
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In conclusion, epidemiological studies have suggested that obesity is an independent risk 
factor for cardiovascular disease and related mortality (Bray and Gray, 1988 and Manson 
etal, 1990).
Most studies have shown that there is a positive correlation between obesity and 
prevalence of NIDDM (Ashley and Kannel, 1974, Knowler et al, 1981, Stem et al, 
1983). Finally, it can be said that GDM patients are more likely to develop NIDDM than 
controls. In addition, hyperandrogenicity, as assessed by decreased SHBG 
concentrations, is an important independent risk factor for NIDDM in women (Haffner 
et al, 1993 b).
In general, obesity is a heterogenous condition. The regional fat distribution seems to be 
an important determinant of the metabolic complications that have been associated with 
obesity.
In this study, women with previous GDM exhibit higher WHR, BMI, and body fat % and 
several abnormalities in lipids and lipoproteins, hyperinsulinemia and insulin resistance, 
higher blood pressure, and a low level of SHBG.
5.8 Raised Blood Pressure in Women with Previous GDM One Year after Delivery 
In this study, the GDM group exhibited higher systolic and diastolic blood pressure and 
higher MAP than the control group.
Blood pressure was significandy correlated with BMI, plasma insulin, and insulin 
resistance index (insulin / glucose ratio). It confirms previous findings by other 
researchers such as Sechi et al (1992). However, this is the first report of raised blood 
pressure in subjects who have had GDM which suggests that hyperinsulinemia due to
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insulin resistance may be the possible underlying mechanism. Fasting insulin 
concentration, BM I, and alcohol consum ption were the significant independent variables 
in multiple regression analysis for systolic blood pressure.
The pathogenic role of hyperinsulinemia is currently unclear. The insulin resistance- 
hyperinsulinemia-hypertension hypothesis was shown in Figure 4-2. Insulin has been 
found to play an important role in the regulation of sodium reabsorption in the distal 
tubules of the kidney (Skott et al, 1989, DeFronzo, 1981). W ater is also reabsorbed 
with sodium (Feldt-Rasmussen et al, 1987). The mechanism could be that insulin 
activates sodium-potassium-adenosine triphosphatase activity in the distal tubules of the 
kidney (Skott et al, 1989) and thus elevates plasma levels of noradrenaline and hence the 
sympathetic tone (Feldt-Rasmussen et al, 1987). In the pathogenesis of hypertension, 
impaired vasoconstriction due to imbalance of vasoactive substances and / or raised 
cytosolicCa2+ and / or a structural vasculopathy is thought to be an important causative 
event. Insulin resistance in certain trans-membranous cation exchange systems may 
increasecytosolicCa2+ (W eidmann et al, 1993).
Another possible mechanism for raised blood pressure in hyperinsulinémie subjects may 
be based on some alteration in their sm ooth muscle cells. Intracellular sodium content is 
increased in erythrocytes from hypertensive patients. If this also occurs in their smooth 
muscle cells, it may cause narrowing of the lumen of small arteries and therefore explain 
the peripheral resistance existed in hypertensive patients (Beck-Nielson et al, 1990). 
Figure 5-2 schematically shows the possible mechanisms for raised blood pressure in the 
insulin resistance state (Meehan et al, 1993).
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Figure 5-2 The insulin resistance-hyperinsulinemia-hypertension hypothesis (Adapted
from  Meehan et al, 1993).
Nevertheless, the role of insulin in the pathogenesis of hypertension is controversial. The 
relation between hyperinsulinemia and blood pressure is not invariable. It is possible that 
insulin play a role in concert with other factors in the development of essential 
hypertension (Meehan et al, 1993) or insulin resistance may be due to other factors such 
as obesity.
Grunfeld and colleagues have found that hyperinsulinemia precedes the onset of clinical 
hypertension in a population of genetically hypertension-prone subjects such as children 
of at least one essential hypertensive parent (Ferrari et al, 1991, Grunfeld et al, 1994).
In the present investigation, simple linear regression showed a significant and positive 
relationship between systolic blood pressure and insulin but not between diastolic blood
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pressure and insulin. However, multiple linear regression indicated that BMI and the 
plasma NEFA level are two strong contributors of the variance of both systolic and 
diastolic blood pressure. As a result BM I and hyperlipidemia and perhaps other factors 
may cause insulin resistance and insulin resistance could be the precursor mechanisms for 
other factors in Figure 5-2
A possible explanation for finding BM I as a strong predictor of hypertension (both 
systolic and diastolic ) can be found in the San Antonio Heart Study which showed that 
insulin was a risk factor for hypertension predominantly in a lean group, with increasing 
risk associated with rising plasma insulin level. However, no such association was seen 
in an obese group. Conceivably, hypertension is heterogeneous and insulin plays a role 
in its development only in lean individuals (Stem, 1983). In our study, GDM subjects 
had significantly greater BMI and body fat % than controls.
From the frequently noted relation between diabetes mellitus, obesity, and hypertension, 
the following pathogenic inter-relationships may be proposed (Figure 5-3) (Weidmann et 
al, 1993).
Several possible mechanisms may be involved in raised blood pressure in obesity, 
including an increased sympathetic tone, hyperaldosteronism, enhanced blood pressure 
sensitivity to salt intake, increased cardiac output due to hypervolemia, and also an 
increased in cystosolic free calcium (Ca2+) and decreased magnesium (M g'+) levels 
(Weidmann et al, 1993 b).
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♦
Different factors
Figure 5-3 Inter-relationship between (predisposition to) hypertension, excess weight 
and metabolic disturbances (Weidmann et al, 1993.a)
Most studies of insulin resistance have concentrated on the regulation of glucose 
metabolism by insulin. A few researchers have reported impaired fatty acid regulation in 
the insulin resistance state (Fraze et al, 1986, Swislocki et al, 1987).- Plasma NEFA and 
TG concentrations were higher and HDL-C lower in a hypertensive group than a 
normotensive group (Pollare et al, 1990).
Singer et al (1985) have reported that 24-hour metabolic profiles of patients with 
hypertension suggested that insulin, glucose, and NEFA concentrations were increased,
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suggesting an impaired sensitivity to insulin for both glucose homeostasis and 
antilipolysis.
Furthermore, Swislocki and Tsuzuki have reported that the serum FFA (NEFA) level is 
elevated both in the fasting state and in response to feeding in the spontaneously 
hypertensive rat (SHR) and they have suggested that this interesting finding is another 
potential locus of insulin resistance in hypertension (Swislocki and Tsuzuki, 1993). It 
may be a model for the relationship between NEFA and blood pressure in the present 
study.
An important link existsbetween obesity, NIDDM, and hypertension. Hypertension is 
understood to contribute to the increased cardiovascular morbidity and mortality in 
patients with obesity and NIDDM (Daly and Landsberg, 1991).
Hypertension in obese individuals with or without NIDDM is clearly related to 
hyperinsulinemia and hyperinsulinemia excites sympathetic nervous system (SNS) 
activity. Both hyperinsulinemia and increased SNS activity cause decreased sodium 
excretion, thus elevating blood pressure (Daly and Landsberg, 1991). This is an possible 
explanation for raised blood pressure in women with previous GDM.
In conclusion, based on the present information, it may be said that there are several 
possible explanation for the relationship between insulin resistance or hyperinsulinemia 
and hypertension.
Firstly, insulin resistance and hypertension may be causally independent but have a 
common underlying mechanism, such as altered cellular electrolyte metabolism, 
increased vascular resistance or decreased capacity to vasodilate (especially in skeletal
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muscles), increased sympathetic nervous system activity and, once it occurs, obesity 
(Weidmann et al, 1993). It may be an explanation for our finding.
Secondly, insulin resistance may occur as a secondary modification during the 
development of hypertension, not affecting its pathogenesis. Insulin resistance and / or 
hyperinsulinemia, regardless of their underlying mechanism and time of occurrence, may 
cause or worsen hypertension (Weidmann et al, 1993).
5.9 Microalbuminuria in Women with Previous GDM One Year after Delivery 
GDM subjects exhibit a significant microalbuminuria compared to controls based upon 
spot urine.
Arterial hypertension causes increased UAER. The possible mechanism for this effect is 
thought an increase in hydrostatic pressure in the glomerular capillaries or a change in 
permeability in the glomerular basement membrane (Parving et al, 1974, Ljungman, 
1990).
Several investigations have suggested that microalbuminuria is strongly related to 
increased cardiovascular disease risk (Haffner et al, 1990 a, Winocour et al, 1992) and 
predicts increased mortality rate (Yudkin et al, 1988, Damsgaard et al, 1990). Ross 
hypothesised that increased UAER is a marker of endothelial dysfunction, including 
increased trans-endothelial permeability of different macromolecules such as albumin 
(Ross, 1986). According to the ‘response-to-injury’ hypothesis, endothelial dysfunction 
is one of the early steprin the atherogenesis process (Ross, 1986).
We found a negative correlation between microalbuminuria and age and it confirms the 
results reported by Watts et al (1988). The underlying mechanism is not clear.
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Microalbuminuria was also related to fasting insulin concentration and insulin / glucose 
ratio (as a marker of insulin resistance) in women with previous GDM. This association 
between microalbuminuria and insulin resistance was reported previously by Nosadini et 
al (1992) in NIDDM or essential hypertension patients with microalbuminuria.
In this study, there is a positive and significant correlation between BMI and 
microalbuminuria in GDM subjects. Hasslacher et al (1993) also have reported a 
correlation between BMI and decline of kidney function in proteinuric NIDDM patients.
Subjects with microalbuminuria have higher arterial pressure than diabetic patients 
without microalbuminuria (Feldt-Rasmussen et al, 1982). We also found that 
microalbuminuric GDM patients have a higher systolic blood pressure than 
normoalbuminuric GDM patients.
Approximately 75% of IDDM patients with nephropathy are hypertensive and 25% of 
them could be normotensive. It is thought that serious morphologic injury might be 
independent of hypertension in IDDM patients (Sherman and Gosking, 1988, Mauer et 
al, 1992). _
In animal models of IDDM, increased glomerular capillary pressure generally precedes 
the development of both systemic hypertension and microalbuminuria. There are no 
comparable data on NIDDM patients. Thus, increased arterial pressure may not be a 
causal factor but rather the process that provokes a different underlying process (Abott 
et al, 1994).
Recently, microalbuminuria was reported to be associated with hyperinsulinemia in non­
diabetic subjects (Haffner et al, 1990 a). Our study showed an association between
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microalbuminuria and increased fasting insulin level in subjects with past medical history 
of GDM.
The microalbuminuric GDM subjects had significantly elevated plasma cholesterol than 
normoalbuminuric subjects. Metacalf et al (1992) recently reported the same finding in 
non-diabetic subjects.
Moreover, the microalbuminuric group demonstrated higher plasma TG levels than the 
normoalbuminuric group, it confirming W oo’s report (Woo et al, 1992). In the present 
study, microalbuminuric GDM patients had significantly higher concentrations of VLDL- 
C and VLDL-TG than normoalbuminuric GDM patients.
Jones et al have reported higher concentration of VLDL-C in EDDM patients and they 
believe prolonged exposure to dyslipidemia and blood pressure and other risk factors 
may result the increased risk of coronary heart disease (Jones et al, 1989). The reasons 
for the apparent effect of hyperlipidemia on kidney function are not fully known.
Animal experiments indicate an increased uptake of lipoproteins by ‘mesangial’ and 
‘epithelial’ cells of the glomerulus are a cause of the negative effect of 
hyperlipoproteinemia on kindney function (Wassermann et al, 1989, Kasiske et al, 1990, 
Grone et al, 1990, Raner et al, 1990). Secondary to increased uptake of lipoproteins by 
mesangial and epithelial cells, proliferation of mesangial cells and increased production of 
mesangial matrix occurs. This promotes the development of glomerulosclerosis 
(Hasslacher et al, 1993).
Several investigations were performed on humans to study the effect of treatment of 
hypercholesterolemia with HMG-CoA reductase inhibitors on proteinuria. Rabelmk et al 
(1990) reported a decrease in protein secretion in nephrotic syndrome patients treated by
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simvastatin. However, Hommel et al (1992) reported no difference in plasma lipoprotein 
and renal function during simvastatin treatment in diabetic nephropathy. Further 
experiments are necessary to clarify this.
Factor VII was significantly and positively related to microalbuminuria in the GDM 
group. A significant positive correlation was found between urinary albumin excretion 
rate and factor VII, by us and by Knobl et al (1993). It may suggest that 
microalbuminuria might be the expression of vascular endothelial damage associated with 
a hypofibrinolytic and hypercoagulative circumstance (Gruden et al, 1994).
In the present study, fasting insulin level presents a significandy contribution in a multiple 
regression model to the development of microalbuminuria in the GDM group. In this 
study, our finding is similar to that of Winocour et al (1992). Nosadini et al have 
suggested that extrahepatic defects in insulin sensitivity seem to precede the development 
of hypertension and microalbuminuria in NIDDM patients (Nosadini et al, 1994).
It may be hypothesised that the relationship between hyperinsulinemia as a causal factor 
and microalbuminuria indicate microalbuminuria as part of the pre-diabetic state. 
Subsequently, hyperinsulinemia and insulin resistance are the strong predictors of the 
development of NIDDM (Bogardus et al, 1987, Saad et al, 1988). Also, raised blood 
pressure and dyslipidemia precede the onset of diabetes (McPhillips et al, 1990, Medalie 
et al, 1975).
The exact mechanism involved in the role of insulin in microalbuminuria is not 
completely clear. Nestler et al have reported that transcapillary escape rate of albumin is 
increased in non-diabetic men in response to marked pharmacological hyperinsulinemia 
(Nestier et al, 1990). Another possible mechanism behind hyperinsulinemia and
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microalbuminuria was suggested by Niskanen and Laakso (1993). They suggested that 
impaired insulin action or hyperinsulinemia at the kidney level could lead intra­
glomerular pathology and subsequent albuminuria.
Animal and human studies in renal disease other than diabetic nephropathy have shown 
that dietary sodium intake influences urinary albumin excretion rate (Donson et al, 
1989, Tuck et al, 1990, Lax et al, 1992). Insulin influences renal sodium handling, 
which causes the sodium retention in diabetic patients (DeFronzo et al, 1992). Sodium 
intake did not show a significant correlation with microalbuminuria in this study.
The existence of microalbuminuria in non-diabetic subjects indicates that hyperglycaemia 
cannot be an essential condition for its development. The relationship between 
microalbuminuria and ischaemic heart disease in both diabetic and non-diabetic subjects 
propose that a similar, non-glucose related mechanism underlies this relationship in both 
groups, with the role of hyperglycaemia only to increase renal protein loss and thus 
progression of glomerulosclerosis to renal failure (Yudkin, 1993).
Haffner et al (1993 a) suggested that microalbuminuria may be a feature of the pre­
diabetic state. This may also be the case in this population of women with history of 
GDM, but follow up studies will be required to see if this is the case
Based on Stiegler’s suggestion, increased albuminuria may be a marker of early and 
accelerated atherosclerosis (Stiegler, 1993).
Microalbuminuria is correlated to a hypercoagulative and hypofibrinolytic state. 
Haemostatic dysfunctions could be a pathogenic link between microalbuminuria and 
cardiovascular disease (Gruden et al, 1994).
Chapter Five Discussion 186
5.10 Coagulopathy in Women with Previous GDM One Year after Delivery
Numerous studies have suggested that coagulation disorders in diabetic patients, which 
seem to be caused by hyperglycaemia (Ceriello, 1993), give rise to a thrombotic 
tendency.
High levels of plasma fibrinogen (Coller et al, 1978, Ganda and Arkin, 1992), factor VII 
(Ceriello et al, 1988), factor VIII, vWF (Osterman and Va-deLoo, 1986), factor X 
antigen and low activity of factor X in plasma (Ceriello et al, 1990) have been reported 
in diabetic patients and thought be due to hyperglycaemia.
The figure 5-5 shows the pathway linking hyperglycaemia and a tendency to thrombosis 
in diabetic patients. Hyperglycaemia may influence thrombosis by two mechanisms; 
either by a mechanism connected with non-enzymatic glycation or by an increased 
oxidative reaction (Ceriello, 1993).
Hyperfibrinogenemia was correlated with body fat % and BMI in the GDM group. A 
similar result was found by Cigolini et al (1994). In addition, dietary fibre intake showed 
an independent and negative correlation with fibrinogen in GDM subjects. The
mechanism of this association is unclear.
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Figure 5-4 Pathway linking hyperglycaemia and thrombosis in diabetes mellitus.
(+ = increased and -  = decreased, Adapted from Ceriello, 1993)
Oral contraceptive use has been shown by Meade et al (1979) to be associated with 
raised plasma fibrinogen levels and fibrinolytic activity, whereas in our study, there was 
no significant correlation between oral contraceptives and fibrinogen.
Factor Vile levels were related positively to BMI in GDM subjects. The same 
relationship was reported previously by Meade et al (1987) in subjects who had given up 
smoking. In addition, Factor Vile also demonstrated significant correlations with lipid 
and lipoproteins such as plasma cholesterol, TG concentrations, VLDL-TG, IDL-C, and 
IDL-TG. The mechanism for these correlations is not clear.
In conclusion, in the present investigation, there were no significant haematologic 
abnormalities in the GDM subjects compared with controls.
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Statistical analysis using simple regression indicates that abnormalities in the coagulation 
system are correlated with aspects of lipid and carbohydrate metabolisms in the GDM 
subjects.
5.11 Dietary Habits in Women with Previous GDM One Year after Delivery
GDM subjects had significantly higher PUFA and apoE intake in comparison with 
controls.
Mensink and Katan (1992) have proposed that dietary fatty acids are not the sole or even 
most important determinant of serum lipid concentrations. Age, genetic background, 
and degree of obesity are stronger determinants.
In our study, total energy and all macronutrients (fat, carbohydrates, and proteins) intake 
were associated with WHR as a marker of obesity particularly central obesity (p < 0.001 
for total energy, fat and carbohydrate intake and p < 0.01 for protein intake). Studies 
indicated that weight gain resulting in obesity occurs when energy intake chronically 
exceeds energy expenditure (Jequier and Schütz, 1983, Woo et al, 1985, Prentice et al, 
1986).
Dietary cholesterol intake did not represent an association with plasma cholesterol in this 
study. Several studies reported no linear relationship between dietary cholesterol intake 
and total cholesterol levels (Shekelle et al, 1981, Katan et al, 1988), whereas others 
report a positive correlation between those two (Lamon-Fava et al, 1994).
Our data demonstrated the negative correlation of dietary fibre intake and total 
cholesterol, apoB, LDL-C, blood pressure, BMI and body fat %. Rouse et al (1983) 
reported that both systolic and diastolic blood pressure were lower in a vegetarian
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population than a meat eating population. The major differences in dietary intake 
between two groups were that the vegetarian population had a higher intake of 
polyunsaturated fat, fibre, potassium, magnesium, and calcium and less protein and 
saturated fat intake.
In addition, other investigators have reported a negative correlation between increased 
fibre from fruit and vegetables and blood pressure (Kestin et al, 1989). Our findings are 
consistent with this result.
Soluble dietary fibre such as pectin and oat-bran increases faecal bile-acid excretion and 
often the excretion of other faecal steroids, causing increased concentrations of hepatic 
lipoprotein B/E receptors. As a result, circulating cholesterol ester-rich lipoproteins are 
removed more rapidly (Williams et al, 1986), resulting in decreased plasma total 
cholesterol. This is an explanation for the negative correlation between fibre intake and 
total plasma cholesterol.
Dietary fibre intake was shown as an independent variable in simple regression analysis 
for BMI. The mechanism by which dietary fibre influences obesity are thought to be due 
to its physiological effects. Dietary fibre fills the stomach and provides a sense of satiety, 
normalizes intestinal transit time, delay gastric emptying and slow the rate of digestion 
and absorption of nutrients (Mahan and Arlin, 1992).
In addition, dietary fibre intake was negatively correlated with plasma fibrinogen level 
and factor Vile. The mechanisms of this associations (if confirmed) are unclear.
Subjects with > 53% of energy intake as carbohydrates in their diet exhibited 
significandy lower HDL-C and apoA-I levels than did subjects with lower carbohydrate 
intake (Lamon-Fava et al, 1994). In the present study, subjects had ~ 45% of energy
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intake as carbohydrate. We found a negative correlation between carbohydrate intake 
and plasma total cholesterol, apoB, LDL-C, and CETP activity in plasma in GDM 
subjects, and perhaps this was because of their relatively low carbohydrate and high fat 
intake.
There were positive correlations between all types of energy intake (fatty acids, protein, 
and carbohydrate) and markers of obesity. It is generally accepted that all sources of 
energy can be stored as adipose tissue in the body.
Micronutrients are the small quantities of vitamins and minerals that play highly specific 
roles in facilitating energy transfer. Vitamins contain no useful energy for the body, but 
generally serve as essential links to help regulate the chain of metabolic reactions that 
facilitate the release of energy bound in the food molecules and control the process of 
tissue synthesis (McArdle et al, 1991 c). The GDM subjects included significantly 
greater quantity of vitamin E in their diet. It is difficult to relate this finding to NIDDM 
and it may be a chance effect.
There was a suggestion that the intake of green leafy vegetables was lower in the insulin 
resistant group of people who had had GDM than in others. Whether this observation is 
a result of chance or whether it reflects reality is notclear. Nevertheless, it seems clear 
that those women who are overweight and who have insulin resistance are not following 
current dietary recommendations.
It may be said that the first step to improve the metabolic abnormalities in the GDM or 
NIDDM subjects who are overweight or obese is weight reduction. The weight loss is 
an effective tool in improving abnormalities in both carbohydrate and lipid metabolism in
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those subjects. A high carbohydrate, low-fat diet such as the Mediterranean diet, is 
correlated with a reduced risk of CHD (Keys et al, 1986).
The reduction in risk of CHD probably is due to contribution in lipid and lipoprotein 
metabolism by these diets. A WHO study group has suggested that less than 30% of 
food energy should be provided by fat and no more than 10% of energy from saturated 
fat.
5.12 Alcohol Consumption in Women with Previous GDM One Year after Delivery
The significant correlation between alcohol intake and apo A-I and HDL-C levels has 
previously been observed by other researchers, but this is the first report in a GDM 
population.
Many studies have observed that alcohol use raised HDL-C both in males (Hubert et al, 
1987, Contaldo et al, 1989, Linn et al, 1989) and in females (Linn et al, 1989, Hubert et 
al, 1987, Bush et al, 1988). The positive correlation between alcohol use and plasma 
apo A-I which we found is consistent with other investigators’ findings (Camargo et al, 
1985, Moore et al, 1988). Alcohol-related HDL-C elevations may be due to increased 
hepatic apo A-I production (Okamoto et al, 1988).
The mechanism by which ethanol influences HDL concentration remains unknown.
The mechanisms underlying the effect of ethanol on FFA is complex. The effects may 
occur through several mechanisms.
(1) Increased mobilization of peripheral fat. These actions are depends on the dose of 
alcohol intake and the dietary factors.
(2) Decreased hepatic fatty acid oxidation.
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(3) Increased hepatic fatty acid production.
(4) Increased formation of fatty acyl esters. A clinical study, using some makers of 
lipolysis, showed an increase of hepatic FFAs with progression of alcoholic liver injury. 
Usually the free fatty acids are bound to the fatty acyl binding protein (FABP) and this 
protein increase by ethanol use. Increased formation of fatty acyl esters tends to 
counteract the accumulation of free fatty acids (Lieber and Pignon, 1989).
5.13 Smoking in Women with Previous GDM One Year after Delivery
In the present study, smoking was not correlated with plasma HDL concentration.
Subjects were not heavy smokers.
Current smoking was correlated with increased plasma TG, IDL-TG, IDL-FC, and 
NEFA concentrations in our investigation. Steiner et al (1987) reported that the men 
who currently smoked had higher levels of IDL-apoB and of IDL-TG in comparison 
with men who never smoked or had not smoked for at least 2 years.
It has previously been postulated that smoking may play a role in the development of 
atherosclerosis and it may be through elevated VLDL remnants levels due to smoking 
(Topping and Turner, 1975, Topping et al, 1977). Other investigators reported a 
correlation between TG and smoking (Simons et al, 1984, Cowan et al, 1985). Our 
findings support all previous findings
Smoking was associated independently with plasma insulin levels (corrected for age, 
BMI, use of contraceptive pill, etc) in GDM subjects. The influence of smoking on 
insulin sensitivity was first studied by Helve et al (1986). They suggested that smoking 
has a negative effect on insulin sensitivity. Facchini et al (1992) have reported that non­
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diabetic smokers are more insulin resistant, hyperinsulinémie, and dyslipidémie than non­
diabetic non-smokers. Attval et al (1993) have found that smoking results in impaired 
insulin action mainly due to decreased peripheral glucose uptake. This results support 
the Facchini et al study.
Some studies have revealed that glycaemic control is worse among diabetic patients who 
smoke than diabetic patients who do not smoke (Lundman et al, 1990, Bott et al, 1994). 
Cigarette smoking has been identified as a risk factor for diabetic nephropathy 
(Muhlhauser et al, 1986, Stegmayr and Lithner, 1987).
Heavy smoking (a packet or more per day) increases the risk of diabetes (NIDDM) in 
women (Rimm et al, 1993), it has also been associated with higher HbAlc levels among 
subjects with normal glucose tolerance (Modan et al, 1988).
The mechanism for any changes in lipids and lipoproteins by smoking is uncertain
5.14 Physical Activity in Women with Previous GDM One Year after 
Delivery
Physical activity was related to plasma insulin levels and WHR in this study. Regular 
physical activity improves glucose tolerance and may induces weight loss (Rauramaa, 
1984) and increases insulin sensitivity (Soman et al, 1979). In addition, short periods of 
exercise can increase plasma glucose concentrations by increasing peripheral and 
splanchnic insulin sensitivity (Delvin et al, 1987).
Both cross-sectional and prospective studies have suggested an increase in the HDL-C 
following exercise training especially after aerobic exercise (McCrory et al, 1994). 
There is no significant correlation between HDL-C and exercise in our study. This
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discrepancy might be due to a dose response relation between the amount of habitual 
exercise and HDL-C elevation (Lakka and Salonen, 1992). It may be said the GDM 
subjects should exercise more to achieve the beneficial metabolic effects of exercise, or it 
is due to sample size.
The significant correlations between exercise and CETP activity, plasma apoA-I, VLDL- 
TG, and NEFA may support the beneficial influence of exercise on lipoprotein 
metabolism
The significant correlation between exercise and CETP activity indicates that exercise is 
associated with an increase in reverse cholesterol transport (Gupta et al, 1993).
There was a significant and negative correlation between exercise and WHR. Horton 
and Geissler (1994) have found that habitual exercise leads to increases daily energy 
expenditure by 8-14% and increase lean body mass (and results loss of body fat and thus 
WHR). Alternatively, fat persons might not like to take exercise, resulting in increased 
obesity. .
Long et al (1994) have suggested that weight loss in patients with clinically severe 
obesity prevents the progression of impaired glucose tolerance to NIDDM by > 30-fold.
Both frequency and intensity of exercise were related to systolic blood pressure in GDM 
subjects. Systolic blood pressure increases in proportion to oxygen consumption and 
cardiac output during physical activity, whereas diastolic blood pressure remains 
relatively unchanged or slightly increased. Following exercise blood pressure falls below 
pre-exercise levels, and may remain lower for several hours (McArdle et al, 1991 b).
Physical activity is an effective, non-dietary, non-pharmacological option for the 
management of mild hypertension. Physical activity produced average falls in blood
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pressure of 11 mmHg systolic and 6 mmHg diastolic respectively in reported series of 
hypertensive patients subjected to various forms of isotonic exercise such as walking, 
running, cycling, swimming and cross-country skiing (Stokes, 1992).
The beneficial effects of physical activity on serum lipids seem to be mediated partially by 
a decreased serum insulin level and body adiposity (Lakka and Salonen, 1992).
In addition, regular physical activity is effective in preventing NIDDM, and the 
protective benefit is particularly pronounced in subjects at the highest risk for developing 
NIDDM (Helmrich et al, 1991).
Results from subgroups analysis showed that the GDM subjects who had positive family 
history of diabetes mellitus, high plasma NEFA concentrations, and were overweight or 
obese (BMI > 25 kg / m2) (subgroup A) had several metabolic abnormalities compared 
with the residual GDM group and controls.
Subgroup A of the GDM group (those who are overweight, have high plasma NEFA 
concentrations, and a positive family history of diabetes mellitus) tended to be 
hyperinsulinémie and hyperlipidémie (significantly higher plasma TG, VLDL-TG, and 
IDL-C concentrations) compared with the residual GDM group.
Subgroup A also tended to be more hyperinsulinémie, hyperlipidémie (significantly 
higher plasma cholesterol, TG, apoB, VLDL-TG, IDL-C, and LDL-C concentrations, 
and greater CETP activity in plasma) compared with controls.
The GDM subjects who had positive family history of diabetes and high plasma levels of 
NEFA but not overweight (BMI < 25 kg / m2) (subgroup B) tended to have better 
metabolic status than the residual GDM group and similar to controls.
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Subgroup B tended to have less insulin resistance (lower fasting insulin concentrations) 
than the residual GDM group but similar to the residual controls.
In addition, subgroup B tended to have significantly lower lipids and lipoprotein 
concentrations (plasma cholesterol, TG, VLDL-TG, and IDL-C concentrations) than the 
residual GDM group but similar to the residual controls.
The subgroup B also had significantly lower BMI and WHR than the residual GDM, but 
similar to the residual controls.
As a result, a comparison of subgroup A and B suggests that being overweight or obese 
is an important factor in developing metabolic disorders in women who have positive 




The purpose of our investigation was to test the hypothesis that certain factors are 
altered in patients who have been diagnosed with GDM compared with controls. 
Identification, treatment, and follow-up of women with GDM are very important because 
GDM subjects are at the risk of adverse maternal, fetal, and neonatal outcomes. 
Subjects who have had GDM are at a high risk of later development of NIDDM.
The present study showed that the GDM subjects (ie subjects who had had GDM in then- 
last pregnancy one year previously) were more overweight or obese than controls. The 
GDM subjects had a family history of diabetes mellitus in first and second degree of 
relatives, particularly in the maternal side.
Obesity like NIDDM is commonly characterized by insulin resistance with increased 
plasma NEFA concentrations. Distribution of excessive fat on the upper body segment 
or abdomen, as measured by WHR is correlated with decreased insulin sensitivity and 
increased risk for developing diabetes (Park, 1993).
The links between insulin resistance and obesity might be multifactorial and bi­
directional. Insulin resistance may precede the obesity or insulin resistance may be due 
to obesity (Park, 1993).
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NEFA may have an important role in the metabolic influence of obesity. Plasma NEFA 
concentration is elevated and fatty acid turnover rate is increased in obesity, and these 
abnormalities are more pronounced in upper body obesity than lower body obesity 
(Jensen et al, 1989).
Increased NEFA concentrations result in increased fatty acid oxidation, and this may lead 
to decreased glucose oxidation and thus decreased glycogen synthetase activity. 
Decreased glycogen synthetase activity associates result in development of insulin 
resistance in both liver and muscle. Therefore, increased availability of NEFA is an 
important link between insulin resistance and obesity (Park, 1993).
Upper body obesity is associated with large fat cells which in turn tend to be insulin 
resistant. Fat localization (upper body or central) is related to increased activity of 
androgens, as manifest by lower SHBG and higher free testosterone. In turn, increased 
activity of androgens is also associated with increasing WHR, increasing plasma glucose 
and insulin concentrations in both fasting and in response to oral glucose challenge, and 
decreased insulin sensitivity in obese pre-menopausal women (Evans et al, 1983).
Low SHBG and high testosterone concentration are caused by abdominal obesity (Evans 
et al, 1983). In the present study, BMI was independently correlated with SHBG levels 
in multiple regression analysis. In addition, low serum SHBG level has been suggested 
as strong independent risk factor for the development of NIDDM in women (Lindstedt et 
al, 1991).
The GDM subjects were overweight or obese, had family history of diabetes, high 
plasma NEFA concentration, and low SHBG level. As a result, the GDM subjects were 
more likely to have hyperinsulinemia and insulin resistance. The GDM subjects exhibited 
higher plasma insulin levels than controls.
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Evidence suggests that insulin resistance and hyperinsulinemia may continue for many 
years in a compensated state with normal glucose tolerance. It appears likely that many 
of the metabolic disorders associated with insulin resistance have their onset during this 
compensated state, long before glucose intolerance or frank diabetes.
Thus, insulin resistance may help explain the metabolic disorders often observed in 
obesity and NIDDM, including dyslipidemia, hypertension, and atherosclerosis (Williams
et al, 1994). The present study suggests that insulin resistance secondary to obesity and 
a family history of diabetes may be cause of dyslipidemia, raised blood pressure, 
microalbuminuria, and impaired glucose tolerance and NIDDM in women with history of
GDM (Figure 6-1).
Figure 6-1 Hypothetical model based on the present study (DM -  diabetes mellitus)
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6.2 Insulin Resistance, Dyslipidemia, and ‘GDM’
Increased availability of FFA is an important link between insulin resistance and obesity. 
The possible mechanism for hyperlipoproteinemia and its related abnormalities found 
with insulin resistant might be that hyperlipoproteinemia may be caused by enhanced 
FFAs flux on the insulin-resistance liver, perhaps resulting from central obesity (Park, 
1993).
Most causes of insulin resistance including diet, central obesity, and physical activity 
result in increased flux of FFAs and (probably) glucose to the liver. Cambien et al 
(1987) reported that hyperinsulinemia insulin is associated with elevated VLDL-TG 
concentrations positively and decreased HDL-C concentration. This appears to be a 
consistent relationship between hyperinsulinemia and hypertriglyceridemia in healthy, 
normal-weight subjects (Zavaroni et al, 1989). The possible underlying mechanism is 
outlined in Figure 6-2.
Incubation of cell lines with VLDL causes insulin resistance due to either a decrease in 
insulin receptors or a post-binding defect (Hunt et al, 1989). Thus, it seems insulin 
resistance promotes dyslipidemia and dyslipidemia may induce insulin resistance.
Winocour et al (1992) have found that hyperinsulinemia is associated with a higher TG / 
apoB ratio and lower HDL-C / apoA-I ratio after adjustment for BMI in women. 
Despite a higher apoA-I and HDL synthetic rate in NIDDM patients than controls, 
plasma HDL-C is reduced in NIDDM patients because of an increased apoA-I and HDL 
fractional clearance rate (Golay et al, 1987).
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LDL is synthesized from hepatic-derived VLDL. DDL particles are produced during the 
conversion of VLDL to LDL, and IDL particles are thought to be atherogenic 
((Nordestgaard and Tybjaerg-Hassan, 1992).
Impaired LPL activity can reduce VLDL removal and therefore indirectly influence the 
flux of material to HDL particles. Additionally, insulin resistance might inhibit CETP or 
LCAT activity. Alterations in the lipolytic cascade may cause more dense LDL particles 
(Howard, 1993).
From the results of this study, it may be concluded that the GDM subjects who have a 
positive family history of diabetes and also are overweight or obese exhibit 
hyperinsulinemia (as a compensatory response to the insulin resistance), resulting in 
dyslipidemia in this population.
Dyslipidemia in the GDM subjects is characterized by hypertriglyceridemia and high 
plasma concentrations of VLDL-TG, high plasma total cholesterol, IDL-C, and LDL-C 
levels, slightly lower HDL-C, higher CETP activity in plasma, and smaller and denser 
LDL and HDL3 particles. There is abundant evidence that hyperinsulinemia and insulin 
resistance appear to be associated with frequency of atherosclerosis (Stout, 1993).
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Figure 6-2 Insulin resistance and lipoprotein abnormalities 
(data from Howard, 1993, Hunt et al, 1989)
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6.3 Insulin Resistance, Raised Blood Pressure, and <GDM>
It has been recognized for many years that hypertension is common in people who are 
obese (Havlik et al, 1983, Modan et al, 1985) and those who have NIDDM (Modan et 
al, 1985, Turner, 1985). On the other hand, exercise (Maiorano et al, 1989) and weight 
loss (MacMahon et al, 1985) has been reported to be effective in lowering the blood 
pressure in obese and diabetic patients by improving insulin sensitivity.
DeFronzo (1982) has reported that improvement of insulin sensitivity, resulting in lower 
plasma insulin concentration is correlated with a reduction in both systolic and diastolic 
blood pressure in ono-diabetic obese patients. Thus, it might be said that insulin 
resistance per se, or through compensated hyperinsulinemia, results in raised systolic and 
diastolic blood pressure (Manicardi et al, 1986).
Studies have proposed that hyperinsulinemia and / or insulin resistance assist sodium 
retention, which plays a n important role in the development of hypertension. Sodium 
retention in turn, results in water reabsorption in the kidney tubules (Sharma et al, 1991, 
DeFronzo, 1981, Kolanowski, 1981).
Hyperinsulinemia may lead to the development of hypertension through activation of the 
sympathetic nervous system (O’Dea et al, 1982, Sowers et al, 1982).
The possible mechanisms underlying raised blood pressure in the GDM subjects are 
summarized in Figure 6-3.
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Figure 6-3 Relationship between insulin resistance, hyperinsulinemia, sympathetic 
nervous system activity, and hypertension.
(CNS = central nervous system, DeFronzo and Ferrannini, 1991)
6.4 Insulin Resistance, Microalbuminuria, and ‘GDM’
It is thought that there is link between microalbuminuria and insulin resistance. 
Angiotensin converting enzyme inhibitor agents such as captopril cause an increase in 
insulin sensitivity (Pollare et al, 1989) and use of these drugs decreases microalbuminuria 
irrespective of their antihypertensive effects (Parving et al, 1989).
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Haffner et al (1990 a) have reported that there is an association between 
microalbuminuria and a number of cardiovascular risk factors such as hyperinsulinemia, 
hypertension, and hypertriglyceridemia in non-diabetic subjects.
Nestler et al (1990) have reported an increased trans-capillary escape of albumin in non­
diabetic subjects. It may be a possible link between microalbuminuria and 
hyperinsulinemia. Insulin resistance and or hyperinsulinemia at kidney level may result in 
intraglomerular pathology and subsequent albuminuria (Niskanen and Laasko, (1993).
In our study, microalbuminuria was correlated with plasma insulin concentration.
6.5 Insulin Resistance, IGT, NIDDM, and ‘GDM’
The pathogenesis of NIDDM can be divided into four phases: genetic susceptibility, 
insulin resistance, IGT, and NIDDM itself (Bennett et al, 1988). Figure 6-4 
demonstrates briefly the pathogenesis of NIDDM.
People who have had GDM with a positive family history of diabetes mellitus have a 
genetic or inherited susceptibility to NIDDM. In addition, they are significantly fatter 
and hyperinsulinémie than controls in the present investigation.
Defects in insulin action may be exist in some subjects years before the onset of overt 
diabetes mellitus. Impaired insulin action is present in individuals at risk for developing 
NIDDM (pre-diabetic), including relatives of NIDDM patients, people with impaired 
glucose tolerance, and in ethnic populations with a high prevalence of NIDDM such as 
Pima Indians (Alzaid and Rizza, 1993).
As a result, we may say that women with previous GDM are likely to develop NIDDM 
later and hyperinsulinemia is its hallmark.
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Several lines of evidence suggest that those who develop overt NIDDM may at first 
manifest only insulin resistance. Acquired factors such as obesity and inactivity may be 
additive (Seely and Olefsky, 1993).
Compensated Insulin 
Resistance
(Normal or Impaired 
Glucose Tolerance)
Figure 6-4 Proposed etiology fo r  the development o f NIDDM (adapted from  Seely and
Olefsky, 1993)
Impaired glucose tolerance (IGT) is a phase occurring after the insulin resistance phase 
and before overt NIDDM (WHO, 1985). IGT subjects represent a greater degree of
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insulin resistance compared with subjects with normal glucose tolerance. Among IGT 
subjects those with the greater insulin resistance are most likely to develop overt 
NIDDM (Bennett et al, 1988).
NIDDM in obese subjects seems to be the end result of a series of changes that occur 
over many years that culminate in the failure to maintain glucose homostasis (Bennett, 
1988).
The proposed pathogenic mechanisms for NIDDM include a primary defect relating to 
the development of insulin resistance and a secondary defect relating to pancreatic insulin 
secretory failure (Bennett, 1988).
It seems NIDDM can be delayed or even prevented if somehow the pancreas could be 
protected from failure. It seems likely this may be achieved by diminishing insulin 
resistance. Weight loss in obese and overweight subjects, regular exercise, a healthy diet 
with low saturated fat and adequate fruit and vegetables, stopping smoking, and 
correction of the medical problems can reduce the degree of insulin resistance degree 
and may delay or prevent NIDDM in GDM subjects.
In conclusion, this study revealed that women with previous GDM are more likely to 
have a family history of diabetes mellitus and be fatter than controls, resulting in 
hyperinsulinemia. Obesity causes higher plasma NEFA concentration and 
hyperandrogenicity and these abnormalities may cause insulin resistance and 
hyperinsulinemia. The GDM subjects demonstrated a cluster of abnormalities related to 
insulin resistance and hyperinsulinemia including dyslipidemia (high cholesterol, TG, 
VLDL-TG, IDL-C, and LDL concentrations, smaller and denser LDL, and greater CETP 
activity in plasma), raised blood pressure, and microalbuminuria.
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Recommendations for Future Research
This study has investigated the metabolic abnormalities in subjects with previous G D M  
(post-GDM ) one year after delivery. In light o f this study, there are several areas in 
which future research could be conducted:
The major areas o f interest will be to determine the crucial factors determining the 
development o f diabetes in these women who have demonstrated a predisposition to 
diabetes, and determining ways in which this slide into diabetes could be arrested.
Two particular study areas are suggested by the work described in this thesis:
* Subgroup analysis showed that being overweight appears to be a very important 
factor in the development o f metabolic disorders in the GDM group. A study based on 
weight reduction in both post-GDM  women and also in women who are at risk of 
development o f GDM (women who have a positive family history o f diabetes and high 
plasma N EFA  concentrations) may show that the abnormalities associated with the 
insulin resistance syndrome can be reversed.
* Another intervention study may examine the effects o f a low fat-high fibre diet and 
enough exercise in the post-GDM  subjects. A low fat-high fibre diet (more fruit and 
vegetable consumption) and physical activity may induce more insulin sensitivity and 
thus reduce the risk o f development o f diabetes mellitus and cardiovascular disease in
the GDM group.
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F IL E :..................... DATE:
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A D D RESS:....................................................................................
TEL EPH O N E  N O :...................................................
DATE O F B IR T H :...................................................
Nam e and address of family / personal doctor:
Nam e and address of two relatives / friends (This will help us locate you if  you move
from the above address):
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Do you presently take any medications:
(please circle correct answer)
No
Yes
(If your answer is yes- please give the name of the medications and briefly give reasons 
for taking them)
Family history of diabetes, eg. parents, brothers, sisters, other relatives; and age 
of onset.
W hat treatm ent for diabetes mellitus were your relatives receiving? (please tick 
the relevant correct answer)
.............. Diet alone
.............. Diet and tablets
.............. Diet and insulin
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Obstetric History:
Num ber of p regnancy :.................................................................................
Num ber of s tillb irth :....................................................................................
Num ber of a b o rtio n :....................................................................................
Number of delivery :.....................................................................................
Date of birth of baby (and maturity- full-term or premature):
Weight of baby at b i r th : ..............................................................................
W ere you on insulin at any stage of your pregnancy?
(please tick the correct answer)
No
Yes (if yes, please give dosage)...................
Have you ever taken oral contraceptive pill?
No
Yes
For how long altogether have you taken the oral contraceptive pill?
less than 6 m onths................................................
between 6 months and 2 years...............................
between 2 and 5 years............................................
between 5 and 10 years..........................................
longer than 10 years................................................
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Are you now taking the oral contraceptive pill?
Yes No
How often do you usually drink alcohol?
I do not drink a lco h o l..........................................
Less than once a w e e k ............................................
On 1 or 2 days a w e e k ............................................
On 3 or 4 days a w e e k ............................................
On 5 or 6 days a w e e k ............................................
Everyday......................................................................
On a day when you drink alcohol, how many drinks do you usually have?
1 or 2 drinks..............................................................
3 or 4 drinks................................................................
5 to 8 drinks.................................................................
9 to 12 drinks...............................................................
13 to 20 drinks.............................................................
More than 20 drinks...................................................
Have you ever smoked cigarettes, cigars or pipe regularly?
Yes No
At what age did you start smoking regularly?
I started smoking regularly at..................years of age.
Have you given up smoking?
yes, I gave up smoking i n ............................. ( month / year).
N o, I still sm oke............................................................................
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If  you have given up smoking please answer the following questions: 
Now much did you smoke?
week
I used to smoke...................manufactured cigarettes a day
....................  grams ‘hand-rolled’ cigarette tobacco per
.....................cigars per week
.....................grams pipe tobacco per week
A nthropometric Measurements:
Usual weight:................................................ Present weight
H eight....................
W aist m easurement: 1.............................................
2.....................................................
3.........................................
Hip m easurem ent: 1.............................................
2.....................................................
3.........................................
Waist / Hip ratio:....................
Skinfold thickness: 1....................... 2.............. ..........3............. .......... Triceps
1....................... 2.............. ..........3.............. ...........Biceps
1....................... 2 ............. .........3 ............. ......... Subscapular
1............ ...........2.............. .........3............. ..........Suprailiac
Blood pressure: 1 2 3.
Appendix I Demographic and Anthropometry Data 300
Data Elements to be Collected from the patient’s medical record and from the 
patient:
This part of the study will involve the collection retrospectively of data from the
patient’s medical records, and from the patient. Access to the patient’s details will be
sought after consent has been given by the patient and agreement negotiated with the
Area Health Service.




Waist to Hip Ratio:
Ethnicity:
Date of diagnosis:
Family history of diabetes:
Family history of cardiovascular disease:
Current dietary intake:
Glaucoma: present / not present 
Diabetic retinopathy:
Evidence of peripheral vascular disease (PVD):
Evidence of renal disease (pyelonephritis, cystitis, etc):




(Chemical Solutions and Assays)
1. G G E  b u ffer  (T ris/B ora te  buffer)
(pH = 8.35)
Measure:
Chemical Concentration (mili molar) Amount in 4 litre
Trizma base(Tris) 90 mM 43.6 g
Boric acid 8 mM 19.79 g
EDTA Na2 3 mM 4.47 g
NaN3 3 mM 0.78 g
Measure 4000 ml water in a big beaker and then add solid chemicals.
This buffer can be used 5-6 times for isolated lipoproteins from plasma. Buffer which 
has been used for whole plasma samples should not be used, subsequently, for density 
d=1.25 on 4-30 % gels due to albumin contamination.
2  Tris buffers
(a) Making 1 litre of 1 molar Tris buffer with pH = 7.4 
Calculation:
g = CVM  => Amount (mass) = Concentration x Volume x Molecular Mass
g =  1 x 1 x 121.1
g = 121.1 gram Tris
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This amount o f Tris is dissolved in 1 litre distilled water in a flask.
Solution is put in beaker and pH is measured (should be pH = 7.4), if  pH is higher than 
7.4, 32% concentrated HCL solution should be added to reach the target pH (pH = 7.4). 
This solution will be used as stock to make TBS buffer.
(b) TBS + 0.005% EDTA + 0,02% N aN, (for 5 1)
Measure:
43.83 gN aC L
0.25 g EDTA 
1 g NaN3
Mix the measured chemicals with 50 ml of Tris buffer
Measure twice 2 litter of distilled water in volumetric flask and last 1 litter
measure in cylinder (but -50 ml of Tris) (950 ml of water).
This buffer can be used for dialysing and dilution.
2  T rack in g  dye
(Sucrose bromophenol blue solution)
Measure and mix:
4 gram of Sucrose (D-glucose)
0.001 gram of bromophenol blue 
Add 10 ml o f Tris borate buffer (TBS)
3. G G E  s ta in  (p ro te in )
Measure 0.4 g page blue stain (brilliant blue)
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Add 950 ml distilled water and stir 2 hours.
Then add 50 ml H C L 04 and stir again 2 hours.
Then filtrate and collect the solution in a labelled bottle.
4. Making 10 % sulfosalycylic acid (SSA)
Mix 10 grams of SSA in 100 ml of distilled water in a volumetric flask and stir it. Then 
filtrate and storage at room temperature
(Note: 10% SSA solution can be reused. After each use it should be filtrated).
This solution is used as a fixer for gels in electrophoresis.
5. Making 5% acetic acid
Measure 950 ml of distilled water in a cylinder and then add 50 ml o f acetic acid, very 
slowly.
6. HDL determination in plasma 
Procedure:
1. Allow specimens and precipitation reagents to equilibrate to room temperature.
2. Using a manual pipette, transfer 1.0 ml. aliquot of plasma into appropriately 
labelled eppendrof tubes.
3. Add IOOjiL  of the combined of detrain sulfate-Mg2+ solution to each tube. 
Immediately after addition of this reagent, mix the contents of each tube in sequence for at 
least 3 seconds, with a vortex-type mixer.
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This amount o f Tris is dissolved in 1 litre distilled water in a flask.
Solution is put in beaker and pH is measured (should be pH = 7.4), if  pH is higher than
7.4, 32% concentrated HCL solution should be added to reach the target pH (pH = 7.4).
This solution will be used as stock to make TBS buffer.
(b) TBS + 0,005% EDTA + 0.02% NaN, (for 5 1)
Measure:
43.83 gN aC L
0.25 g EDTA 
1 g NaN3
Mix the measured chemicals with 50 ml of Tris buffer
Measure twice 2 litter o f distilled water in volumetric flask and last 1 litter
measure in cylinder (but -50 ml of Tris) (950 ml of water).
This buffer can be used for dialysing and dilution.
2. Tracking dye
(Sucrose bromophenol blue solution)
Measure and mix:
4 gram of Sucrose (D-glucose)
0.001 gram of bromophenol blue 
Add 10 ml of Tris borate buffer (TBS)
3. GGE stain (protein)
Measure 0.4 g page blue stain (brilliant blue)
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Add 950 ml distilled water and stir 2 hours.
Then add 50 ml H C L 04 and stir again 2 hours.
Then filtrate and collect the solution in a labelled bottle.
4. M a k in g  10  % su lfo sa ly c y lic  a c id  (SSA )
Mix 10 grams of SSA in 100 ml of distilled water in a volumetric flask and stir it. Then 
filtrate and storage at room temperature
(Note: 10% SSA solution can be reused. After each use it should be filtrated).
This solution is used as a fixer for gels in electrophoresis.
5. M a k in g  5%  a c e tic  a c id
Measure 950 ml o f distilled water in a cylinder and then add 50 ml o f acetic acid, very 
slowly.
6. H D L  d e term in a tio n  in  p la sm a  
Procedure:
1. Allow specimens and precipitation reagents to equilibrate to room temperature.
2. Using a manual pipette, transfer 1.0 ml. aliquot of plasma into appropriately 
labelled eppendrof tubes.
3. Add IOOjiL o f the combined of detrain sulfate-Mg2+ solution to each tube. 
Immediately after addition of this reagent, mix the contents of each tube in sequence for at 
least 3 seconds, with a vortex-type mixer.
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4. Allow the tubes to stand at room temperature for 10 minutes before sedimenting 
the insoluble lipoproteins by centrifugation.
5. Centrifuge tubes for 30 minutes with a refrigerated centrifuge (4°C, 1500xg) or 
with an unrefrigerated benchtop centrifuge at 1000 rpm for 15 minutes.
6. Remove tubes from the centrifuge and inspect supranatants for turbidity. 
Transfer the clear supernatants solution by a Pasture pipette to a second labelled vial for 
later compositional analysis.
N o te :  Any turbidity or cloudiness in the supranatant indicates incomplete sedimentation 
of VLDL, IDL, and LDL and consequent contamination and overestimation of HDL. 
This is usually observed in high triglycerides levels in samples.
7. Turbid supranatant can be conveniently cleared by one of the following methods:
(a) Without separating the turbid supranatant from the precipitate, add to the separation 
tube 1.0 ml. o f 0.15 mol/L NaCl solution and another lOOpL of combined precipitant
reagent.
Mix thoroughly with a vortex-type mixer, then centrifuge as previously described.
Obtain the clear supranatant for analysis. Supernatant cholesterol must be multiplied x 2 
to correct for this dilution.
(b) Alternatively, the turbidity can be removed by ultrafiltration with an 0.22 pm filter.
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A ppendix II C hem ical Solutions and A ssays 305
7. P ro c ed u re  f o r  H D L  R cu lio labelled  in th e  c h o le s try l e s te r  m oie ty
1. A volume of 50 ml human plasma (from a healthy volunteer) was adjusted to
density of 1.13 g/ml with solid KBr and ultracentrifuged for 24 hours at 49,000 rpm in a 
TL-50.3 rotor at, at 4°C, by using a L8-70 Centrifuge (Beckman, USA).
2. The plasma fraction of d > 1.13 g! ml was recovered by tube slicing and dialyzed 
overnight against TBS (buffer was changed several times during dialyzing period).
3. A quantity of 200 jimol of [ la ,  2 a  (n)-3H]-cholesterol (specific activity, 46.3 Ci
/mmol) in plastic scintillation vial was evaporated to dryness under a stream of nitrogen 
for approximately 1 hour.
4. Dried radiolab el led cholesterol was then redissolved in 50 jil o f ethanol.
5. The plasma fraction of 1.13 g/ml was added to the radiolabelled cholesterol 
solution under gentle stirring.
6. The mixture was incubated for 24 hours at 37°C in a shaking water bath to allow 
cholesterol esterification by the LCAT (lecithinxholesterol acyltransferase) reaction.
7. After incubation period, the solution was measured and adjusted to density 1.13 
g/ml with solid KBr and subjected to centrifugation, for 24 hours at 49000 rpm in a 50.3 
rotor, at 4°C, by using a L8-70M centrifuge (Beckmann, USA). The aim of this last
centrifugation was to remove any radiolabelled lipoproteins of density < 1.13 g/ml, 
possibly produced during the incubation period.
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8. After slicing, infranatant was collected in cylinder and measured.
9. The measured plasma fraction was adjusted to density >1.21 g/ml with solid KBr 
and centrifugated for 40 hours at 49000 rpm in a TL-50.3 rotor at 4°C.
10. After slicing, supernatant was recovered as HDL3 radiolabelled.
11. (Washing Spin): KBr solution density = 1.21 was added to HDL3 radiolabelled 
sample and subjected to ultracentrifugation for 16 hours at 100000 rpm in a TLA-100.4 
rotor, at 4°C, by using a tabletop TL-100 centrifuge (Beckmann, USA)
12. After slicing supranatant was dialyzed against TBS for 24 hours (buffer was 
changed several times).
13. Thin layer chromatography (TLC) was done on radiolabelled HDL3. 
Approximately 95 % of total radioactivity was in cholesteryl ester (CE) as ascertained by 
(TLC).
8. TLC determination o f cholesterol ester (CE) in radiolabelled HDL3 and LDL
Prepare following solutions:
1. Extraction solution
160 ml isopropanol 
40 ml n-heptane
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4 ml 1 N (0 .5M )H 2S O 4
2. Developing solution for TLC plates
45 ml hexane 
20 ml diethyl ether
1.5 ml methanol 
1 ml acetic acid
The recovery of cholesterol ester is determined by adding a know amount of ^ C -
cholesteryl oleate to the extraction solution. Prepare stock solution by adding 10 ul ^ C -  
cholesteryl oleate to 100 ml extraction solution. Prepare working solution by diluting 
stock solution 1:8 with extraction solution (ie. 0.5 ml stock + 3.5 ml extraction solution). 
From this, take 2.5 ml at next step. 
procedure:
1. Add 5 p.1 radiolabelled HDL3 or radiolabelled LDL to 495 \i\ TBS buffer (pH = 
7.4).
2. Add 40 |il unlabelled HDL3 or LDL (carrier lipoprotein)
3. Add 2.5 ml extraction solution (with 14C-cholesteryl oleate)
4. Cap and vortex
5. Stand at room temperature 20 minutes
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6. Add 1.5 ml n-heptane and 1 ml water
7. Cap and vortex
8. Stand at room temperature for 15 minutes. Prepare tank and TLC plate
9. Transfer 800 p.1 o f heptane (top) phase to a scintillation vial labelled ‘CE’ 
(cholesteryl ester)
10. Transfer 400 |il o f heptane (top) phase to a scintillation vial label TC (total count)
11. Dry sample under N 2 gas
12. Add 10 ml scintillation fluid to TC vial
13. Add 200 jil chloroform to CE vial and dissolve dried lipid
14. Spot 100 jil o f solution from CE vial onto silica gel TLC plate
15. Put the silica gel TLC plate in tank and develop until solvent is front about 2 cm 
from top o f the silica gel TLC plate (CE runs with solvent front)
16. Remove the silica gel TLC plate from tank and dry in fume cupboard
17. Develop with iodine (few crystals)
18. Scrape CE band into scintillation vial. Add 10 ml scintillation fluid
19. Express CE counts as % of total 3H counts
20. Calculate recovery of 14C-cholesteryl oleate
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CE vial count /  TC vial count x 100 = X (% recovery of CE)
9, CETP activity % in plasma Procedure:
1. 100 jil plasma was mixed with 50 \û  [3H] HDL3 (containing 2.5 nmol cholesterol.
2.2 x 105 counts/minute per 50 p.1)
2. Incubate it for 3 hours at 37°C.
3. Place the tubes immediately on ice.
4. Precipitated the apo B containing lipoproteins with dextran sulfate-Mg2+ 
(W am icketal, 1982)
The CETP assay procedure is summarized in Table 1
5. Supranatants (0.8 o f total volume) were collected in plastic scintillation vials. A 
volume of 10 mL of scintillation fluid (Instagel, Pachard Instrument Company, IL, USA) 
was added to each vial and the radioactivity was assayed for 10 minute in a ‘Hewlett- 
Packard scintillation counter’.
The percentage o f radioactivity transferred to apo B containing lipoproteins was 
calculated, as the difference between the total radioactivity o f the assay and the 
radioactivity o f the supranatant after precipitation of the VLDL, EDL, and LDL, with 
adjustment for non-specific transfer.
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Table-1: Summerized CETP assay procedure










50 |il 150 nl 3.h TBS 165 Hi 132 Hi
3,4 100
111
50 |il 150 Hi 3.h Dextr
sulfate
165 Hi 132 Hi
5,6 50 nl 100 Hi 
(+cont)
150 Hi 3.h Dextr
sulfate
165 Hi 132 Hi
7,8 50 Hi subject
sample
150 Hi 3.h Dextr
sulfate
165 Hi 132 Hi
9,10 50 Hi subject
sample
150 nl 3.h Dextr
sulfate
165 Hi 132 Hi
























CHOL Contents MPR 1 MPR 2 MPR 3 Preparation and stability of the reagent solutionBottle 1
Cholesterol
reagent
10 10 4 MPR 1: Dissolve contents of one bottle 1 by adding 32 ml 
redist. water.
MPR 2: Dissolve contents of one bottle 1 by adding 100 ml 
redist. water.
MPR 3: Dissolve contents of one bottle 1 by adding 500 ml 
redist. water.
The reagent solution is ready to use after 10 minutes.
Stable for four weeks at +2 to 8°C
seven days at +15 to 25°C.
MPR 1 1442341 10 x 32 ml 2
MPR 2 1442350  1 0 x  100 ml 2
MPR 3 236 691 4 x 500 ml
C ho leste ro l CHOD-PAP method
Method
Siedel, J., et al. (1983). Clin. Chem. 29:1075.
Kattermann, R., et al. (1984). Clin. Chem. Clin. Biochem. 22: 
245.
Trinder, P. (1969). Ann. clin. Biochem. 6:24.
Test principle , , ,
,_ 1 , , . Cholesterol esterase , , .
Cholesterol esters + H20 --------------------------------» Cholesterol +
RCOOH
, , . , _ Cholesterol oxIdase ,
Cholesterol + 0 2 --------------------------------> A -cholestenone +
l-|20 2
2 H20 2 + 4-aminophenazone + phenol - 4-(p-benzo- 
quinone-monoimino)-phenazone + 4 H20
Clinical in terpretation according to the recommendations of 




<  200 mg/dl




if HDL cholesterol 
<  35 mg/dl
Cholesterol
Triglycerides
>  300 mg/dl
>  200 mg/dl
Yes
Values in mmol/l:
Cholesterol: 35 mg/dl = 0.9 mmol/l
200 mg/dl = 5.2 mmol/l 
300 mg/dl = 7.8 mmol/l
Triglycerides: 200 mg/dl = 2.3 mmol/l
Sample material
Serum, heparinized plasma or EDTA plasma 
Stable for six days at +4 to 25°C 
four months at -20°C.
Procedure
Wavelength: Hg 546 nm (470-560 nm) 
Spectrophotometer: 500 nm 
Cuvette: 1 cm light path 
Incubation temperature: 20-25°C or 37°C 
Measure against reagent blank (RB).
One reagent blank is sufficient for each assay series.
Pipette into test tubes:
RB Sample
sample material 
reagent solution 2.00 ml
0.02 ml 
2.00 ml
Mix, and incubate RB and sample for 10 min al 20-25uC 
or 5 min at 37°C.
Read absorbance of sample against RB within 1 hour =
A
' ' s a m p le *
Dilution threshold
1000 mg/dl (25.9 mmol/l)
At higher cholesterol concentrations, dilute 0.1 ml of sample 
material with 0.2 ml of 0.9% NaCI solution and repeat assay 
(result x 3).
Calculation
of the concentration (c) of cholesterol in the sample:
Wavelength mg/dl mmol/l
Hg 546 nm c = 853 x Asample c = 22.1 x Asampte
500 nm c — 575 x Ason,pie c = 14.9 x Aso,„ple
Concentrations of the reagent solution
Tris buffer: 100 mmol/l, pH 7.7; Mg2*: 50 mmol/l; 4-amino­
phenazone: 1 mmol/l; sodium cholate: 10 mmol/l; phenol:
6 mmol/l; 3,4-dichlorophenol: 4 mmol/l; fatty alcohol polygly­
col ether: 0.3%; cholesterol esterase §  0.4 U/ml; cholesterol 
oxidase ^  0.25 U/ml; peroxidase S 0.2 U/ml
Quality control
Accuracy: Precinorm® U, Precinorm* L, Precipath® U, 
Precipath® L
Precision: Precinorm® UPX 
Please note
If difficulties encountered in quality control point to inade­
quate linear response on the part of the photometer, or if 
measurements cannot be taken at Hg 546 nm or 500 nm, a 
calibration curve must be constructed using Preciset® Cho­
lesterol (Cat.No. 125 512). The cholesterol values are read off 
the curve.
Bilirubin concentrations above 4 mg/dl interfere with the test 
(results up to 10% too low).
Hemoglobin concentrations up to 200 mg/dl do not affect 
the test.
Reference
1 Study Group, European Atherosclerosis Society. 
Strategies for the prevention of coronary heart disease:
A policy statement of the European Atherosclerosis Society. 
(1987). Eur. Heart J. 8:77.
April 1993
493.1264.0381 101 (ii)
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Enzymatic colorimetric method 
Cat. No 310 328 for 2 x 90 ml
Method
Stahler, F., et al. (1977). Med. Lab. 30: 29. 
Trinder, P. (1969). Ann. din. Biochem. 6: 24.
Test principle
. . . „  cholesterol oxidase . . ,. „
cholesterol + 0 ,  --------------—-------------->-A -choleslenone + H ,0 ,
POD
2 H ,O j + 4-amlnophenazone + phenol -------> 4-(p-benzoquinone-mono-
iminojphenazone + 4 H ,0
Normal values for Iree cholesterol:
22-30%  of total cholesterol
Reference: Wybenga, D. R., and J. A. Inkpen. (1974). Lipids. Page 1421 II 
in Henry, R J.. el al., eds. Clinical Chemistry: Principles and 
Technics, 2nd ed. Harper & Row, Publishers. Inc., New York. 
. San Francisco, and London.
Sample material
Serum, heparinized plasma or EDTA plasma
Reagents
Contents
•j Buffer (potassium phosphate) 
Phenol 
methanol








0.4 mo I/I; pH 7.7 
20 mmol/l
1.85 mol/l




s  12 U/ml 
â  8 U/ml
Quality control
For control of accuracy: Precilip' E.L., Preclnorm L
Preparation and stability of solutions 
1 , 2 and 3 Use solutions undiluted.
Stable up to the expiry dale specilied when stored al i 2 to +̂ C .
¿J Cholesterol reagent:
Pipette 0.5 ml ol sol. 3 into bottle 2 and add the entire contents ol one 









ca. 4 5 5 0.05
ca. 9 10 10 0.10
ca 19 20 20 0.20
ca 39 40 40 0.40
Stable for two weeks at -t- 2 to + 8̂ C 
two days at- + 15 to 25°C.
CJ Reagent for sample blank:
(req'd only for assays on hemolytic or turbid sera)
Mix equal volumes of solutions t and 2 and store away Irom liqhl 
Stable for two weeks at + 2 to + 8°C 
two days at + 15 to 25"C.
Procedure A
Sample material: clear, non-hemolylic serum 
Wavelength: Hg 546 nm (470-560 nm)
Spectrophotometer: 500 nm 
Glass cuvette: 1 cm light path 
Incubation temperature: 20-25°C or 37°C
Measure against reagent blank (RB)




solution 4 2.00 ml
0.02 ml 
2.00 ml
Mix and incubate RB and sample lor 20 min al 20-25°C or 10 min al 
37°C. Read absorbance ol sample against RB within 2 hours (AA).
Procedure B
Sample material: serum or plasma 
Wavelength: Hg 546 nm (470-560 nm) 
Spectrophotometer: 500 nm 
Cuvette: 1 cm light path 
Incubation temperature: 20-25°C or 37°C
Measure against sample blank (SB)
Determine AAnB once per series to correct lor the intrinsic colour of the 
cholesterol reagent by using redist. water instead of sample in the assay.
Pipette into cuvette:
SB Sample
solution 4 - 2.00 ml
solution 5 2.00 ml “
sample 0.02 ml 0.02 ml
Mix and incubate SB and sample (or 20 min at 20-25°C or for 10 min
at 37’C Read absorbance ol sample against SB within 2 hrs.. and
subtract AAna Irom AA„mpie. AA — AA,ample AArb
Calculation
ol the concentration (c) of Iree cholesterol in the sample:
Wavelength m g/100 ml mmol/l
Hg 546 nm c = 855 x AA c = 22.1 x AA
500 nm c = 585 x AA c = 15.1 x AA
Please note
If difficulties encountered in quality control point to inadequate linear 
response on the part ol the photometer, or If measurements cannot be 
taken at Hg 546 nm or 500 nm, a calibration curve must be constructed 
using Preciset"-' Cholesterol (Cat.No. 125 512). The cholesterol values 
are read off the curve.
A slight yellow coloration of solution 2 does not allec! the lest.
Even low concentrations of ascorbic acid and u-methyldopa in the 
specimen depress the free cholesterol level.
Solutions 1 and 2 contain methanol, which is poisonous. Do not swallow 
or inhale vapors. Avoid contact with skin. If solution comes into contact 
with skin or mucous membranes, flush immediately with large quantities 
ol water. If solution comes into contact with eyes, immediately flush 
liberally with water and consult an ophthalmologist.


























Perldochrom® Triglycerides GPO-PAP 
Cat.No. 701882 for 6 x 13 ml reagent 
Cat.No. 701 904 for 15 x 32 ml reagent
Test-Combination Triglycerides GPO-PAP
Cat.No. 701912 for 5 x 100 ml reagent
Additional reagent lor measurement against standard: 
Precimat1* Glycerol, Cat.No. 166 588
Method
Enzymatic hydrolysis of triglycerides with subsequent deter­
mination of the liberated glycerol by colorimetry.
References:
Mod. according to Wahleleld, A. W. (1974).
Triglycerides. Delermination aller Enzymatic Hydrolysis. Page 183111. in 
H.U. Bergmeyer, ed. Methods ot Enzymatic Analysis. 2nd English ed. 
(Transl. Irom 3rd German ed.). Verlag Chemie Weinheim and Academic 
Press, Inc., New York and London. 4 vols.
Nägele, U. (Boehringer Mannheim GmbH), personal communication. 
Trinder, P. (1969). Ann. Clin. Biochem. 6:24.
Test principle ..
lipase-
triglycerides +  3 H ,0 ---------- ► glycerol +  3 RCOOH
glycerol +  ATP-----*- glycerol-3-phosphate +  ADP
glycerol-3-phosphate +  O, — dihydroxyacetone phosphate +  H20 2
peroxidaseH2Oj +  4-aminophenazone +  4-chlorophenol —c-----------------►
4-(p-benzoquinone-mono-imino)-phenazone +  2 HaO +  HCI
Sample material
Serum, heparinized plasma or EDTA plasma
Reagents
1 Buffer solution
2 Reagent strips or lyophilisate
Reagent concentrations In solution
•1 Trls buffer: 0.15 mol/l, pH 7.6; magnesium sulphate: 17.5 
mmol/l; EDTA, disodlum salt: 10 mmol/l; 4-chlorophenol: 
3.5 mmol/l; sodium cholate: 0.15%; potassium hexacyano- 
lerrate (II): 6 pmol/l; hydroxypolyethoxy-n-alkanes: 0.12%
p  ATP ^  0.5 mmol/l; 4-aminophenazone: 0.35 mmol/l; lipase ^  
3 U/ml; glycerol phosphate oxidase S 2.5 U/ml; glycerol 
kinase ^  0.2 U/ml; peroxidase ^  0.15 U/ml
Quality control
For control of accuracy: Precinorm® U, Precinorm* L, 
Precipath® U. Precipath"1 L
For precision control: Precinorm''' UPX
Preparation and stability of reagent solution
Peridochrom"Triglycerides GPO-PAP
Do not touch the reagent patches or surrounding area.
Immerse one reagent strip in one bottle of buffer solution and use to 
stir the bottle contents for ca. 10 sec. Allow to stand In buffer solution 
for 5 min, stir once again for ca. 10 sec, and then discard reagent strip.
Test-Combination Triglycerides GPO-PAP
Connect one bottle 1 to one bottle 2 with one of the adapters provided 
in the kit and flush several times to ensure complete dissolution of the 
lyophilisate.
Reagent solution from different bottles may be pooled forlarge series 
Stable for two weeks at +2  to 8°C 
two days at +15 to 25°C.
Sample preparation
The sample can be stored up to three days at +4°C




Cuvette: 1 cm light path
Incubation temperature: 20-25°C or 37°C
Measure against reagent blank. One reagent blank Is sufficient for 
each series.
Pipette Into test tubes:
serum or plasma 0.02 ml
reagent solution 2.00 ml
Mix. and incubate at 20-25°C for 10 min.
Read absorbance of sample against reagent blank within 60 min **
Â sample*
If incubating at 37°C (10 min), the absorbance of the standard must be 
determined once for each assay series using Precimat* Glycerol 
instead of serum or plasma. The absorbance of the sample and the 
standard must be read within 30 min.
Calculation via factor
Obtain the concentration (c) of triglycerides in the sample from the 
enclosed table of values or calculate as follows:
Incubation temperature: 20-25°C
Wavelength c (mg/100 ml] c (mmol/l]
Hg 546 nm 1040 x Aiamp,e 11.9 x Asampla
500 nm 760 x Aiampl, 8 66 x Asample
Incubation temperature: 20-25°C or 37°C
c (mg/100 ml] — 200 x
ŝtandard
c (mmol/l] — 2.29 x
A&iandard
If the triglyceride concentration exceeds 1000 mg/100ml (11.4 mmol/l), 
dilute sample 1 +  5 with 0.9% NaCI solution and repeat assay 
(result x 6).
Clinical interpretation





<  200 mg/100 ml
<  200 mg/100 ml
No
Cholesterol 200-300 mg/100 ml
Yes,
if HDL cholesterol 
<  35 mg/100 ml
Cholesterol
Triglycerides
>  300 mg/100 ml
>  200 mg/100 ml Yes
Values In mmol/l:
Cholesterol: 35 mg/100 ml =  0.9 mmol/l
200 mg/100 ml =  5.2 mmol/l 
300 mg/100 ml =  7.8 mmol/l 
Triglycerides: 200 mg/100 ml =  2.3 mmol/l
Reference: Study Group, European Atherosclerosis Society.
Strategies lor the prevention ol coronary heart disease:
A policy statement ol the European Atherosclerosis Society. 
(1987). .
Eur. Heart J. 8 :77.
Calculation via standard
Calculate the concentration (c) of triglycerides as follows:
Boehringer Mannheim GmbH 
Diagnostica March 1991
Appendix II Chemical Solutions and Assays 314
UNIMATE 3  APOA
: Apolipoprotein A
Art. 07 3688 0 
1
Intended use
Unimate'3 APOA is an in vitro diagnostic reagent intended for the quantitative 




Human apolipoprotein A-l forms a precipitate with a specific antiserum which 




Samples should be fresh, stored for a maximum of 1 week at +2 to +8 °C or 








115-220 mg/dL (1.15-2.2 g/L) 
115-190 mg/dL (1.15-1.9 g/L)
60-150 mg/dL (0.6-1.5 g/L) 
70-160 mg/dL (0.7-1.6 g/L)
Ratio Apolipoprotein B/Apolipoprotein A-1 
Females 0.35-1.15 ■
Males 0.45-1.25
Forthe IFCC Reference Preparation SP1 (October 1992 WHO-IRP) for apolipo­
protein A-1 and the IFCC Reference Preparation SP3-07 for apolipoprotein B 
the following additional reference values apply:
Apolipoprotein A-1 Apolipoprotein B
Females 1.20-2.20 g/L 0.55-1.25 g/L
Males 1.10-2.00 g/L 0.55-1.35 g/L
Quality control
Apolipoproteins T Control, art. 07 3721 6 (US # 42391)
Kit contents
R Reagent, 4 x 10.5 mL
Anti-Apo A-1 T antiserum (sheep)
Antiserum specific for human apolipoprotein A-1, in phosphate buffer stabi­
lized with 0.09% sodium azide.
Reagents 
Working reagent
The reagent R is ready to use. Warm up the reagent to room temperature prior 
to assay. . . .
The reagent, once opened is stable for 4 weeks at +2 to +8 °C in the original 
bottle if it is immediately and tightly closed after use.
Additionally required (not delivered with the kit):
Apolipoproteins T Standard, art. 07 3720 8 (US # 42390)
Apolipoproteins T Control, art. 07 3721 6 (US # 42391)
NaCI solution 154 mmol/L (0.9%)
Procedure
For applications on COBAS® instruments please refer to the corresponding 
test instruction manuals.
Notes
Measuring range: 35-550 mg/dL (0.35-5.5 g/L).
The measuring range is determined by the batch specific apolipoprotein A-1 in 
the standard serum and the serial dilutions selected.
The reagent R contains < 0.1 % sodium azide as preservative. Avoid swallow­
ing and contact with skin or mucous membranes.
References , „  _..
1 Becker W„ Rapp, W., Schenk, H.G., Storiko, K.: Z Klin Chem Klin Bio-
chem 6, 113-122 (1968). L n u
2. Thomas, L.: Labor und Diagnose, 1. Ed., p. 628. Marburg/Lahn. Die Medi­
zinische Verlagsgesellschaft, 1978. . ,
3. Dati, F., Lammers, M., Adam, A., Sondag, D., Stienen, L.: Lab Med 13, 
87—90 (1989)
4. Albers, J.J., Marcovina, S.M., Kennedy, H.: Clin Chem 38,658-662 (1992).
5. Dati, F.: IFCC program for the standardization of assays for apolipoprotein 
A-1 and B; in: Progress in Clinical Biochemistry, pp. 419-423. Ed. K. Miyai, 
T. Kanno, E. Ishikawa. New York: Elsevier. 1992.






e d f ¡ esp 
Ed.Nov. 90
A rt 07 2995 7 (4x10.5 ml)
Antiserum (rabbit) for the quantitative immunological 
determination of human apolipoprotein B in serum.
For in vitro diagnostic use
Also required: .
T Standard Apolipoproteins (Roche> (art. 07 30688) 
NaCI solution 154 m mol/l (0.9%)
General information
Method Immunoturbidimetric.
Principle1 Human apolipoprotein B forms with a specific antiserum a
precipitin which is determined turbidimetrically (measurement 
of cloudiness) by a fixed time method at 340 nm (or 334 or 
365 nm).
Sample2 Fresh serum or stored for a maximum of 1 week at + 2 to + 8 °C.
Very turbid (lipemic) samples should be diluted prior assay. '
Package T Antiserum Apolipoprotein B 10.5 ml per bottle
Antiserum specific for human apolipoprotein B in phosphate 
buffer stabilized with sodium azide.
The bottles, when unopened, are stable at +  2 to +8°C until the 
expiry date stated on the labels.
Reference Apo A-1
values3 Male 1.15-1.90 g/l (median 1.45 g/l)
Female 1.15-2.20 g/l (median 1.60 g/l)
Apo B 
Male 0.70-1.60 g/l (median 1.15 g/l)
Female . 0.60-1.50 g/l (median 1.05 g/l)
Ratio Apo B/Apo A-1 
Male 0.45-1.25 (median 0.80)
Female 0.35-1.15 (median 0.65)
Quality control T Control Apolipoproteins <Roche> (art. 07 3069 6)
Manual procedure
Preparations Reagent -
The T Antiserum. Apolipoprotein B is ready to use. Prior assay 
warm up the reagent to room temperature. The reagent, once 
opened is stable 4 weeks at + 2 to + 8 °C. 1 weekat +15 to + 25 °C 
in the original bottle if it is immediately and tightly closed after 
use.
Samples and controls
Dilute the samples and controls with NaCI (0.9%) in ratio 1:21 
(1 + 20). ■
Main standard
Reconstitute T Standard Apolipoproteins <Roche> with 0.5 ml of 
distilled water. Allow to stand at +15 to + 25 °C for 30 minutes. 
Then gently swirl for 1 minute. The reconstituted standard is 
ready to use and is stable for 1 week at + 2  to +8°C.
Standard serial dilutions
Dilute the reconstituted T Standard Apolipoproteins <Roche> 
with NaCI solution in a geometric series, starting with 1:6 in 
order to have the following series: 1 :6 .1 :12.1:24.1:4 8 .1:96. 
For diluting this pipetting schema can be used: .
Solutions Dilutions 
1:6 1:12 1:24 1:48 1:96










NaCI 0.9% 500 300 300 300 300
The dilutions of the standard are stable during 1 week at + 2  to 
+ 8°C if stored in closed vials (risk of contamination).
Bibliographie 1. Becker, W.. Rapp. W., Schenk, H. G., Störiko, K.: Z Klin Chem 
Kim Biochem 6. 113-122 (1968).
2. Thomas. L : Labor und Diagnose. 1.Ed.. p.628. Marburg/ 
Lahn: Die Medizinische Verlagsgesellschaft. 1978.
3. Dati, F.. Lammers. M., Adam. A.. Sondag. D., Stienen. L.: Lab 





























Diet and Health 
Booklet
A B O U T  T H IS  S T U D Y
This survey is one ol a series designed to describe the current health and 
nutrition status of groups ol Australians. It lorms part ol a study on aspects 
ol health which has been outlined In a covering letter to you.
In this booklet there are a number ol questions which provide information on 
lood habits and usual dietary intake. Such information  ̂essential il we are 
to identify any nutrition problems and understand the relationships between 
diet and disease in the general population and in groups of people at special 
risk. You may be a member of the general public in good health or you may be 
a person with a health problem. Information from both groups of people Is 
necessary.
All the Information you give us will be treated in the strictest confidence. No 
personal details that can Identity you will be revealed to anyone, and your 
name will not be attached to this information: instead, a code number will be 
used. If the study In which you are Involved Is one In which we may want to 
contact you some time In the future, we need to keep your name, address, 
contacts and code number securely on file, but separately from other 
information relating to you. All such identifying information which may be 
used to contact you in the future will be kept in a secure place by Professor 
Calvert.
Please answer all the sections carefully. You may have made arrangements 
to return the booklet to a research associate. If you have not made any such 
arrangement, please return the booklet to me as soon as possible.
Thank you for your help.
Dennis Calvert
Professor ol Medicine and Public Health 
Medical Research Unit
lllawarra Regional Hospital (Wollongong Campus) 
Crown St
WOLLONGONG NSW 2500 
Telephone (042) 266594
Please ring me on this number if you have any problems. Subsequent 
enquiries may be directed to Ms Kim Roser, Secretary to the Human Ethics 





























0-1 In general, how has your health been in the Iasi year? (Please circle one)
Very Good Good Fair Poor Very Poor
Q-2 How much ot an ellect do you think the following things have on the health ol people
like yoursell?
(Circle one lor each)
Ealing the wrong foods Bad effect Moderate No effect Don’t know
Smoking Bad effect\ Moderate No effect Don't know
Air and chemical pollullon Bad effect Moderate No effect Don't know
Working In a dirty Job, with dusl 
or chemicals
Bad effect Moderate No effect Don't know
Drinking loo much alcohol Bad effect Moderate No effect Don't know
Hot having a good dcclor Bad effect Moderate No effect Don’t know
Having parents who have or had 
poor heallh
Bad effect Moderate No effect Don't know
Not keeping weigh! under control Bad effect Moderate No effect Don't know
Excess slress caused by work, 
lack ol work or work ail home
Bad effect Moderate No effect Don’t know
Lack ol exercise or physical 
activity
Bad effect Moderate No effect Don't know
Problems wilhin the lamily Bad effect Moderate No effect Don't know
Nol living In a clean, sale house 
and neighbourhood
Bad effect Moderate No effect Don't know
Bad luck Bad effect Moderate No effect Don't know




Moderate No effect Don't know
These are questions about your current health and that ol close family or friends, as these factors may 
Influence the way you eat.
Q-3 (a) Have you or your spouse (if relevant) ever had any ol I he following conditions?
(Circle YES or NO)
YOURSELF YOUR SPOUSE
(husband/wlfe/partner etc)
Diabetes YES NO YES NO
High blood pressure YES NO YES NO
High blood cholesterol YES NO YES NO
Heart problems (including angina) YES NO YES NO
Bowel complaints YES NO YES NO
A malignant growth or cancer YES NO YES NO
Arthritis YES NO YES NO
Any other medical condition YES NO YES NO
(please describe).
Q-3 (b) Has any other close lamily member or friend (parent, child, sister, brother, close
friend) ever suffered from any of the following? (Circle YES or NO for each and tells us 




High blood pressure YES NO
High blood cholesterol YES NO
Heart problems (Including angina) YES NO
Obesity YES NO
Dowel complaints YES NO
A malignant growth or cancer YES NO
Arthritis YES NO
Other condition (please specify)
Q-4 Are you currently on any type ol medication? (Circle one number)
1 No
2 Yes































This section Is about the kinds of foods you usually eat. On the next few pages you 
will find lists of foods, separated by questions about your dietary habits.
Read through each list of foods and record about how often you usually eat these 
foods. We realise that your food Intake may vary from time to time, so Just try to give 
us the best ovprall picture of your diet that you can.
We are interested In YOUR diet, not that of someone else In your household.
THIS IS HOW TO ANSWER
We are going to ask you "About how often do you usually eat these foods?"
Use the following simple code to write your answer In the space next to each food.
If you NEVER have a food...........................................write N
If you RARELY have a food (less than once a month) ....write R
If you usually eat a food
About once a MONTH................................................. write 1M
About twice a MONTH................................................write 2M
About three times a MONTH........................................write 3M
About once a WEEK.......
About twice a WEEK......





(4W, 5W, 6W, etc)
About once a DAY 






Alongside each food there Is a "standard serve" size. The "standard" serve Is not 
necessarily a "normal" serve, It Is simply there to help us measure food Intake. If you 
usually eat more or Ies9 than the standard serve size for a particular food, please 
Indicate on the COMMENTS line how much more, or less, Is eaten at a time.
For example, if when you eat Icecream you have one "scoop" Instead of our 
"standard" serve of two "scoops", Indicate how often Icecream Is eaten, and then write 
"one scoop only" on the comments line.
On the opposite page you will see some examples of how to fill out the questionnaire. 





Tim es a T im es a
RARELY MONTH W EEK
R i M jW
and so on
T im es a 
DAY
and so on
HERE ARE SOME EXAMPLES
COMMENTS
C u stard  
B oiled  egg  




3 slices (each 
0.5 cm thick)
1 Cup
M . . .




B eetro o t - c an n ed 2 slices ,2M.. one slice._______
The person above has, on average
- A standard serve of custard three times a week
- Two boiled eggs three times a month
- Rarely eats cucumber
- Four cups of tea every day
- Half a standard serve (1 slice) of beetroot - canned, 
twice a month
We realise that some people have an exact Idea of how often they eat particular 
foods, whilst others only have an approximate Idea. Be as accurate as you can 
but do not spend too much time choosing your answers.














































(NOT hamburger buns) 
Fried rice
Boiled rice
Instant noodles (Maggl etc) 
Other pasta
(spaghetti, macaroni etc)
C O M M EN TS






1 cup (cooked) 
1 cup (cooked) 
1 cup (cooked) 
1 cup (cooked)
Q-1 How many slices o l bread do you usually eal? Remember the bread In toast and sandwiches. 
If you do not eat bread, write 'none'.
_________ slices/day OR_________ slices/week .
Q-2 What type of bread do you usually eal? (Circle Ihe number beside one answer)
1 Wholemeal or mixed grain
2 While
3 About half Ihe lime wholemeal and hall while
4 Other breads (eg rye, HI-FIbe)
(please specify type).......................................................................
5 I do nol eal bread
Q-3 Do you eal low-salt types of bread? (Circle one answer)




3 Table or cooking margarine
4 Reduced-fat margarine (eg Era)
5 Drlpping/Lard
6 I don't use anything
7 I don't eat bread or crackers
0 Something else: please name.............................................................................
Q-5 For whatever spread you use is it usually the regular variety or reduced-sail?
(Circle one answer)
1 I usually use Ihe regular variety 2 I usually use the reduced-salt variety 
Q-6 What types o l breakfast cereals do you most commonly eal?
Please name: ........................................................................................................
Q-7 IIyou eal muesli is if:- (Circle one answer)
1 Homemade muesli 2 Pre-packaged muesli
Q-8 How many cups ol milk do you usually add lo breakfast cereal, porridge or muesli?
(Circle Ihe number closes! lo Ihe amount you have)
1 None
2 About a hall a cup
3 About one cup
4 About one and a hall cups
5 About two cups or more (please slate how much............................................. )
Q-9 What type of milk do you usually add lo cereals, porridge or muesli? (eg whole milk, Skimmer, Rev, 
Tone, Trim, powdered skim, Shape, High-Low, goat's milk, condensed/evaporaled milk etc)?
Type ol milk added:...........................................................................................
Q-10 How many teaspoons ol sugar or honey do you usually add lo cereal, porridge or muesli?
(Note: I dessertspoon = 2 teaspoons)
Wrile Ihe number of teaspoons you have here: .................
Q-11 Do you add sail lo your porridge? (Circle one number)
1 Yes
2 No
3 I don't eat porridge






























HO W TO  ANSWER 
Tim es a T im es a Tim es a
NEVER RARELY MONTH WEEK DAY




ABOUT HOW OFTEN DO YOU USUALLY EAT THESE FOODS?
C E R E A L F O O D S  C O M M E N T S
Crumpet or Muffin 1 ......... .............................
Croissant 1 ......... ...............................
Fruit Loaf/Curranl bread 1 slice ........... .....................................
Sweet bun/Doughnut 1 ......... ...............................
Crispbread/Cracker 2 ......... .............................
Salted biscuits 3 ......... ...............................
Plain sweet biscuits 2 ......... ............................
Fancy biscuits (eg choc-coated) 2 ......... ............................
Cake 1 small cake or ......... ...............................
1 slice large cake
Milk pudding (eg rice, sago) i/2cup 
Steamed sponge - suet 1/4 small pudding
Q-1 What types of cake do you most commonly eat? (eg fruit cake, cheesecake, sponge cake, 
iced sponge, tea-cake etc)
Please ñamé ..............................................................
Q-2 Are the cakes you most commonly e a t: (Circle one answer)
1 Pre-made wrapped cakes
2 Frozen wrapped cakes (eg Sara-Lee)
3 Bought homestyle cakes (eg from bakery)
4. Homemade (packet mix)
5 Homemade (own Ingredients)
6 I do not eat cake a
HOWTO ANSWER
Tim es a T im es a T im es a
NEVER RARELY MONTH W EEK DAY
N R jW I D3
and so on and so on
HOW OFTEN DO YOU USUALLY HAVE THESE DRINKS?
BEVERAGES
Suslagen (made wllh powder) 1 cup
Suslagen Gold small carton 
(300 ml)
Carton of other flavoured milk 








Glass of milk (as such) 1 glass
Milk shake/Thlck shake regular size
Tea 1 cup
Herbal lea 1 cup
Inslanl coffee 1 cup
Ground coffee (eg llller/drlp) 1 cup
Decalfelnaled coflee 1 cup
Coffee subslllule (eg Caro) 1 cup
CM Do you have m ilk :
COMMENTS
(Circle one breach)
in your lea? YES NO DON’T DRINK TEA
in your coffee? YES NO DON'T DRINK COFFEE





























3 About hall and hall?
4 I do nol drink these drinks.
Q-3 What type of milk do you usually add lo (ea/collee /cocoa/chocolate etc? (Please slate 
the type of milk used eg whole milk, Skimmer, Rev, Trim, Tone, powdered skim, Shape, 
High-Low, goal's milk, condensed milk, evaporated milk ole).
Type of milk added.....................................................................................
Q-4 How many teaspoons of sugar/honey do you usually have In each cup o l :
(Circle one number lor each drink)
Q-2 Do you make your cocoa/chocolale/Milo/Akta■ Vile w ith : (Circle one number)
Tea? 0 1 2 3 4 5 6
Coffee? 0 1 2 3 4 5 6
Coffee substitute? o' 1t 2 3 4 5 6
Cocoa? 0 1I 2 3 4 5 6
Milo/Quik/Chocolale? 0 1 2 3 4 5 6
Q-5 When you are choosing Ihe type of milk lhat you use how important are the following factors? 





Healthiness.... . . . . . . . . . . . . . . . . . 1 2
Convenience of storage..... 1 2
Weight (eg easy to carry).... 1 2
> VERY 
IMPORTANT
3 4 cn 6 7
3 4 cn 6 7
3 4 5 6 7
3 4 5 6 7
CO 4 5 6 7
10
HOW TO ANSWER
Tim es a T im es a T im es a
N E V E R  R A R E L Y M O N T H  W E E K D A Y
N R m  j w 3
and so on and so on
HOW O FTEN  DO YO U U S U A LLY  EA T TH E S E  FO O D S ?
D A IRY PR O DU C TS M d  EGGS C O M M EN TS
Cheese 30 qrams (1 slice) ............
Low-lal Collage Cheese 100qm ............
(1/2 carlon)
Cream 1 lablespoon ............
Yoghurt 200 qm (1 carlon) ............
Icecream (Irom a lub) 2 scoops (SUMMER! ............
(WINTER) ............
Icecream dcsserls 1 sorvlnq (SUMMER! ...........
(eg Symphony, Vlenella)
(WINTER! ...........
Icecream (on a sllck/cone) 1 icocronm(SUMMER!............
(WINTER! ............
Vllarl 1 cone (SUMMER) ............
(WINTER! ............
Ice Block/lcy Pole 1 (SUMMER! ...........
(WINTER! ............
Cuslard 1/2 cup ...........
Fried egg 1 oqq ...........
Dolled egg 1 L’qq ...........





























4 1 Always or nearly always2 Sometimes •
3 Rarely or never
4 I do no! ealcheese
Q-2 When you eat cheese, do you have the reduced -fa t varieties? (Circle one number)
1 Always or nearly always
2 Sometimes
3 Rarely or never
4 I do £¿1 eat cheese
Q-3 When you  eat yoghurt which type is it?  (Circle one number)
1 Plain (eg not fat-reduced)
2 Plain, low-fat
3 Fruit flavoured (not fat-reduced)
4 Fruit flavoured, low-fat
5 Frozen yoghurt
6 I do nol eat yoghurt
Q-1 When you eal cheese, do you have the reduced-salt varieties? (Circle one number)
Q-4 When you eat ice-cream, diet-ice o r s im ila r is it u su a lly?  (Circle one num ber)
1 Low calorie
2 Regular Ice-cream
3 Other (please slate.................................................................................. )
Q-5 In recent years have you  m ade any changes to you r intake o f the following foods?  
(Circle one for each food)
I am having I am having I am having
Milk ........ ....... ............... MORE LESS the SAME
Cheese .............. ............... MORE LESS the SAME
Eggs ............... ............... MORE LESS the SAME
Coflee............... ................MORE LESS the SAME
Tea ............... ................ MORE LESS the SAME
12
HOWTO ANSWER
T im es a T im es a T im es a
NEVER RARELY MONTH W EEK DAY




ABOUT HOW OFTEN DO YOU USUALLY EAT THESE FOODS?
MEATS COMMENTS
Sleak (ealen as such)
Pork chop 
Lamb chop 





















2 thick or 3 thin 








1/2 liver (150 gm)
2 kidneys 
1/2 cup



































Tim es a Tim es a Tim es a
NEVER RARELY MONTH WEEK DAY
N R m3 i w W3
and  so  on and  so on
ABOUT HOW OFTEN DO YOU USUALLY EAT THESE FOODS?
M IX E P  P IS H E S COMMENTS
Hamburger WITH bun 1 medium ...........
Hamburger pally (WITHOUT bun) 1 medium ...........
Pizza (frozen) 1 mini or 1/4 .................
large pizza
Pizza (homemade or take-away) 1/2 small or 1/4 ...........
large pizza
Sausage roll 1 large, 2 small ..........
Meat pie 1 pie ..........
Meal pie 1 indiv. pie OR ........
(homemade) 1 slice large pie
Paslle 1 ........ •-------------------------
Crumbed veal (schnllzel) 1 large piece ..........
Slew/Casserole/Curry/Goulash 1 cup ..... .
(with meat or chicken)
Slew/Casserole/Curry/Goulash 1 cup ..........
(wllhoul meat or chicken)
Chinese meat & veg dish 1 cup .......... ----------------------
Savoury ples/paslrles 1 indiv. pie QR ..........
(eg quiche) 1 slice large pie
Mince meal (ealen as such) 1 cup .........
Mince meat dishes 1 piece (Bx8x4cm).........
(eg shepherds pie)
Spicy mince added to 1/2 cup mince .........
pastas (eg spag. sauce) 14
HOWTO ANSWER
Times a Times a Times a
NEVER RARELY MONTH WEEK DAY
N R ; m3 1W3 I D3
and so on and so on
ABOUT HOW OFTEN DO YOU USUALLY EAT THESE FOODS?
CHICKEN. FISH and SEAFOOD.: COMMENTS
Roasl/Barbecue chicken
Boiled chicken 
Crumbed, fried chicken 
Chlcken/Flsh nuggels 
Fish fried
Fish without baiter 
(sleamed/grllled/bolled)
Canned fish (luna, salmon elc)
Fish fingers
Seafood (prawns, crab, 
lobster elc)
Mornay dishes
2 slices breast or ... 
1 drumstick/2 wings
as above 








Q-1 IIyou eat the following meals, how are they usually cooked? (Circle one lor each food)
Steak FRIED GRILLED/BAKED MICROWAVED DON'T EAT
Chops FRIED GRILLED/BAKED MICROWAVED DON'T EAT
Sausages FRIED GRILLED/BAKED MICROWAVED DON'T EAT
Bacon FRIED GRILLED/BAKED MICROWAVED DON'T EAT
0 2  When you eat meal with fat on it, do you eat: (Circle one number)
1 All of the lai
2 Most of the fat
3 About hall ol the fai
A Lillie or none ol Ihe fai 



























0 3  Do you take the skin oft chicken? (Circle one number)
1 Always or nearly always
2 Sometimes (about hall the time or less)
3 Rarely (less than a quarter of the time)
4 Never
5 I do not eat chicken




4 Other coating; please name.................................................................
5 Fried without coaling
0 5  When you eat fish coated in batter, crumbs etc how often is it: (Circle one (or each)
Coated at home......... ... ALWAYS SOMETIMES RARELY NEVER
Pre-packed, frozen 
cooked at home......... ... ALWAYS SOMETIMES RARELY NEVER
Bought ready cooked 
from fish shop............ ... ALWAYS SOMETIMES RARELY NEVER
06 How often do you eat complete main meals bough l from the fre eze r section at the shops? 
(eg Lean Cuisine, TV dinners) (Circle one number)
1 Daily
2 About weekly
3 About once a fortnight
4 About monthly or less
5 Never




3 About once a fortnight
4 About monthly or less
5 Never




3 About once a fortnight




Times a Times a Times a
NEVER RARELY MONTH WEEK DAY
N R ¡M ;W  ¡D3 « 3
and so on and so on
ABOUT HOW OFTEN DO YOU USUALLY EAT THESE FOODS?
CANNED and DRIED VEGETABLES
Potato-canned 2*3 small
Potato-packet (powdered) 1/3 cup (cooked)
Potato salad 1/3 cup
Carrots - canned 1/3 cup
Beetroot-canned 2 slices
Green beans-canned 1/3 cup
Haricot, Lima beans - canned 1/3 cup
Baked beans In tomato sauce 1/3 cup
Green peas - canned 1/3 cup
Lentils -drled/canned 1/3 cup




Mushrooms-canned 6-7 small ones
Mushrooms - canned In sauce 1/3 cup
Olives 3 medium




























HOW TO ANSWER 
Times a Times a Times a
NEVER RARELY MONTH WEEK DAY




The following list of foods contains some vegetables that may be eaten much more frequently 
at some times of the year than others (eg In the warmer or cooler weather). Please fill in how 
often each food os eaten in BOTH the warmer months of the year (SUMMER) and the cooler 
months (WINTER).
For example- If you usually have:
A standard serve of peas about twice a week during the warmer months of the year 
and about every day during the cooler months:
and:
Two medium potatoes (roasted) a week throughout the year:
You would write......
Summer Winter
Green peas 1 cup .fr.W.. iLD ...______
Potato*roasted 1 medium ..l.V.1/.. ^ ^
ABOUT HOW OFTEN DO YOU USUALLY EAT THESE FOODS?
SEASONAL VEGETABLES Summer Winter
Potato* fresh Smashed 1/3 cup ........................
(with milk)
Potato-fresh, bolted 1 medium ........................
Potato-roasted 1 medium ........................
French Frles/Hot chips 17-18 chips ........................
Potato Gems/ about 5 ......................
Pommes Noisettes
Carrots (fresh/frozen) 1/3 cup ........................
Turnip, Swede(fresh/lrozen) 1/3 cup ........................
Broad beans (IreshJIrozen) i/2cup .......................
Green beans (fresh/frozen) i/3cup 18 .......................






















1 small cob 
1 medium sized 
1/4 cup 
1 medium
Tomato - fresh 1 medium
Tomato - grllled/lrled 1/2 medium
Lettuce 2 small leaves
Cucumber 3 slices (each 
0.5 cm thick)
Coleslaw 1/2 cup
Celery (Iresh/lrozen) one 15cm stick
Capsicum (Green Pepper) 
(Iresh/lrozen)
2 strips (each 
0.5 cm thick)
Mushrooms - Iresh 6-7 small ones
Sprouted bean shoots 1/3 cup





























CM When you use canned vegetables, are they reduced-salt varieties? (Circle one number)
1 Always or nearly always
2 Sometimes
3 Never or rarely
4 Only for some vegetables (please slate which.......................................................
Q-2 Is salt added to the cooking water when boiling the following foods? (Circle one lor each food)
Vegetables USUALLY SOMETIMES NEVER
Pasta and rice USUALLY SOMETIMES ' NEVER




4 Sailing is highly varied
5 Salt is flQl added to cooking water
CM H ow  often do you  a d d  sa il to meals a fte r they are cooked? (Circle one number)
1 Rarely or never
2 Sometimes
3 Always or nearly always
Q-5 When you add salt at Ihe table, how much do you usually add?
(Circle one number)
1 A light sprinkle
2 A medium sprinkle
3 A heavy sprinkle
4 Sailing is highly varied
5 I do not add salt at Ihe table
Q-6 When your vegetables are cooked which o f the following methods is Ihe one m o s t c o m m o n ly  
used? (Circle one num ber)
1 Boiled In a little water
2 Boiled in a lot ol water
3 Steamed




1 VegeLoble oils (olive, sunflower etc) 4 Drlpplng/lard/mealjulcea
2 Cooking or table morgarlne 5 Polyunsaturated margarine
3 Butter 6 Nothing
From ¡he list above wrile which type of tat/oil is most commonfy used:
(a) When roasling/frylng meals/lish........................... .......................................
(b) When roasling/frylng vegetables.................................................................
(c) On vegetables when served (eg butter on peas)...............................................





Times a Times a Times a
NEVER RARELY MONTH WEEK DAY
N R m3 ■w 3
and so on and so or
HOW OFTEN DO YOU USUALLY EAT THESE FOODS?
E E L llI
Orange, Mandarin, Grapefruit 1 medium
Apple, Pear - Iresh/baked 1 medium
Banana 1 medium
Fresh fruit salad 1 cup
Dried fruit (apple/aprlcol etc) 4-5 pieces
Raisins, sultanas or currants 1/3 cup
Fruit In syrup or slewed 
(Including fruit salads)
1/2 cup
Fruit canned In waler(low-cal) 
(Including fruit salads)
1/2 cup
Fruit plo or pastry 
or fritters
























HO W TO  ANSWER
Tim es a T im es a T im es a
RARELY MONTH W EEK DAY
; m  i w  jR D
and so on and so on
The Irull3 listed below are only available tor a short lime during the year. There loro ive only want you to 
record how often you have them when they are IN SEASON.
HO W  OFTEN DO YOU EAT TH ESE FOODS WHEN THEY AR E IN SEASON?
COMMENTSSEASONAL FRUITS
Berries * fresh/lrozen 3/4 cup
Melon (nol watermelon) 1 large slice
Peach-fresh 1 medium
Plum-fresh 3-4 plums
Nectarine - fresh 1 medium
Apricot - fresh 3 apricots
Grapes - fresh about 20
Pineapple-Iresh 1 slice
Avocado 1/2 an avocado
Please lis t Im re , a lo n g  w ith  y o u r  s ta n d a rd  se rve  s ize , any o th e r fru it  th a t yo u  eat 
(eg manfo; purecd, canned/bollled fruits)
HOW  OFTEN DO YOU U S U A LLY  EAT TH ESE FOODS? 
HUTS anti SHACKS  
Potato crisps, Twlstles etc
COMMENTS
Peanuts (Iresh)
Nuts - salted & cooked
Olher unsalted nuts 
(fresh walnuls/almonds etc)







T im es a T im es a T im es a
NEVER RARELY MONTH W EEK DAY







ABOUT HOW OFTEN DO YOU USUALLY EAT THESE FOODS?
SOUPS COMMENTS
Canned soup (ealen as such) 1 cup (WINTER)..................................................
(SUMMER)..................................................
Packet soup (ealen as such) 1 cup (WINTER)..................................................
(SUMMER)..................................................
Homemade soup (ealen as such) 1 cup (WINTER)..................................................
(SUMMER).................................................
Write an example of the type of soup you most often eat (eg canned tomato; 
homemade pea and ham)
Below we have listed a number of products that may be used as Ingredients when you 
are cooking (for example you might add these foods to casseroles, stews etc).
Please fill In how often you would use these foods as Ingredients in cooking.
Canned or Packet soup mixes ......... .........................................
Bottled sauces (eg soy sauce, lomalo sauce) ......... ............ ............................
Gravy mlxes/powders ......... .........................................
Slock cubes/powders ......... ........................................
Canned tomatoes ......... ........................................
Tomato pastes/purees ......... ........................................
Olher pureed foods (eg apple, baby foods) ......... .........................................






























HOW TO ANSWER 
Tim es a Tim es a Tim es a
NEVER RARELY MONTH WEEK DAY
N r  ; m3 l\l \f3 I D3
a n d  s o  on a n d  so  on
ABOUT HOW OFTEN DO YOU USUALLY EAT THESE FOODS?
CONFECTIONERY. JAMS and SAUCES COMMENTS
Chocolate 1 small bar 
(50 grams)






































and so on and so on
ABOUT HOW OFTEN DO YOU USUALLY HAVE THESE FOODS?
COMMENTS
Glass ol cordial medium glass
Glass of cola (eg Coca-Cola) medium glass
Glass of fizzy drink 
Includes mineral waler with Juice
medium glass
Glass of low-calorle llzzy drink medium glass
Fruii drink (eg Fruit Box) 1 carton (250 ml)
Pure fruit Juice medium glass
Vegetable Juice small glass
Water/Sprlng waler medium glass
Mineral waler medium glass
Low-alcohol beer medium glass 
230 mis
Beer medium glass 
230 mis
Alcoholic cider medium glass 
230 mis
Wine 1 wine glass
Wine Cooler 1 wine glass
Sherry/Porl/LIqueur 1 standard serve



























II you have any other loods or drinks that we have not mentioned, at least once a month, please 
write them down here and tell us how olten you have them using the same response scale as before 
(eg 1D, 3M etc).
HOW TO ANSWER
Tim es a T im es a Tim es a
NEVER RARELY MONTH WEEK DAY
N R I M
3 | W 3
and so on and so on
FOODS AND DRINKS I CONSUME THAT HAVE NOT BEEN MENTIONED:
Name of Food Your usual serve 
size
How often 
do you eat It?
VITAMIN AND MINERAL SUPPLEMENTS
If you take any vitamins or minerals, or any other dietary supplement, such as fibre tablets, lecithin, kelp, 
yeast, 'slimming' products, etc, please till in the table below. (Check Ihe label on the box or bottle it you 
are unsure of some ol Ihe answers).
BRAND NAME OF PRODUCT SIZE OF DOSE
(e.g. Nyal) (e.g. vitamin C pill) (e.g. 250 mg)
NUMBER OF DOSES 
(e.g. 2 per day)
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S H O P P I N G
Q-1 In your household, who does most oflhe shopping? (Circle two It necessary)
1 Self
2 Spouse/Partner
3 Someone else (specify who............ .................................................................... )
Q-2 How much do you feel that your eating habits are influenced by





Lack of money.................. ........ 1 2 3 4 5
Transport problems............ .........1 2 3 4 5
Availability of foods in shops.. ........ 1 2 3 4 5
Nutritional value of food...... ........ 1 2 3 4 5
Physical disabilities............ ........ 1 2 3 4 5
Some other factor..............
(please state..................
........ 1 2 3 4 5




3 Never noticed them
0 4  When you look at the information on food labels, do you ever use it to avoid  a particular ingredient 
ornutnent, or avoid gelling too much of it? (Circle one number)
1 I don’t look al food label information
2 No
3 Yes - If so, whal do you try to avoid?
(Please be specific)................................................................................
0 5  When you look at the nutrients or ingredients listed on food labels, do you use this information to 
compare different brands? (Circle one number)
1 I don't look at food label information
2 I don't use it to compare brands
3 I sometimes use it to compare brands
4 I ollen use It to compare brands
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Q-6 When you are choosing between brands of sim ilar items (eg two types of high fibre breakfast 
cereal or two varieties of low-salt margarine), how Important would these factors be to you?
(Circle one number for each)
NOT SO __________________ > VERY
IMPORTANT IMPORTANT
Price........................................ ... 1 2 3 4 5 6 7
T a s te ....................................... ....1 2 3 4 5 6 7
Fat, sail or sugar content............... ....1 2 3 4 5 6 7
Additives or preservatives............. ....1 2 3 4 5 6 7
Convenience o( packaging.... . . . . . . . . . ....1 2 3 4 5 6 7
Endorsement by health authorities........1 v 2 3 4 5 6 7
Health claims by the manufacturer..... . . .1 2 3 4 5 6 7
Q-7 (a) What do you think are the advantages, If any, of canned foods?
Q-7 (b) What do you think are the disadvantages, If any, of canned foods ?
Q-8 (a) What do you think are the advantages, If any, of frozen foods ?
Q-8 (b) W/ial do you think are the disadvantages, if any, of frozen foods ?
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NUTRITIONAL RATING
Q-1 How would you rale Ifw nutritional value of the following? (Circle one (or each food)
VERY _______________ w VERY
POOR 7  GOOD
Fresh fish.......................... ..1 2 3 4 5
Fresh carrots.................... ..1 2 3 4 5
Frozen fruits..................... ..1 2 3 4 5
Complete frozen meals...... ..1 2 3 4 5
Canned fish...................... ..1 2 3 4 5
Canned peas.................... ..1 2 3 4 5
Frozen mixed vegetables...,.1 2 3 4 5
Canned meats................. ....1 2 3 4 5
Frozen pizza........................1 2 3 4 5
Fresh peas....................... ...1 2 3 4 5
Frozen carrots................. ...1 2 3 4 5
Canned fruit..................... ...1 2 3 4 5
Frozen fish....................... ...1 2 3 4 5
Frozen peas.................... ...1 2 3 4 5
Takeaway pizza............... ,...1 2 3 4 5
Fresh red meat................ ....1 2 3 4 5
Frozen meats.................. ....1 2 3 4 5
Complete canned meals ........1 2 3 4 5
Canned carrots................ ....1 2 3 4 5
Fresh fruit....................... ....1 2 3 4 5






























D IE T A R Y  C H A N G E S
Q-1 Have you tried to make any of the following changes to you r diet In the last few years? 
(Circle one answer for each)
Increase fibre Inlake YES NO
Reduce fat inlake YES NO
Reduce sugar Intake YES NO
Increase caldum inlake YES NO
Reduce sail inlake YES NO
Eat less food In general YES NO
Something else YES NO
(please describe...........................................................................
Q-2 If you have NOT TRIED to make changes stale, In your own words, why not?
0*3 Ifyou have TRIED to make dietary changes, either successfully or unsuccessfully, in the last few 
years, whal were the m ajor difficulties you encountered?
CM Ifyou have TRIED to make changes:
In your own words, what specific  changes have you tried to make to the foods you eat or your 
cooking methods etc?___________________________________________ • • •
Why have you made these changes?_
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CM Whal is your current height? ________ (eel________ inches OR ____________ centimetres
What is your current weight? ______ stones______ pounds OR_________ kilograms
Q-2 About how often do you exercise? (Please circle one number)
1 Less than once a week
2 Once or twice a week
3 Three times a week or more
4 NOT AT ALL-»go to Question 3 below
Q-2(a) About how long do you exercise for each lime? (Circle one number)
1 Less than 20 minutes
2 20-30 minutes
3 More than 30 minutes
Q-2(b) How much of the exercise you do makes you puff and sweat? (Circle one number)
1 None ol it
2 Some of it
3 Most or all ol it
Q-3 (a) Have you ever smoked on a regular basis? (Please circle one number)
1 YES
2 NO
Q-3 (b) Do you cu rren tly  smoke cigarettes, pipes or cigars? (Please circle, and write in amount)
1 YES, I smoke____________ cigs/day
2 YES, I smoke____________ cigars/day
3 YES, I smoke____________ pipes/day




























ÿ -------------- - ----------------:— — ---------------------------------------------- ■-------------- -----------
I Please answer these questions accurately so that we can examine general relationships between lifestyles
I and diet. Let us reassure you aoain that this inlormation will be kept completely conlldenllat
..................... ........................ ....................... .... , JJ
Q-1 Your sex: (Circle one)
1 Male
2 Female
Q-2 Your present age:______ YEARS
Q-3 What is your usual occupation? ,
Even if you are retired or otherwise not 
currently employed, please stale what your 
occupation usually would be. (Be specilic)
0 4  Are you (circle numbor(s))
0 8  Which one ol these best describes your 
situation? (Circle one number)
1 Living with spouse or partner and
dependent children
2 Living with spouse or partner
3 Living alone v/illi dependent children
4 Living alone
5 living with my family (eg mother, lather,
brother, sister)
6 Share house or Hat with others
7 Living with my child's family
(eg daughter or son's family)
0 Retirement home 
9 Another situation; please describe:
1 Employed lull-lime _________________________
2 Employed part-time




0 9  If you were born overseas, (or how long 
0 5  If you live with a spouse or partner, what is . have you lived in Australia? 
his/her usual occupation? (Be specific)
YEARS
0 6  lls your spouse/partner (circle number(s))
1 Employed lull-lime
2 Employed part-time




Q-10 What is the current level of income (before 
lax) in yo ilr household? (circle number 
next to range)
1 nil - $7,000 per year
2 $7,001-$15,000 per year 
,3 $15,001-$25,000 per year
4 $25,001-$40,000 per year
5 $40,001 and over per year
6 l do not wish to answer this question
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ft*************************************************************
At this stage, we ask you to please go back through the questionnaire and 
check that have answered all questions
YOUR COMMENTS
Thank you very much for your help. We realise that you had to give up 
some of your time to answer our questions. We would like you to know that 
wc appreciate this help.
We believe that the results from this survey will be useful in determining 
what people eat, and in llie future, possible relationships between diet and 
disease.
If you have any further comments to make about the design of this 
questionnaire please feel free to write them down here. We might be able to 
incorporate your suggestions in our future work.
Thank you again for your help.
Copyright CSIRO Division of Human Nutrition. Designed for research
purposes only.

